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Endothelins (ETs) are a family of biologically active peptides, of which 
endothelin-1 (ET-1) is the best characterized and the most biological relevant 
isoform in humans. ET-1 is a powerful vasoconstrictor and bronchoconstrictor and 
mitogenic peptide which can be synthesized and released by different pulmonary 
cells, among them pulmonary fibroblasts and airway epithelial cells. Endothelinergic 
system has been involved in multiple physiological function relating to the respiratory 
system (Hay et al., 1993), but it is also considered to have a potentially pathogenic 
effects and appears to be implicated in the pathogenesis of various lung disease like 
pulmonary hypertension, pulmonary fibrosis and fibrotic remodeling processes 
associated with chronic inflammatory and obstructive airway diseases such as 
bronchial asthma and chronic obstructive pulmonary disease (COPD) (Hay, 1999; 
Fagan et al., 2001; Polikepahad et al., 2006). Thus, the endothelinergic system 
emerged as a potential target for pharmacological intervention in the treatment of 
these diseases. These pathological conditions are characterized mainly by increased 
growth of connective tissue cells and excessive synthesis and secretion of matrix 
proteins, resulting in an increased extracellular matrix (ECM) deposition that lead to 
significant functional limitations of the lung tissue. Pulmonary fibroblasts are 
connective tissue cells and are the main cells responsible for the synthesis, 
deposition and remodeling of ECM in tissues. Thus, they significantly participate in 
pathophysiologic events of airway remodelling. Therefore, endothelinergic 
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1.1. Role of fibroblasts in airway remodeling process 
1.1.1. Lung fibroblasts  
Fibroblasts are connective tissue cells of mesenchymal origin that are widely 
distributed in all lung structures. They represent the most abundant cell type in the 
lung interstitium. Fibroblasts are typically spindle-shaped cells with an oval flat 
nucleus, but they do not express markers of other differentiated cell types. They are 
ubiquitous cells that provide mechanical strength to tissues by generating ECM 
components which form a supporting framework. Fibroblasts are considered to be 
the main cells responsible for the synthesis, deposition and remodelling of ECM. The 
ability of fibroblasts to respond to many different mediators which they release or 
which are produced by other resident cells like epithelial and endothelial cells, as 
well as mediators derived from circulation allows autocrine and/or reciprocal 
paracrine interactions, thereby maintaining tissue homeostasis (Kalluri et al., 2006; 
Laurent et al., 2007). These interactions control the morphogenesis of tissue 
structures and accordingly, fibroblasts play a crucial role during tissue development, 
differentiation and repair in many organs including lung (Phan, 2008; Westergren-
Thorsson et al., 2010). In addition, there is evidence that in fibrotic disease like 
idiopathic pulmonary fibrosis (IPF), ET-1, transforming growth factor-β (TGF-β), 
platelet-derived growth factor and connective tissue growth factor (CTGF) are 
capable of promoting fibroblasts activation, migration and proliferation as well as 
accumulation (Datta et al., 2011).  
Fibroblasts in normal tissues exhibit cell-ECM contacts and produce little 
matrix proteins. They are generally held by cross-linked ECM, but in injured tissue, 
this links to the ECM are lost (Tomasek et al., 2002). This alteration in 
microenvironment in turn activates fibroblasts to proliferate as well as to synthesize 
ECM components (Hinz et al., 2007b). Local over expression of cytokines and/or 
growth factors like TGF-β and ET-1 during the pathogenesis of lung fibrosis induces 
resident lung fibroblasts to synthesize elevated levels of ECM components (Datta et 
al., 2011). Fibroblasts are metabolically active cells, capable of continuously 
synthesizing and secreting ECM components like collagens and proteoglycans. 
However, the amount they produce is tightly controlled by secreting enzymes that 
control ECM degradation including matrix metalloproteinases (MMPs) (Laurent et al., 
2007). In addition fibroblasts also produce tissue inhibitors of metalloproteinases, 
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thus regulating tissue architecture and matrix turnover rates. The main ECM 
components produced by lung fibroblasts are fibrillar collagens; predominantly type I 
and III collagens, along with protoglycan and fibronectin. These are important ECM 
proteins for both, the organizational and structural pulmonary architecture network 
(Prockop et al., 1995; Westergren-Thorsson et al., 2010). 
Lung fibroblasts play an essential role in the repair processes following lung 
injury. Accordingly, after tissue injury, fibroblasts become activated to migrate into 
the damaged tissue and are stimulated to synthesize and secret collagen and 
fibronectin-rich matrix for wound closure (Kuhn et al., 1991; Hinz, 2007a). However, 
the healing process can become pathological causing continuous activation of the 
fibroblasts proliferation as well as excessive production and accumulation of 
interstitial ECM proteins in particular collagen that progressively leads to alterations 
in tissue architecture with impairment of organ function (Wynn, 2008). This alteration 
is believed to be a histopathological feature of chronic pulmonary diseases such as 
bronchial asthma, COPD (Hogg et al., 2004; Bergeron et al., 2006; Rennard et al., 
2011) and idiopathic pulmonary fibrosis (Selman et al., 2001). 
Human lung fibroblasts are frequently utilized during in vitro studies. This is a 
suitable technique to investigate pro- and anti-fibrotic processes in these cells along 
with the structural changes at the cellular level. The fibroblasts and in particular lung 
fibroblasts are not a unique cell population. Fibroblasts exhibit phenotypic 
heterogeneity and considerable regional variation in size, shape, synthesis 
performance and their content of alpha-smooth muscle actin (α-SMA) (Kotaru et al., 
2006; Zhou et al., 2011). In contrast to other cells types, lung fibroblasts do not have 
a typical surface marker that allows a definite characterization and classification to 
subpopulations (Phan, 2008). 
1.1.2. Myofibroblasts 
Myofibroblasts are fibroblast-like cells, characterized by the expression of α-
SMA, the actin isoform typical of smooth muscle cells, conferring a highly contractile 
activity to these cells (Hinz et al., 2001). The expression of α-SMA is the most 
commonly used molecular marker for myofibroblast identification. This allow to 
assessing the differentiation state of fibroblasts into myofibroblasts during 
experimental and clinical conditions. The morphologic and biochemical characters of 
myofibroblasts are intermediate between fibroblasts and smooth muscle cells 
  Introduction 
4 
 
(Gabbiani, 1992). Myofibroblasts play a central role in producing ECM proteins, 
including collagen (Hinz et al., 2007b). In comparison with fibroblasts, they 
synthesize considerably more matrix proteins, thus contributing to the structural 
remodeling of the connective tissue. Myofibroblasts are also responsible for the 
synthesis of enzymes involved in ECM degradation such as matrix metalloproteinase 
2 (MMP-2) (Desmouliere et al., 2004). The functional activity of myofibroblasts in part 
proceeds through expression of α-SMA, a protein which promotes wound contraction 
and thereby contributes to wound healing (Grinnell, 1994; Tomasek et al., 2002). By 
synthesizing elevated levels of both ECM and matrix degrading components, α-SMA-
producing myofibroblasts also promote tissue repair and wound healing 
(Desmouliere et al., 2005). For normal healing to occur, wound myofibroblasts must 
undergo apoptosis (Desmouliere et al., 1995a); however, if the tissue repair process 
does not appropriately terminate (failure of apoptosis), myofibroblasts accumulate at 
the site of the lesion, resulting in an extensive ECM synthesis, persistent tissue 
contraction and scar formation (Tomasek et al., 2002), thereby contributing to the 
development of fibrosis. Myofibroblasts are thought to be a major source of 
cytokines, chemokines and profibrogenic growth factors (Kuhn et al., 1991; Zhang et 
al., 1994). Under pathological conditions, excessive production of these factors can 
lead to lung remodeling and inflammation that may affect lung function (Hinz et al., 
2007b). Myofibroblast numbers were found to be elevated in the airways of 
asthmatic subjects (Brewster et al., 1990; Gabbrielli et al., 1994; Holgate et al., 
2000). 
Myofibroblasts can originate from several cell types, including resident 
fibroblasts (Phan, 2002), circulating fibrocytes attracted to regions of lung injury 
(Schmidt et al., 2003; Lama et al., 2006), endothelial-mesenchymal transition 
(EndMT) (Hashimoto et al., 2010) and epithelial-mesenchymal transition (EMT) 
(Willis et al., 2005; Kim et al., 2006). However, it is postulated that resident 
fibroblasts are the most obvious source of myofibroblasts in lung fibrosis (Hinz et al., 
2007b).  
ET-1 can promote the induction of the myofibroblast phenotype. For example, 
ET-1 has been demonstrated to transdifferentiate resident fibroblasts into 
myofibroblasts in various tissues, including the lung (Lagares et al., 2012). In 
addition, ET-1 can also induce EMT/EndMT in epithelial/endothelial cells as a source 
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of myofibroblasts in the fibrotic disease (Jain et al., 2007; Piera-Velazquez et al., 
2011). Moreover, ET-1 has been shown to be able to promote myofibroblast 
resistance to apoptosis and thereby may contribute to the persistence of fibrotic 
response (Horowitz et al., 2012). Furthermore, TGF-β, a main promoter of fibrosis, 
induces transdifferentiation of fibroblasts in vitro through a Smad3-dependent 
mechanism (Hu et al., 2003).  
 
1.2. Extracellular matrix (ECM) 
ECM is a complex network of macromolecules (proteins) that provide 
structural and biochemical support to the surrounding cells. ECM represents the 
main part of the connective tissue of the respiratory airways and plays an essential 
role in determining physical and mechanical properties of airway structure. ECM 
macromolecules also contribute to a number of cell functions like migration, 
proliferation, differentiation, survival and communication (Daley et al., 2008). Due to 
these multiple actions, it is believed that alteration in the ECM structure can cause 
dramatic effects on tissue homeostasis and may promote progression of disease like 
tissue fibrosis and cancer. Lung fibroblasts are the main producer of ECM proteins in 
airways. Composition and structure of the ECM vary considerably in the different 
types of connective tissues and determine the functional and biological 
characteristics. ECM protein production is increased by profibrotic factors like TGF-β, 
CTGF, granulocyte macrophage colony stimulating factor (GM-CSF) and ET-1 
(Abraham, 2008; Burgess, 2009). The ECM in airways is subjected to a continuous 
turnover of more than 10% of the total ECM per day (McAnulty et al., 1988). Thus, a 
dynamic equilibrium between synthesis and degradation of the ECM maintains the 
physiological balance (Laurent, 1986; Fernandes et al., 2006). Degradation of ECM 
is tightly controlled by a diversity of proteases and binding proteins, mainly the 
MMPs and their inhibitors, the tissue inhibitors of MMPs (TIMPs) and A disintegrin 
and metalloproteinases (ADAMs) (Parks et al., 2001; Page-McCaw et al., 2007). 
Two main classes of extracellular macromolecules make up the matrix (i) 
polysaccharide chains of the class called glycosaminoglycans (GAGs), which are 
covalently linked to proteins in the form of proteoglycans. This includes hyaluronic 
acid, heparan sulfate, keratan sulfate and chondroitin sulfate, and (ii) fibrous 
proteins, including collagen, elastin, fibronectin and laminin, which have both 
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structural and adhesive functions. Collagens constitute the main component of the 
ECM proteins, and are gaining attention from scientists in different fields, ranging 
from biochemistry to regenerative medicine. As in the present study the collagen 
production was investigated more closely, collagens as component of the ECM will 
be described in more detail. Collagens are a family of fibrous proteins, and are the 
most prevalent proteins in human body, accounting for about 30% of the total protein 
mass (Myllyharju et al., 2004; Ricard-Blum, 2011) and constitute about 15% of the 
dry weight of human lung tissue (Laurent, 1986). At least 28 different collagen types 
have been identified so far, and are numbered as I-XXVIII (Heino, 2007; Shoulders 
et al., 2009). They are differentiated according to their tissue localization, their 
molecular structure, their aggregation behaviour in the extracellular space and their 
function. Classically, collagens can be categorized as fibril-forming collagens and 
non-fibrillar collagens according to their polymeric structures. However, the non-
fibrillar collagens can be further divided into several subgroups based on their 
supramolecular organization and other characteristics: fibril-associated collagens 
with interrupted triple helices (FACITs), network-forming collagens, membrane-
associated collagens with interrupted triple helices (MACITs), collagens forming 
anchoring fibrils and collagens with multiple triple-helix domains and interruptions 
(MULTIPLEXINs) (Gelse et al., 2003; Myllyharju et al., 2004; Veit et al., 2006; 
Shoulders et al., 2009). In the human body, the most abundant and widespread 
family of collagens, with about 90% of the total collagen, consists of the fibril-forming 
collagens (Gelse et al., 2003), which include type I, II, III, V, XI, XXIV, XXVII, existing 
as fibrils in the ECM. Although the relatively high structural diversity among the 
different collagen types, all types of collagen have a triple-stranded helical structure 
composed of three polypeptide chains (α-chains) and are held together to form long 
thin fibrils arranged in bundles (rope like superhelix), which can be of varying lengths 
(Gelse et al., 2003; Ricard-Blum, 2011). Collagens are extremely rich in proline and 
glycine, which are essential in the formation of the triple-stranded helix. Proline, 
because of its ring structure, stabilizes the helical structure in each α chain, whereas 
glycine, the smallest amino acid enables the tight packing of the triple helical α 
chains to form the final collagen superhelix. The hydroxylation of proline by collagen 
prolyl 4-hydroxylase enzymes further increases the thermal stability of triple helices 
(Myllyharju, 2008). The long stiff chains contain characteristic repeating peptide 
triplets of glycine-X-Y with varied length, in which the X-position is often occupied by 
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proline and the Y-position by hydroxyproline (Prockop et al., 1995; Gelse et al., 
2003). Collagens are synthesized as the collagen precursor, procollagen molecules 
containing N- and C-terminal propeptide extensions. These soluble propeptides are 
proteolytically cleaved by specific procollagen proteinases during their secretion into 
the ECM to yield insoluble mature collagen, thereby triggering spontaneous self 
assembly of collagen molecules into fibrils. The C-terminal propeptides are essential 
in initiating the association of the α-chains and ensure solubility in the extracellular 
space, while the N-terminal propeptides influence fibril shape and diameter (Hulmes, 
2002). 
1.3. Endothelin  
1.3.1. Endothelin biology 
In 1985, Hickey and co-workers reported the presence of a peptidergic 
endothelium-derived constricting factor produced by bovine aortic endothelial cells 
(Hickey et al., 1985). This factor was subsequently isolated from cultured 
supernatant of porcine aortic endothelial cells, sequenced, cloned and named 
endothelin (ET), which is known today as endothelin-1 (ET-1). It is a potent 
vasoconstrictor peptide consisting of 21 amino acid residues (Yanagisawa et al., 
1988). Following the discovery of ET-1, analysis of the human gene encoding ET 
demonstrated the presence of two other genes encoding ET-like peptides and 
referred to endothelin-2 (ET-2) and endothelin-3 (ET-3), which are each encoded by 
a separate and unique gene (Inoue et al., 1989). The human genes of ET-1, ET-2 
and ET-3 are located on chromosomes 6, 1 and 20, respectively (Arinami et al., 
1991). All the three ET isoforms possess 21 amino acids residues with rather similar 
sequences, but ET-1 differ in their mature structure from ET-2 and ET-3 by two and 
six amino acid residues, respectively (Fig. 1-1) (Yanagisawa et al., 1988). All of the 
ET isoforms share a common structure, with two intra-chain disulphide bridges 
linking the cysteine amino acids (positions 1–15 and 3–11) at the N-terminal end and 
hydrophobic amino acids at the C-terminal end of the peptide (Fig.1-1). The N-
terminal end determines the binding affinity of the peptide to the receptor, whereas  
the C-terminal end consists of the amino acids that bind to the receptor (Inoue et al., 
1989). Each endothelin isoform is expressed in various cell types and tissues with 
distinct proportions, however ET-1 is the only isoform expressed by endothelial cells 
(Inoue et al., 1989; Sakurai et al., 1991). 
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Among all ET isoforms, ET-1 is the best characterized, the most potent 
vasoconstrictor peptide, the most abundant and physiologically relevant isoform in 
humans and may exert both beneficial and detrimental effects (Kedzierski et al., 
2001; Abraham, 2008). Therefore, ET-1 is in the focus of the current thesis. 
 
 
Figure 1-1: Primary sequences of the three ET isoforms. Amino acids that differ from the 
ET-1 sequence in ET-2 and ET-3 are shown in grey. Adapted from (Kedzierski et al., 2001). 
 
1.3.2. Biosynthesis of endothelin 
Although the endothelial cells are considered the main physiological source of 
ET-1 in humans (Boscoe et al., 2000), many other cell types can synthesize and 
release ET-1, including epithelial cells, fibroblasts, macrophages, vascular smooth 
muscle cells, cardiomyocytes (Kedzierski et al., 2001) implying numerous potential 
roles for ET-1 in various aspects of human physiology, pathology, and 
pharmacology. ET-1 synthesis requires several processing steps before the mature 
peptide is formed. The biosynthesis of all three endothelin isoforms (ET-1, ET-2 and 
ET-3) follows a similar pattern. ETs synthesis is initiated by the transcription of the 
prepro-endothelin (ppET) genes (Fig.1-2). The translation of ppET mRNA results in 
the generation of a 212 amino acid ppET peptide, a large inactive precursor of ET 
peptides. The precursor ppET is proteolytically cleaved within the cell at dibasic sites 
by a furin-like endopeptidase enzyme to a 38 (human) or 39 (porcine) amino acid 
intermediate molecule, referred to as big endothelin (big ET) or proendothelin (pET) 
(Inoue et al., 1989). pET-1 has some vasoconstrictive activity. It displays about two 
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orders of magnitude less vasoconstrictor potency than the active ET-1 (Kashiwabara 
et al., 1989; D'Orleans-Juste et al., 2003). Each of proendothelins (pET-1, pET-2 and 
pET-3) is indiscriminately further cleaved at Trp21-Val22 bond by an endothelin 
converting enzyme (ECE), a membrane-bound zinc metalloendoprotease, which 
cleaves 17 (human) or 18 (porcine) amino acids from the C-terminus of big ET to 
generate its corresponding 21 amino acid, bioactive ET peptide (Fig.1-2) (Kedzierski 
et al., 2001; Masaki, 2004).  
 
 
                    
                              Furin-like protease            Furin-like protease            Furin-like protease 
                      
 
                              ECE1, ECE2      ECE1, ECE2, 
                                 Non-ECE proteases          ECE1, ECE2                     ECE3 
                              Chymase 




                                            
 
Figure 1-2: Schematic diagram of the endothelins biosynthesis. ppET, prepro-endothelin; 
ECE, endothelin converting enzyme; ET-A, endothelin receptor-A; ET-B, endothelin 
receptor-B.   
 
1.3.3. Endothelin converting enzyme (ECE) 
ECEs are membrane-bound zinc metallopeptidases that catalyze the final 
step in the ppET activation to the bioactive ET. Three isoforms of ECE have so far 
been described known as ECE-1, ECE-2 and ECE-3, with different specificities for 
the isoforms of big ET (D'Orleans-Juste et al., 2003). ECE-1 and ECE-2 are most 
prominent (Emoto et al., 1995), and can generate all three ETs isoforms. However, 
ECE-1 is the major functional converting enzyme ECE for all three ET isoforms 
(Emoto et al., 1995; Yanagisawa et al., 2000). It exists as a dimer on the cell surface 
ET-B receptor ET-A receptor 
ppET-1 mRNA 
ppET-1 
bigET-3 bigET-2 bigET-1 
ET-3 ET-2 ET-1 
ppET-2 mRNA ppET-3 mRNA 
ppET-2 ppET-3 
Gi, Gq Gq, Gs… 
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(Xu et al., 1994). Both ECE-1 and ECE-2 display preference for big ET-1 over big 
ET-2 or big ET-3.  
Four functionally distinct isoforms of human ECE-1, (ECE-1a-d) have been identified 
to date (Shimada et al., 1995; Valdenaire et al., 1995; Schweizer et al., 1997; Hunter 
et al., 2006), with similar enzymatic properties and identical efficiency. They are 
derived from alternative splicing of a single gene but, there are subtle differences 
amongst the four isoforms in the cytoplasmic N-terminus, resulting in distinct cellular 
localization (Schweizer et al., 1997; Jafri et al., 2003). The different localization of 
ECE-1 isoforms means that ECE-1 can convert big ETs to the bioactive ET both 
intracellularly and extracellularly. These isoforms of ECE-1 display similar specific 
activity and identical efficiency for conversion of big ET-1 to the bioactive ET-1, but 
are less efficient for conversion of big ET-2 and big ET-3.  
ECE-2 shares 59% identity with ECE-1, and converts ETs with about similar 
efficiency as ECE-1. ECE-2 also consists of four isoforms with varying N-terminus 
that may confer different intracellular, but no extracellular localization (Emoto et al., 
1995; Ikeda et al., 2002). ECE-2 has an acidic optimal pH of 5.5, with virtually no 
activity at neutral pH 7.0 (Emoto et al., 1995), suggesting that ECE-2 acts as an 
intracellular enzyme and particularly in association with the trans-Golgi network, in 
which the pH is acidic (Emoto et al., 1995).  
ECE-3 was isolated from bovine iris microsomes, in which ET-3 concentrations are 
higher than those of ET-1 (Hasegawa et al., 1998). It has preference for big ET-3 
rather than for big ET-1 (Hasegawa et al., 1998). 
In addition, non-ECE proteases such as chymase, a mast cell-derived serine 
protease and MMP-2 could also be involved in the cleavage of bigET-1 to a 31 and 
32 amino acid intermediate ET-1 peptides respectively, that can subsequently be 
cleaved by a neutral endopeptidase enzyme (NEP) and/or ECE to the biologically 
active ET-1 (Nakano et al., 1997; Honore et al., 2002; D'Orleans-Juste et al., 2003; 
Fecteau et al., 2005; Simard et al., 2009). 
 
1.3.4. Regulation of endotheline-1 (ET-1) expression and secretion 
The expression of ET-1 is regulated primarily at the mRNA level that involves 
both transcriptional and posttranscriptional mechanisms (Inoue et al., 1989; 
Rodriguez-Pascual et al., 2003; Mawji et al., 2004). The ET-1 mRNA is relatively 
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labile with an intracellular half life of less than an hour (Bloch et al., 1989; Inoue et 
al., 1989), which is partly due to the presence of three destabilizing AUUUA motifs 
(suicide motifs) in the 3’-untranslated region (Inoue et al., 1989). The intrinsic mRNA 
instability confers on the ET-1 gene the capacity to respond quickly to changes in 
transcriptional activity. Thus, the combined actions of ET-1 transcription and rapid 
mRNA turnover allow for stringent control over its expression. In fact, alteration in 
ET-1 synthesis has been demonstrated in some studies that can be affected by 
modification of ET-1 mRNA stability (Douthwaite et al., 2003; Mawji et al., 2004; 
Rodriguez-Pascual et al., 2008). ET-1 is not stored but instead produced and 
released in response to various stimuli, which differ between different tissues 
(Haynes et al., 1998). The expression of ET-1 gene, ET-1 synthesis and release are 
elevated in response to physiological and pathological stimuli such as shear stress, 
hypoxia, catecolamines, angiotensin II, cytokines like TGF-β and tumor necrosis 
factor-alpha (TNF-α), interleukins and other growth factors (Teder et al., 2000; 
Kedzierski et al., 2001). On the other hand, ET-1 synthesis in endothelial cells is 
inhibited by nitric oxide, prostacycline, heparin and natriuretic peptide (Kedzierski et 
al., 2001). Plasma levels of ET-1 in the circulation of healthy individuals are in the 
picomolar range (1–10 pmol/L), lower than those required for many of the biological 
actions of ET-1 (Haynes et al., 1998). Thus, the circulating ET-1 levels might not 
correspond to the full biological ET-1 effect. Therefore, under normal physiological 
conditions ET-1 is considered to function in a paracrine/autocrine manner at various 
sites in the body (Kedzierski et al., 2001) rather than as circulating hormone (Wagner 
et al., 1992; Haynes et al., 1998). 
 
1.3.5. ET-1 clearance 
Although the biological effects of ET-1 may last considerably longer, the 
plasma clearance of circulating ET-1 is very rapid, with a half life of less than two 
minutes (Gasic et al., 1992), which may explain the low plasma levels of ET-1. In the 
rat, the half life as determined by intravenously injected, labelled ET-1 was less than 
one minute, whereas the pressor effects were maintained for about one hour (Sirvio 
et al., 1990). Nonetheless, levels of ET-1 in the plasma reflect a balance between its 
production and clearance (Kirkby et al., 2008). ET-1 appears to undergo either 
receptor- or enzyme-mediated degradation. ET-1 is mainly cleared by ET-B receptor-
  Introduction 
12 
 
mediated degradation, and is in addition degraded by NEP. The lung act as the main 
site for production (Dupuis et al., 1996b) and clearance of circulating ET-1 (Anggard 
et al., 1989). In a single passage through the lung, about 50% of circulating ET-1 is 
cleared, but about the same amount of ET-1 is newly released into the circulation 
(Dupuis et al., 1996b). The lung in addition plays a major target for ET-1 effects. In 
the rat, the highest levels of ET-1 mRNA and immunoreactive ET-1 has been found 
in the lung in comparison with other organs (Matsumoto et al., 1989). ET-1-like 
immunoreactivity and mRNA expression have been demonstrated also in healthy 
human lung tissue (Giaid et al., 1993). 
 
1.3.6. Endothelin receptors 
The downstream effects of ET-1 are mediated by two distinct receptor 
subtypes termed ET-A receptor (Arai et al., 1990) and ET-B receptor (Sakurai et al., 
1990). These receptors are members of the rhodopsin class A seven 
transmembrane guanine nucleotide-binding protein coupled receptor (GPCR) 
subfamily, which mediate various cellular events by activation of heterotrimeric 
guanine nucleotide binding proteins (G proteins). The human ET-A and ET-B 
receptors are encoded by distinct genes located on chromosomes 4 and 13, 
respectively (Sakurai et al., 1992). The human ET-A receptor consist of 427 amino 
acids, and shares about 64% sequence homology with the estimated 442 amino 
acids human ET-B receptor (Adachi et al., 1991). Both receptors have seven trans-
membrane domains of 22-26 hydrophobic amino acids residues with an extracellular 
N-terminus and a cytoplasmic (intracellular) C-terminus. (Arai et al., 1990; Sakurai et 
al., 1990). Although they share high sequence similarity, the activated ET-A and ET-
B receptors have quite different signalling transduction and targeting mechanisms 
(Aramori et al., 1992; Takimoto et al., 1996), and accordingly may mediate different 
responses. They exhibit distinct affinities for the different ET isoforms. The ET-A 
receptor binds ET-1 and ET-2 with greater affinity than ET-3, whereas the ET-B 
receptor binds all the three ET isoforms (ET-1, ET-2 and ET-3) with similar affinity 
(Sakurai et al., 1992). Therefore, ET-B receptor is considered as a non isopeptide 
selective receptor. There are multiple agonists recognized by the ET-B receptor, 
including sarafotoxin 6c and IRL1620 (Watts, 2010), but up to date, no selective 
agonists have been described for the ET-A receptor. Nevertheless, selective 
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competitive peptide and nonpeptide antagonists for ET-A as well as ET-B receptors 
proved to be important tools to study the function of each receptor type (Davenport, 
2002). 
Both ET receptors (ET-A and ET-B) are widely distributed in a variety of human 
tissues and cells including lung, heart, kidney and brain, but with different expression 
levels (Davenport et al., 1989; Jones et al., 1989). The distribution and expression 
levels of ET receptors varies among different organs and tissues, and may also 
dependent on the developmental stage and change during pathological conditions 
(Frommer et al., 2008). The density of ET receptors binding sites is particularly high 
in the lung and heart (Simonson et al., 1990). ET-A receptors in normal lungs are 
predominantly expressed on mesenchymal cells such as vascular and airway 
fibroblasts and smooth muscle cells (Fagan et al., 2001; Abraham, 2008). ET-B 
receptors, although mainly expressed on the endothelium (Fagan et al., 2001), are  
also expressed on other mesenchymal cells (Abraham, 2008). Both receptors (ET-A 
and ET-B) often act synergistically, but can also modulate some functions 
independently of one another and exhibit somewhat different physiological roles. For 
instance, ET-1-induced activation of ET-A receptors on smooth muscle cells causes 
vasoconstriction, cell growth and cell adhesion. Conversely, binding of ET-1 to 
endothelial ET-B receptors leads to vasodilation through the release of nitric oxide 
(NO) and prostacycline which also exhibit anti-proliferative properties, inhibits ECE-1 
expression and prevents apoptosis (D'Orleans-Juste et al., 2002; Alonso et al., 
2003). Importantly, ET-B receptors on endothelial cells are involved in the clearance 
of circulating ET-1 (Dupuis et al., 1996b). In some tissues the ET-B receptors 
mediate vasoconstriction and cell proliferation, thus both receptor subtypes 
implicated in the profibrotic effects of ET-1 (Clozel et al., 2005; Clozel et al., 2006).  
 
1.3.7. Endothelin receptor-mediated signaling pathways 
Given that ET receptors belong to GPCRs, their signal transduction was 
initially interpreted as sequential series of events initiated by binding of the agonist to 
its receptor, leading to activation of a heterotrimeric G protein which in turn is linked 
to either stimulatory or inhibitory second messenger pathways. The resulting change 
in second messenger concentration then leads to further downstream effector 
events, frequently activation of protein kinases. G-proteins transduce various cellular 
effects, including enzyme activation/deactivation, downstream gene transcription, 
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protein synthesis, and cell division. The heterotrimeric G-proteins are composed of 
three subunits, designated alpha, beta, and gamma (α, β and ϒ), and are classified 
according to their alpha subunit. Therefore, G proteins in general are referred to their 
Gα-subunit. So far, at least 23 distinct α-, 5 β- and 12 ϒ-subunits have been 
identified. G proteins are typically divided into four main subfamilies based on their 
amino acid sequence similarity and coupling specificity of the Gα subunit, namely 
Gαs, Gαi, Gαq/11 and Gα12/13 (Simon et al., 1991). Each Gα sub-family activates a 
specific profile of effectors. G-proteins change between their active and inactive state 
by binding guanosine triphosphate (GTP) or guanosine diphosphate (GDP) 
nucleotides. In the inactive state, the α-subunit of the G protein binds GDP, the Gα-
GDP is tightly associated with the Gβγ-complex, and this heterotrimeric is attached 
to the cytoplasmic surface of the plasma membrane (Fig.1-3). When bound to GTP, 
G protein is in the active state and can activate directly different effector molecules. 
The intrinsic GTPase activity of Gα leads to hydrolysis of GTP to GDP and the re-
association of Gα-GDP and Gβγ subunits with termination of signalling (Fig.1-3). The 
stimulation of the ET receptors induces the exchange of the GDP to GTP. The 
binding of GTP leads to dissociation of βγ-complex from α-subunit, consequently 
both subunits can activate distinct downstream intracellular effectors (Hamm, 1998).  
GPCRs downstream pathways have been divided into two sub-groups, pertussis 
toxin- (PTX) sensitive (coupled to Gi/o) or PTX-insensitive (coupled to Gq/11, Gs, or 
G12/13) (Albert et al., 2002; Pierce et al., 2002). PTX, an exotoxin produced by 
Bordetella pertussis, has been widely used as a pharmacological tool to characterize 
the involvement of heterotrimeric G-proteins in signalling. This bacterial toxin 
catalyses the ADP-ribosylation of the α subunits of the Gi family, and thereby inhibit 
Gi-mediated signalling (Bokoch et al., 1983). Both ET receptors are capable of 
coupling to several G proteins, including Gαi/Gαo (PTX-sensitive), Gαq/Gα11 and 
Gα11/12 (PTX-insensitive) as well as Gαs, although the coupling efficiency of each 
receptor subtype to G proteins may be different depending on the expression level of 
each G protein subtype in the cell (Aramori et al., 1992; Takigawa et al., 1995; Arai 
et al., 2003). This suggests that the downstream signaling may differ depending on 
the G protein involved (Aramori et al., 1992; Takigawa et al., 1995). Thus, the overall 
effects induced by ET-1-mediated activation of ET receptors may differ in various cell 
types. The PTX-insensitive coupling to phospholipase C (PLC) is mediated by Gαq 
and Gα11/12, whereas the PTX-sensitive coupling to adenylyl cyclase inhibition is 
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mediated by Gαi, Gαo, Gαi1, Gαi2 and Gαi3. Adenylyl cyclase converts adenosine 
triphosphate (ATP) into cyclic adenosine monophosphate (cAMP).  
Downstream signalling of ET-A receptor is primarily mediated by the activation of G-
proteins of the Gαq/11 subfamily, resulting in activation of PLC that cleaves 
phosphotidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-triphosphate (IP3) 
and diacylglycerol (DAG) (Aramori et al., 1992; Eguchi et al., 1993b). IP3 and DAG 
are two second messengers that activate the release of Ca2+ and protein kinase C 
(PKC), respectively, promoting further signaling cascades. ET-A receptor can also 
couple to Gαs resulting in activation of adenylyl cyclase and cAMP production 
(Takagi et al., 1995).  
ET-B receptors can also couple to Gαq/11, but in contrast to ET-A receptors, they 
predominantly couple to Gαi/o, Gαi3 (Aramori et al., 1992; Eguchi et al., 1993b; Gohla 
et al., 1999). Accordingly, activation of the ET-B receptors is associated with 
inhibition of cAMP formation as well as activation of PIP2 hydrolysis and production 
of IP3 and DAG. (Eguchi et al., 1993a). Thus, the two ET receptor subtypes couple to 
multiple but distinct signal transduction.  
 
Figure 1-3: Schematic diagram of the guanine nucleotide cycle governing G protein coupled 
receptor (GPCR)-mediated activation of heterotrimeric G protein-coupled signaling. ET-1, 
endotheline-1; GDP, Guanosine diphosphate; GEF, Guanine nucleotide exchange factor; 
GTP, Guanosine Triphosphate.  
 
1.4. Adrenergic and cholinergic system of the airways 
Human airways are innervated by efferent and afferent autonomic nerves 
which control various features of airway function. The innervations of the lung can be 
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divided into cholinergic and adrenergic pathways, along with non-adrenergic non-
cholinergic pathways. It is well recognized that human lung fibroblasts are under the 
regulation of both adrenergic and cholinergic (acetylcholine) mechanisms, mediated 
via β-adrenoreceptor and by muscarinic receptors, respectively. Based on their 
bronchodilatory effects, β2-adrenergic agonists and anticholinergic drugs represent 
major components in the treatment of bronchial asthma and/or COPD. However, the 
action of these drugs is not confined to bronchodilation (Racké et al., 2008; Bateman 
et al., 2009). Thus, it was recently demonstrated in our laboratory that pro-fibrotic 
features such as proliferation and collagen synthesis in human lung fibroblasts are 
stimulated by muscarinic receptors (Matthiesen et al., 2006; Haag et al., 2008a), but 
inhibited by β2-adrenoceptors (Lamyel et al., 2011). Therefore, in one part of this 
study, a possible regulation of the ET-1 gene expression in human lung fibroblasts 




Three subtypes of β-adrenoreceptors have so far been identified (β1, β2 and 
β3) (Bylund et al., 1994). They belong to the GPCR Rhodopsin family, which are 
encoded by three different genes located on human chromosomes 10, 5 and 8, 
respectively. Among these three subtypes, the β2-adrenoceptor is widely distributed 
in various human tissues and cells (Barnes, 1995). Within the human lung, β2-
adrenoceptors but not β1- or β3- adrenoceptors are expressed in lung fibroblasts, 
epithelial, and smooth muscle cells (Mak et al., 1996; Lamyel et al., 2011). 
Generally, β2-adrenoceptors couple to the stimulatory G proteins (Gαs), resulting in 
cAMP production. However, they are also able to interact with other G protein 
families, such as the inhibitory Gαi and Gαq family (Rubenstein et al., 1991; Wenzel-
Seifert et al., 2000). 
Adenosine 3′,5′ cyclic monophosphate (cAMP) has long been identified as 
signal transduction molecule, acting as second messenger in response to a variety 
of extracellular signals (Beavo et al., 2002). The cAMP signaling pathways is initiated 
typically by the activation of Gαs protein. Following receptor ligand binding, the α 
subunit of the Gs protein activates adenylyl cyclase, which triggers the generation of 
cAMP from ATP (Fig.1-4) (Hanoune et al., 2001). In addition, adenylyl cyclase 
activity can be inhibited by ligands that activate Gαi and/or cAMP can be degraded 
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by phosphodiesterase. Thus, the intracellular levels of cAMP are regulated by the 
balance between the activities of two enzymes, adenylyl cyclase and 
phosphodiesterase (Maurice et al., 2003; Tasken et al., 2004). 
Intracellular cAMP regulates various cellular functions as primarily through 
two downstream effectors, PKA (protein kinase A), the classic effector of cAMP 
(Skalhegg et al., 2000), and the alternative cAMP effectors Epac (Exchange protein 
directly activated by cAMP).  
 
Figure 1-4: Schematic diagram of cAMP-mediated signaling pathways in the cells. AC, 
adenylyl cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; 
5'AMP, 5'-adenosine monophosphate; Epac1/2, exchange protein directly activated by 
cAMP; GDP, guanosine diphosphate; GTP, guanosine triphosphate; PDE, 
phosphodiesterase, PKA, protein kinase A. 
 
1.4.1.1. Protein kinase A (PKA) 
PKA, the best characterized cAMP effector, is a serine/threonine kinase that 
in its inactive state exists as a heterotetramer holenzyme of two regulatory and two 
catalytic subunits. Three different genes encode for the catalytic subunits (Cα, Cβ, 
and Cγ) and four different genes for the regulatory subunits (RIα, RIβ, RIIα, and 
RIIβ), that are differentially expressed in various tissues and display different 
subcellular localization. Two types of the heterotetrameric PKA holoenzyme have 
been reported, type I (RIα2C2, RIβ2C2) which is predominantly found in cytoplasmic, 
and type II (RIIα2C2, RIIβ2C2) which is mainly associated with specific subcellular 
structures and compartments (Taylor et al., 2004; Pidoux et al., 2010). The variations 
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in tissue distribution and the composition of PKA holoenzymes may be related to the 
variety of biological functions that are mediated by PKA (Skalhegg et al., 2000).  
Activation of PKA occurs upon elevation of cAMP levels. Accordingly, the 
cooperative binding of two cAMP molecules to each of the regulatory subunits 
induces conformational changes that lead to dissociation of the holoenzyme and the 
release of catalytic subunits, which in turn become enzymatically active. The active 
catalytic subunits can then affect a variety of different cellular activities by 
phosphorylating a wide range of cytoplasmic and nuclear enzymes on serine and/or 
threonine residues, thereby playing an essential role in the regulation of various 
cellular functions such as gene regulation, cell cycle, proliferation, differentiation, 
collagen synthesis, cell migration and metabolism (Tasken et al., 2004; Cheng et al., 
2008)  
1.4.1.2. Exchange proteins activated by cAMP (Epac) 
Epac, also known as cAMP- regulated guanine-exchange factors (cAMP-
GEF), is another important intracellular cAMP effector. Epac is a guanine nucleotide 
exchange factor (GEF) for the Ras family of small GTPases, Rap (Bos, 2006). Rap 
cycles between an inactive GDP-bound form and an active GTP-bound form. Two 
isoforms of Epac (Epac1 and Epac2) which share similar structures have been 
identified (de Rooij et al., 1998; Kawasaki et al., 1998). They are encoded by two 
distinct genes. Epac1 is ubiquitously expressed, whereas Epac2 is mainly expressed 
in the brain and endocrine tissue (Kawasaki et al., 1998). Epac proteins are multi-
domain proteins containing a catalytic subunit at the C-terminus and a regulatory 
subunit at the N-terminus, whereas Epac2 has an additional N-terminal cyclic-
nucleotide-binding (CNB) domain, which is not required for the regulation of Epac 2 
in vitro (Bos, 2006). The regulatory subunit consist of a Dishevelled-Egl-10-Pleckstrin 
(DEP) domain (Fig.1-5), which is responsible for membrane localization, and a 
cAMP-binding domains (CBD) homologous to the CBD of PKA, that is needed for 
activation by cAMP (de Rooij et al., 1998). The catalytic subunit, which possesses 
GEF activity, is composed of (i) a Ras exchange motif (REM) which functions as 
bridge between the regulatory and the catalytic region to stabilize the CDC25 
homology domain, (ii) a Ras association domain (RA) (Fig.1-5) which allows 
particularly Epac2 interaction with Ras (Li et al., 2006), and (iii) a CDC25 homology 
domain (CDC25HD) responsible for the guanine nucleotide exchange function of 
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Epac-proteins (Li et al., 2006). Crystallographic studies demonstrated that, in the 
absence of cAMP, the CNB domains sterically hinder Rap binding to the catalytic 
site, thereby maintaining Epac proteins in an auto-inhibited state (Rehmann et al., 
2003; Rehmann et al., 2006). The binding of cAMP to Epac relieves the catalytic 
domain from the inhibitory constraints to enable interactions with their effectors 
(Rehmann et al., 2003; Rehmann et al., 2006).  
Epac proteins (Epac1 and Epac2) bind cAMP with affinities similar to that of PKA, 
suggesting that Epac and PKA respond to similar cAMP concentrations (Dao et al., 
2006). Furthermore, Epac and PKA can act independently (Huang et al., 2008; Haag 
et al., 2008b), synergistically (Hochbaum et al., 2008; Petersen et al., 2008) or 
antagonistically (Mei et al., 2002; Huston et al., 2008) in regulating specific cellular 
functions on downstream signalling targets, depending upon specific cellular 
contexts and their relative abundance, distribution, and localization.  
Epac proteins are important for cell functioning. Hence, it is well known that they are 
implicated in several cAMP-mediated cellular functions, such as gene expression, 
cell differentiation, cell adhesion, secretion/exocytosis, cell-cell junction and 
apoptosis (Bos, 2006; Cheng et al., 2008; Roscioni et al., 2008). 
 
 
Figure 1-5: Schematic diagram of multi-domain proteins of Epac1 and Epac2. CNB, cAMP-
binding domain; DEP, Desheveled-Egl-10-Pleckstrin; CDC25-HD, CDC25-homology 
domain; REM, Ras exchange motif; RA, Ras-association domain. Adapted from (Bos, 2006). 
 
Cell-permeable cAMP analogs, such as 8-pCPT-2'-O-Me-cAMP and 6-Bnz-
cAMP which selectively activate Epac or PKA, respectively, have been identified. 
These analogs are generally used as specific pharmacological tools to study and 
distinguish between Epac- and PKA-mediated signalling pathways (Enserink et al., 
2002; Christensen et al., 2003; Holz et al., 2008). In addition, as Epac proteins are 
insensitive to PKA inhibitors, PKA inhibitors such as Rp-8-CPT-cAMPS might be 
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used to further verify PKA- and Epac-dependent cAMP signalling (Holz et al., 2008). 
Specific pharmacological inhibitors of Epac proteins are not available. 
1.4.2. Muscarinic receptors  
Five subtypes of muscarinic acetylcholine receptors (M1-M5) have been 
described thus far, which are encoded by five different genes located on 
chromosomes 11, 7, 1, 11 and 15, respectively (Caulfield et al., 1998). They are 
members of the superfamily of hormones and neurotransmitter receptors. Muscarinic 
acetylcholine receptors belong to the GPCRs Rhodopsin family (Wess, 1996), which 
regulate the activities of both ion channels and enzymes involved in the regulation of 
intracellular second messenger pathways. Muscarinic receptors are widely 
expressed in various tissue, and are involved in many functional processes, 
including the regulation of smooth muscle contraction, cellular proliferation and 
mucus secretion. M1, M2, and M3 receptors represented the main muscarinic 
receptors in airways and lung tissue of most mammals including human (van Koppen 
et al., 1987). M1 receptors are mainly expressed in the peripheral lung tissues and 
the alveolar walls (Roffel et al., 1987; Mak et al., 1992). The M2 receptor is located 
mainly on the cell membrane of smooth muscle cells, where it acts as functional 
antagonism to β2-adrenoceptor-induced airway smooth muscle-mediated relaxation, 
and as presynaptic inhibitory autoreceptor on parasympathetic nerve endings 
(Zaagsma et al., 1997; Belmonte, 2005). M3 receptors are the predominant 
muscarinic receptors on submucosal glands and thus significantly involved in the 
pathophysiological mucus formation (Barnes, 2004). In human lung fibroblasts, M1-
M4 have been detected, but the M2 receptor represented the major subtype 
(Matthiesen et al., 2006). Activation of M2 receptors in human lung fibroblasts, 
enhanced proliferation (Matthiesen et al., 2006; Matthiesen et al., 2007) and collagen 
synthesis (Haag et al., 2008a) through activation of the ERK1/-2 MAPK pathway. In 
addition, muscarinic receptors are also involved in the human lung fibroblasts 
transition into myofibroblasts, through increase in ERK1/-2 MAPK phosphorylation, 
RhoA activation, cAMP inhibition and autocrine TGF-β release (Milara et al., 2012). 
M1, M3 and M5 receptors couple predominantly to Gαq proteins (PTX-insensitive) to 
activate PLC, and thereby inducing formation of IP3 and DAG, resulting in increase 
in intracellular calcium release and activation of PKC, respectively (Wess, 1996). M2 
and M4 receptors preferentially couple to the inhibitory G protein (Gi/o) (PTX-
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sensitive), inducing inhibition of adenylyl cyclase, thus reduce cAMP production. 
However, the M2 receptors can also couple to Gαs and Gαq/11 family, resulting in 
stimulation of cAMP synthesis and phosphatidylinositol accumulation, respectively 
(Michal et al., 2007). 
 
1.5. Mitogen activated protein kinases (MAPKs) 
MAPKs are serine/threonine kinases that play key roles in signal transduction 
from the cell surface to the nucleus. MAPKs regulate a diverse range of cellular 
processes, including growth, proliferation, differentiation and apoptosis and are 
implicate in a number of disease states including chronic inflammation and cancer. In 
mammalian cells, five different families of MAPKs have been identified, the 
extracellular signal-regulated kinases (ERK1/-2), c-Jun N-terminal kinases (JNK1,2 
and 3); p38 kinase isoforms (α, β, γ and δ), ERK3/-4 and the ERK5 (Roux et al., 
2004). Among these families, ERK1/-2, JNKs and p38 kinases are implicated in 
human diseases and are targets for drug development (English et al., 2002; Manning 
et al., 2003).  
MAPK signalling pathways can be activated by a vast array of extracellular 
stimuli. However, every MAPK-family usually becomes activated in response to a 
particular set of stimuli. In general, ERK1/-2 is activated primarily in response to 
mitogenic stimuli like cytokines, growth factors and hormones. On the other hand, 
JNK and p38 MAPK cascades, which are also called stress-activated protein kinases 
(SAPKs), are mainly activated in response to stress stimuli like inflammation and 
apoptosis (Fig.1-6) (Roux et al., 2004; Qi et al., 2005; Whitmarsh, 2007). Each family 
of MAPK cascades consist of a core module of three evolutionarily conserved, 
sequentially acting protein kinases termed, MAPK, MAPK kinase (MAPKK), and 
MAPKK kinase (MAPKKK). Activation of MAPK is achieved by phosphorylation of 
both conserved threonine and tyrosine residue within their activation loop, which is 
catalyzed by dual specificity MAPK kinases (MAPKK or MEK). MEK activity, in turn, 
is regulated via phosphorylation by a MEK kinase (MAPKKK or MEKK) and/or by G-
protein (Roux et al., 2004; Qi et al., 2005). In this study the ERK1/-2 signaling was 
investigated more closely, therefore the following description will focus on ERK1/-2 
as components of MAPKs. 
  Introduction 
22 
 
ERK is the best characterized MAPK families and the Raf/MEK/ERK pathway 
represented one of the best characterized MAPK signalling pathways (Rossomando 
et al., 1989; Peyssonnaux et al., 2001). The mammalian ERK module also know as 
classical mitogen kinase cascade consists of the MAPKKKs A-Raf, B-Raf, and Raf-1, 
the dual specificity kinase MEK, (MAPKK MEK1/-2) and the classical MAPK ERK1/-
2. Human ERK1/-2 exhibit 84% sequence homology and are uniquely activated 
through the sequential phosphorylation of the classical MAPK cascade.  
 
Mitogens   Stress/cytokines   
                                       
                                   ERKs            JNKs   p38 
 
         Proliferation        Inflammation 
         Differentiation        Differentiation 
         Growth                  Cell death 
         Survival 
Figure 1-6: Schematic diagram of MAPK signaling pathways in mammalian cells. 
 
1.5.1. Raf/MEK/ERK pathway (MAPK signalling cascade) 
The cellular response to mitogens including growth factors, inflammatory 
cytokines is frequently mediated by GPCR or intrinsic protein receptor tyrosine 
kinases (RTKs). Raf/MEK/ERK signaling cascade is strongly activated by mitogenic 
stimuli like growth factors and inflammatory cytokines, often initiated by agonist 
stimulation of cell surface receptors, like RTKs and GPCR, and mediated through 
various isoforms of the small GTP binding protein Ras (McKay et al., 2007).  
The binding of a ligand to the corresponding RTK induces its oligomerisation and 
subsequent autophosphorylation in tyrosine residues. The activated RTKs promote 
Ras activation through recruitment adaptor proteins bearing SH2 and SH3 motifs 
(Shc and Grbr2, growth factor receptor-bound protein 2) that bind to an exchange 
factor for Ras, SOS (Son of Sevenless). SOS catalyzes the conversion of inactive 
Ras–GDP to active Ras–GTP. Ras–GTP promotes the activation of Raf isoforms 
and recruits them to the plasma membrane. The activated Raf in turn phosphorylates 
the dual specificity kinases MEK1/-2, which in turn phosphorylate ERK1/-2 within a 











  Introduction 
23 
 
cascade is such that activation of solely 5% of Ras molecules is sufficient to induce 
full activation of ERKs (Hallberg et al., 1994). In quiescent cells, MAPKs are 
anchored in the cytoplasm due to interaction with a variety of anchoring proteins, 
including MEK1/-2, however upon activation they dissociate from the cytoplasmic 
anchoring complex and translocate into the nucleus (Volmat et al., 2001; Shaul et al., 
2007). The most important role of MAPKs is the regulation of gene expression. For 
this action, activated MAPKs translocate to the nucleus and regulate the activity of 
different transcription factors (Volmat et al., 2001; Shaul et al., 2007).  
 
1.5.2. G-protein coupled receptor signaling to ERK MAPK 
It is well established that many of the cellular responses mediated by GPCR 
do not only involve the stimulation of conventional second-messenger-generating 
system, but result from the functional integration of a complex network of intracellular 
signalling pathways. Among these, the MAPK pathways, those mediated by ERK1/-
2, JNK and p38 MAPK, are strongly activated by GPCR (Caunt et al., 2006; 
Goldsmith et al., 2007). One of the main cellular effectors activated by GPCRs is 
ERK (Rozengurt, 2007). G-protein-dependent ERK activation leads to the 
translocation of active ERK to the nucleus. The subcellular location of activated 
ERK1/-2 determines the downstream signaling cascades (Luttrell et al., 2003). 
Various substrates of ERK1/-2 are found in the nucleus, including nuclear 
transcription factors that participate in gene transcription, cell proliferation and 
differentiation. Activation of MAP kinases, particularly of ERK1/-2 is now recognized 
to be a major signal transduction pathway of many GPCRs. 
Most of the mechanisms by which GPCRs activate ERK entail transduction by 
heterotrimeric G proteins. Gαi and Gαq were the first identify subunits involved in 
GPCR-mediated activation of MAPK (Gutkind, 2000; Marinissen et al., 2001). 
Suggested mechanisms for MAPK stimulation are through PLCβ, PKC, second 
messengers and/or the small G protein (Gutkind, 2000; Marinissen et al., 2001).  
Activation of MAPK by GPCR can be mediated through their Gα and/or Gβγ subunits 
of the G protein (Crespo et al., 1994; Marinissen et al., 1999) depending on the 
MAPK and the specific stimulus. Because of the abundance of Gi proteins, their βγ 
subunits are considered to be a main source of the βγ subunit used for transduction 
in heterologous pathways (Belcheva et al., 2002). The βγ-complex can activate 
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PLCβ and thereby induce ERK activation (Schwindinger et al., 2001; Rozengurt, 
2007). 
There are different mechanisms by which GPCRs activate ERK. Gαi-coupled 
receptors often act through Gβγ-mediated effects on phosphatidylinositol 3-kinase 
(PI3K), while Gαq/11-coupled receptors-directed phosphorylation and activation of 
ERK involves a pathway that is sensitive to inhibitors of PLC, PKC and/or 
intracellular Ca2+ (Werry et al., 2005).  
ET-1-mediated responses, including MAPK activation, are mediated by Gαq, G11/12, 
Gαi, and Gβϒ (Miyauchi et al., 1999; Arai et al., 2003). Activation of ERK1/-2 in 
response to ET-1 in human VSMCs is predominantly mediated by ET-A receptors 
through upstream signal molecule, including PKC, PKA and PI3K (Chen et al., 
2009). Furthermore, activation of the ERK1/-2 cascade by GPCRs signaling via PTX-
sensitive and -insensitive G proteins has been reported for a broad array of ligands, 
including ET-1 (van Biesen et al., 1996), and ET-1 signaling to MAPK involves βγ-
dependent and independent pathways (Miyauchi et al., 1999).  
 
1.6. Rho kinase 
Rho kinase is a serine-thronine kinase, the main effector of Rho and the main 
downstream targets of RhoA, which exists in two isoforms: Rock1 (Rho-associated 
protein kinase-1) and Rock2 (Rho-associated protein kinase-2) (Fukata et al., 2001). 
Rho (Ras homologous) protein is a subfamily member of the small GTPases 
superfamily related to Ras, that act as key regulator of extracellular-stimulus-
mediated signaling networks that regulate a variety of fundamental cellular activities, 
including actin organization, cell cycle progression and transcriptional regulation of 
gene expression (Etienne-Manneville et al., 2002; Shimokawa et al., 2007). Of the 
more than twenty identified human Rho GTPases, Rho, Rac1 and Cdc42 are the 
most intensively characterized family members (Wennerberg et al., 2004). The 
activation of Rho is regulated by GTPase activating proteins (GAPs), guanine 
nucleotide exchange factors (GEFs), and guanine nucleotide dissociation inhibitors 
(GDIs). GAPs enhance the intrinsic GTP hydrolysis rate and thus attenuate Rho 
protein activity by promoting the formation of the inactive GDP-bound form, whereas 
GEFs catalyze the exchange of GDP for GTP and thereby activate Rho. GDIs inhibit 
GDP/GTP exchange and activation of the Rho GTPases (Sah et al., 2000; Satoh et 
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al., 2011). Furthermore, the majority of Rho protein members undergo carboxy (C)-
terminal post-translational modification by isoprenoid lipids, which is important for 
facilitating their membrane association and subcellular localization crucial for their 
biological activity, and which can also play essential roles in protein-protein 
interactions and protein stability. Rho proteins have a carboxyl-terminal CAAX 
tetrapeptide motif (C=cysteine, A=aliphatic amino acid, X= terminal amino acid) that 
is necessary for post-translational modification. The post-translational modification 
also termed protein prenylation, is initiated by the attachment of an isoprenoid lipid to 
the conserved cysteine residue of the tetrapeptide motif. Either farnesyl or 
geranylgeranyl isoprenoid is covalently attached to this cysteine by protein 
farnesyltransferase or protein geranylgeranyltransferase-I, respectively. Prenylation 
is followed by a proteolytic cleavage of the terminal AAX residues and finally the 
prenylated cysteine is methylated. 
1.6.1. G-protein coupled receptor signaling to Rho kinase 
Activation of GPCRs switches RhoA from an inactive, GDP-bound 
conformation to an active GTP-bound conformation, which binds to and activates 
target molecules (Loirand et al., 2006). It is well documented that, RhoA, and in turn 
Rho kinase can be activated by a large variety of GPCRs-induced signaling 
(Bhattacharya et al., 2004) particularly downstream of G12/13 protein subtypes of the 
G-protein family through interaction with specific RhoGEFs (Sah et al., 2000). For 
instance, G12/13 can recruit RGS domain-containing GEFs such as PDZRhoGEF, 
Leukemia-associated Rho GEF (LARG) and p115-RhoGEF (Fukuhara et al., 2000). 
RhoGEFs may also inactivate these G12/13 G-protein by elevating their GTPase 
activity via regulator of G protein signaling (RGS) domain of p115RhoGEF, a 
GTPase-activating protein for G12/13 (Kozasa et al., 1998; Chen et al., 2005; Hains et 
al., 2006). In NIH3T3 cells, ET-1 has been shown to mediate Rho activation through 
the G12/13 (Mao et al., 1998). RhoA can also be activated by Gq/11 coupled receptors, 
which normally couple to PLC, this is facilitated exclusively by a Gq/11-selective GEF, 
p63RhoGEF (Lutz et al., 2005). The majority of GPCR that regulate cellular Rho-
dependent responses, including actin cytoskeletal responses, smooth muscle 
contraction, gene transcription and cell growth can couple to more than a single 
class of heterotrimeric G-protein. For example lysophosphatidic acid (LPA) and 
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thrombin mediate cellular responses through both pertussis toxin-sensitive and 
insensitive G-proteins (Sah et al., 2000). 
In cardiomyocyte, ET-1-induced alterations in cell size, protein production, gene 
transcription and myofibril organization are inhibited by RhoA and Rho-kinase 
inhibitors such as C3 toxin (bacterial toxin C3 transferase from clostridium botulinum) 
and Y-27632 respectively (Kuwahara et al., 1999; Charron et al., 2001). The ROCK 
inhibitor Y-27632 totally blocked ET-1-mediated contraction in the granulation tissue 
of sprague-dawley rats, suggesting that activation of Rho/ROCK pathway by ET-1 is 
critical in regulating in vivo myofibroblast contraction (Tomasek et al., 2006). In 
addition, Rho/ROCK signalling is required for ET-1-induced myofibroblast resistance 
to apoptosis (Horowitz et al., 2012). In Swiss 3T3 cells, inhibition of RhoA by C3 
toxin or by a dominant-negative mutant caused cells to arrest in the G1 phase of cell 
cycle (Yamamoto et al., 1993), suggesting an important role for Rho in regulating cell 
proliferation. Furthermore, activation of Rho by Escherichia coli cytotoxic necrotizing 
factor-1 reduced cell cycle inhibitory protein p27Kip1 and increased DNA synthesis in 
human smooth muscle cells (Laufs et al., 1999), thus Rho is crucially involved in 
regulation of cell proliferation. 
 
1.7. Transforming growth factor-β (TGF-β) 
TGF-β is the prototypic member of the TGF-β superfamily, an evolutionary 
conserved family of structurally related dimeric cytokines, which regulate an 
extensive range of cellular processes, including cell proliferation, cell differentiation, 
apoptosis, cell migration and cell cycle progression. In addition to this, TGF-β plays 
also an essential part in embryonal development, tissue repair and immune system 
modulation (Blobe et al., 2000; Massague et al., 2000b; Attisano et al., 2002). In 
humans, the TGF-β superfamily consists of at least 33 related polypeptides (Derynck 
et al., 2008), including TGF-β isoforms, activins, inhibins, growth differentiation 
factors and bone morphogenetic proteins (BMPs). Members of the TGF-β 
superfamily are expressed in most cell types (Feng et al., 2005). All TGF-β 
superfamily members share a cluster of conserved cysteine residues that form a 
common cysteine knot structure held together by intermolecular disulfide bonds 
(Heldin et al., 1997; Attisano et al., 1998; Massague, 1998). In humans, three 
structurally almost identical isoforms of TGF-β (Grande, 1997) encoded by separate 
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genes have been described, TGF-β1 (Derynck et al., 1985), TGF-β2 (de Martin et 
al., 1987; Madisen et al., 1988) and TGF-β3 (Derynck et al., 1988). Among these 
three isoforms, TGF-β1 is the most abundant and ubiquitously expressed isoform in 
most human tissues and cell types including lung cells (Pelton et al., 1990; Bragg et 
al., 2001), and is most prominently expressed in many diseases characterised by 
fibrosis (Border et al., 1992). Therefore TGF-β1 will be the focus of this thesis, 
referred to as TGF-β. 
1.7.1. Synthesis and secretion of TGF-β 
All isoform of TGF-β are initially synthesized as a biologically inactive, large 
precursor proteins (Homodimeric proproteins), which are held together by three 
intermolecular disulfide bonds. These dimeric proproteins contain of the N-terminal 
latency-associated peptide (LAP), propepetide and the C-terminal mature TGF-β 
peptide, dimeric growth factor (Lawrence et al., 1984; Gentry et al., 1988; Gentry et 
al., 1990), which are protolytically cleaved by furin-like proteases to yield mature 
growth factor dimer and propeptide dimer, while in the secretory pathway (Fig.1-7) 
(Dubois et al., 1995). Although cleavage from mature growth factor, the propeptide 
LAP remains non-covalently associated with the dimeric growth factor and their 
interaction makes the mature TGF-β inactive. This complex is referred to as latent 
TGF-β or small latent complex (SLC), which is unable to generate signaling through 
high-affinity TGF-β receptors (Miyazono et al., 1988). Once the SLC has attached to 
the ECM proteins, LAP is disulfide bonded to a larger secretory glycoprotein known 
as latent transforming growth factor binding protein (LTBP), resulting in the formation 
of large latent complex (LLC) (Saharinen et al., 2000), which subsequently becomes 
covalently linked to ECM proteins. LTBP facilitates the release of L-TGF-β (Miyazono 
et al., 1991) and allows cells to deposit L-TGF-β in their ECM, which requires 
activation before being able to bind to cell surface TGF-β receptors and to exert a 
target function (Annes et al., 2003; Rifkin, 2005). TGF-β is secreted as either a SLC 
or LLC. However most cells, including lung fibroblasts, secrete TGF-β into 
extracellular matrix as a large latent complex (LLC). There are four LTBPs which 
have varying degree of functional and structural similarities and differences. LTBP-1 
and -3 form effectively complexes with all three TGF-β isoforms, whereas LTBP-4 
can form complexes only with TGF-β1 (Saharinen et al., 2000). On the contrary, 
LTBP-2 is unable to form complexes with any of the TGF-βs (Saharinen et al., 2000). 
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To initiate TGF-β signalling, latent TGF-β requires biological activation by 
release of the mature TGF-β from latent precursor (LAP). Activation of latent TGF-β 
is a rate-limiting step in TGF-β bioavailability (Annes et al., 2003). There are several 
mechanisms by which TGF-β may be activated, including proteolytic activation which 
occurs through interaction with matrix metalloproteinases (MMP-2 and -9), 
thrombospondin-1 (TSP-1), plasmin or the integrins β6 and β8 (Gibbons et al., 1992; 
Annes et al., 2003; Leask et al., 2004; Jenkins, 2008). TGF-β can also be activated 
through physical processes such as acidification, extreme temperature changes, and 
oxidation (Sullivan et al., 2008). Moreover, synthesis of TGF-β and its release from 
the inactive latent complex can be increased by variety of molecules such as ET-1 
and angiotensin II (Leask et al., 2004) as well as inflammatory mediators like TNF-α 
(Sullivan et al., 2009). Once released from LAP, TGF-β can act in an autocrine or 
paracrine manner. 
 
Figure 1-7: Schematic diagram of the biosynthesis of transforming growth factor-β (TGF-β). 
LAP, latency-associated peptide. Adapted from (ten Dijke et al., 2007). 
 
1.7.2. TGF-β signaling 
The TGF-β family members signal through a heteromeric complex of 
transmembrane type I and type II serine/threonine receptors (Heldin et al., 1997; 
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Derynck et al., 2003; ten Dijke et al., 2004; Massague et al., 2005). In humans, 
seven type I receptors (also known as Activin receptor like kinases, ALK1-ALK7) and 
five type II receptors have been identified, which are generally considered to exist as 
homodimers (Derynck et al., 2003). The type I receptor is characterized by a highly 
conserved GS domain containing a repetitive glycine serine motif between the 
transmembrane and kinase domains (Rosenzweig et al., 1995). 
The TGF-β signaling is initiated by binding of the active TGF-β molecule to 
the TGF-β type II receptor (TβR-II), which induces recruitment of TβR-I forming a 
heterotetrameric complex (Fig.1-8). The constitutively active TβR-II phosphorylates 
TβR-I on serine residues within its GS domain causing activation of type I receptors 
(Fig.1-8) (de Caestecker, 2004). Intracellular signalling of TGF-β is primarily 
mediated through the Smad pathway although a number of non-Smad signaling 
pathways have also been demonstrated (Derynck et al., 2003; Shi et al., 2003). 
Smads are intracellular proteins, which play a fundamental role in the transduction of 
receptor signals to specific target genes in the nucleus. Eight Smad homologs have 
been identified in humans (Smad 1-8) (Heldin et al., 1997), constituting three 
functional classes: the receptor-regulated Smads (R-Smad), comediator Smads (Co-
Smad) and inhibitory Smads (I-Smad). The binding of type I receptor to the Smad 
2/3 proteins is facilitated by the Smad anchor for receptor activation protein (SARA) 
(Attisano et al., 2000). R-Smads (Smads1, 2, 3, 5 and 8) are directly phosphorylated 
and activated by the type I receptor kinases. Phosphorylated R-Smads in turn form 
heteromeric complexes with the Co-Smad, Smad4. These complexes translocate to 
the nucleus where they bind to DNA and regulate the transcription of target genes, 
either alone or in association with other nuclear cofactors (Massague, 2000). The I-
Smads (Smad 6 and 7) prevent TGF-β signaling by competing with R-Smads for 
binding to activated type I receptors or Co-Smad interaction, thereby inhibiting R-
Smad phosphorylation (Shi et al., 2003). Among the R-Smads, Smad2 and Smad3 
are substrates for TGF-β type I receptors and mediate both TGF-β and activin 
signals, whereas Smad 1, 5 and 8 are BMP receptors substrates and mediate BMP 
signals (Attisano et al., 1998). The R-Smads and Co-Smad contain two conserved 
domains, termed mad homology (MH) domains 1 and 2 (Shi et al., 1997; Shi et al., 
1998). With the exception of Smad2, the MH1 domain is responsible for DNA 
binding, whereas MH2 domain mediates protein-protein interactions with Co-Smads 
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and with TβRI receptor, and is involved in the transcriptional activation (Lebrin et al., 
2005).  
The specificity of biological responses is defined by the type I receptor, which 
targets particular Smad proteins and thereby initiates distinct intracellular signaling 
cascades (Massague, 1998; Attisano et al., 2002). ALK1, ALK2, ALK3 and ALK6 
mediated phosphorylation of Smad1, Smad5 and Smad8, whereas ALK4, ALK5 and 
ALK7 phosphorylate Smad2 and Smad3. ALK5 is the main TβR-1 that mediates the 
majority of cellular responses to the three TGF-β isoforms (Massague, 1998; 
Massague et al., 2000a), meaning that their major pathway go through 
phosphorylation and dimerization of Smad 2/3. However, in endothelial cells, it has 
been reported that TGF-β can also signal through ALK1 and subsequent activation 
of the Smad 1/5/8 signaling cascade (Oh et al., 2000; Goumans et al., 2003)  
 
Figure 1-8: Schematic diagram of transforming growth factor–β (TGF-β) signal transduction. 
R-Smads in the cytoplasm (1) are recruited to the TGF-β receptors (TβRs; 1), where they 
are phosphorylated (P; 3). A complex of SMAD2 and/or SMAD3 with the common Smad, 
Smad4, is formed (4), which is subsequently translocated to the nucleus, where it regulates 
gene transcription (5). SARA, Smad anchor for receptor activation. Taken from (Schnaper et 
al., 2003). 
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1.8. Role of ET-1 in lung disease 
As mentioned previously, ET-1 appears to be implicated in the pathogenesis 
of several lung diseases, including pulmonary fibrosis, pulmonary hypertension and 
fibrotic remodeling processes associated with chronic inflammatory and obstructive 
airway diseases such as bronchial asthma and COPD. 
 
1.8.1. Pulmonary fibrosis 
Pulmonary fibrosis is a recognized feature of various chronic lung diseases, 
and is central to the pathogenesis of idiopathic pulmonary fibrosis (IPF), a disease of 
unknown aetiology. It is characterized by excessive proliferation of fibroblasts, 
excessive deposition of ECM proteins, increase in collagen content of the lung, the 
presence of distinct accumulations of mesenchymal cells in ‘fibroblastic foci’ 
(fibroblasts and myofibroblasts) and alteration of the architecture of the lung resulting 
in loss of lung function and, eventually, respiratory failure. IPF is thought to be a 
consequence of abnormal wound healing resulting in progressive scarification 
(Selman et al., 2001; Thannickal et al., 2004). Various cell types are involved in the 
pathogenesis of pulmonary fibrosis, including fibroblasts, epithelial cells and smooth 
muscle cells. Accumulating evidence suggests that ET-1 is a potentially essential 
contributor in the pathobiology of fibrosing disorders, including those that affect the 
lung. In vitro data show that ET-1 promotes pulmonary fibroblasts proliferation 
(Peacock et al., 1992; Shahar et al., 1999; Gallelli et al., 2005) and differentiation 
into myofibroblasts through the ET-A receptor (Shahar et al., 1999; Shi-Wen et al., 
2004) as well as it promotes myofibroblasts resistance to apoptosis (Horowitz et al., 
2012). ET-1 also affects production and degradation of matrix by promoting ECM 
proteins synthesis, inhibiting matrix metalloproteinase-1 expression and promoting 
matrix remodelling (Xu et al., 1998; Xu et al., 2004; Abraham, 2008). ET-1 displays 
also strong mitogen activity for endothelial cells and vascular smooth muscle cells 
(Komuro et al., 1988; Pedram et al., 1997). Additionally, ET-1 has also been 
described to promote alveolar epithelial cells transition into fibroblast-like cells, 
fibrotic mesenchymal cells (epithelial mesenchymal transition, EMT) (Jain et al., 
2007). Spontaneous increase of ET-1 secretion has been reported by alveolar 
macrophages recovered from the bronchoalveolar lavage (BAL) of patients with 
idiopathic pulmonary fibrosis (IPF) (Shahar et al., 1999). The alveolar-associated 
fibroblasts from patients with IPF show increased expression of α-SMA and 
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increased ET-1-induced contraction (Fireman et al., 2001). Moreover, patients with 
idiopathic pulmonary fibrosis have elevated levels of ET-1 in both their plasma and 
bronchoalveolar lavage fluid (Uguccioni et al., 1995; Reichenberger et al., 2001). 
The increased levels of circulating ET-1 in patients with lung fibrosis is correlated 
with the severity of the disease, and is paralleled by an increase in ET-1 synthesis in 
vivo (Abraham et al., 1997). An increased expression of ECE-1 and co-localised with 
ET-1 and big ET-1 has also been reported in patient with IPF, and is significantly 
correlated with disease severity (Saleh et al., 1997). In an experimental model of 
pulmonary fibrosis induced by bleomycin, levels of ET-1 and ECE are increased 
(Park et al., 1997; Mutsaers et al., 1998) as well as expression of ET receptors 
(Wendel et al., 2004). The elevation in the ET-1 level in the lung occurred before the 
increase in collagen content and was localized within developing fibrotic lesions 
(Mutsaers et al., 1998). Inhibition of ET receptors with bosentan, a non selective ET 
receptor antagonist, reduced bleomycin-induced pulmonary fibrosis (Park et al., 
1997). Additionally, transgenic mice overexpressing ET-1 spontaneously developed 
lung fibrosis associated with the accumulation of inflammatory cells, primarily CD4+ 
cells (Hocher et al., 2000). The overexpression of ET-1 directly in the lungs of mice 
initiated a fibrogenic response characterized by elevated ECM deposition and 
myofibroblast formation (Lagares et al., 2012). Numerous cytokines have been 
implicated in the pathogenesis of lung fibrosis, however TGF-β is the most profibrotic 
mediator characterized to date and is thought to have a central role in various 
remodeling diseases, including pulmonary fibrosis (Khalil et al., 1996; Coker et al., 
1997; Thannickal et al., 2004). In both normal and fibrotic fibroblasts, TGF-β 
promotes ET-1 release, which in turn drives production of matrix protein and ECM 
contraction (Shi-wen et al., 2007). Furthermore, in ET-1 dependent manner, TGF-β 
induced the expression of profibrotic genes, including type-I collagen, fibronectin and 
CCN2 and to contract a collagen gel matrix in human lung fibroblasts (Shi-wen et al., 
2007). TGF-β and ET-1 can induce resistance to apoptosis in lung fibroblasts 
through the pro-survival PI3/AKT signalling pathway (Kulasekaran et al., 2009). 
Additionally, ET-1 enhanced TGF-β synthesis and initiation of EMT was attenuated 
by a TGF-β-neutralising antibody, demonstrating that ET-1 is an essential mediator 
of EMT in alveolar epithelial cells, probably acting through ET-A-mediated TGF-β 
production (Jain et al., 2007).  
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1.8.2. Bronchial asthma 
Asthma is a chronic inflammatory airway disease characterized by bronchial 
inflammation and airflow limitation that result in recurrent episodes of cough, wheeze 
and shortness of breath. Various cell types play a role in this chronic disease, in 
particular, CD4+ T lymphocytes, esinophils and mast cells (Jeffery, 2001), and their 
mediators, especially TGF-β, IL-4, IL-5, IL-13, IL-17, leukotrienes , platelet-derived 
growth factor (PDGF) and granulocyte macrophage-colony stimulating factor (GM–
CSF) (Busse et al., 2001). Airway limitations in asthma is recurrent and caused by a 
variety of changes in the airways, these include bronchoconstriction and 
hyperreactivity with influx of inflammatory cells, mucus production, oedema, and 
structural alteration in the airways (airway remodling). It is well known that ET-1 has 
a number of activities that may contribute to each of these processes (Hay, 1999). 
ET-1 causes immediate bronchoconstriction in asthmatic patients (Redington et al., 
1995; Chalmers et al., 1997), it also stimulates mucus secretion, airway oedema, 
smooth muscle mitogenesis, and bronchial hyperresponsiveness (Hay, 1999). In 
addition, ET-1 has been reported to increase bronchial reactivity to inhaled antigens 
(Noguchi et al., 1995) as well as an influx of inflammatory cells (Landgraf et al., 
2008). It also enhances cytokine production (Chalmers et al., 1999) and airway 
remodelling (Glassberg et al., 1994; Finsnes et al., 1998; Goldie, 1999). Airway 
remodeling is a major feature of asthma (Mauad et al., 2007), and is implicated in the 
accelerated and progressive loss of lung function observed in asthmatic subjects 
over time (Lange et al., 1998; Pascual et al., 2005). ET-1 may contribute significantly 
to the remodeling of the airway reported in asthmatic airways by slowing epithelial 
cell migration (Dosanjh et al., 2003), increasing production of ECM proteins and 
differentiation of fibroblasts into myofibroblasts as well as proliferation of airway 
fibroblasts and smooth muscle cells (Marini et al., 1996; Shahar et al., 1999; Xu et 
al., 2004).  
Elevated ET-1 levels have been detected in BAL (Mattoli et al., 1991; Redington et 
al., 1995) and bronchial biopsies of asthmatic patients (Redington et al., 1995). The 
levels of ET-1 in BAL fluid were declined after treatment of acute asthma 
exacerbations with glucocorticoids and β2-adrenergic agonists or phosphodiesterase 
inhibitors (Mattoli et al., 1991; Aoki et al., 1994; Chen et al., 1995). Moreover, ET-1 
immunoreactivity was found to be expressed at high levels in bronchial biopsy 
specimens of patients with asthma (Springall et al., 1991). An increase in ET-1 
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plasma concentration has also been reported in asthmatic patients and was related 
to the severity of asthma (Chen et al., 1995). The increase in ET-1 possibly reflects 
its increased local production from endothelial and/or other cells in the airways of 
asthmatic subjects. Airway inflammation also leads to increased ET-1 synthesis 
(Finsnes et al., 1998). Moreover, ET-1 may exert important pro-inflammatory effects 
in the airways, being both a chemoattractant and an up-regulator of other 
inflammatory mediators such as the interleukins IL-6 and IL-8, and granulocyte-
macrophage colony stimulating factor (GM-CSF) (Mullol et al., 1996). ET-1 also acts 
as a co-mitogen with a number of growth factors and induces the expression of pro-
inflammatory and pro-fibrotic factors including TGF-β (Dubé et al., 2000), TNF-α 
(Chanez et al., 1996) and fibronectin (Marini et al., 1996).  
Pro-inflammatory cytokines, such as TGF-β (Shi-Wen et al., 2006), interleukin (IL)-1 
(Yoshizumi et al., 1990) and TNF-α (Chanez et al., 1996) increase the expression of 
ET-1. There are several lines of evidence that these cytokines are implicated in the 
inflammatory response of asthma. Levels of TGF-β, TNF-α and IL-1 are elevated in 
BAL fluid from symptomatic subjects with asthma (Broide et al., 1992; Redington et 
al., 1997; Chaudhari et al., 2006). An increased expression of TGF-β and TNF-α has 
been reported in bronchial biopsies from asthmatic subjects with asthma compared 
with normal subjects (Bradding et al., 1994; Vignola et al., 1997). Accordingly, 
exposure of bronchial epithelial and/or other cells in the airways to these cytokines 
may account for the increased production and release of ET-1. It has been shown 
that the selective ET-A antagonist BQ-123 inhibited immediate and late phase 
asthmatic responses in guinea pigs (Uchida et al., 1996), and blocking of both ET 
receptors (ET-A and ET-B) additionally caused a reduction of airway inflammatory 
response in antigen-challenged animals (Finsnes et al., 1997; Fujitani et al., 1997), 
suggesting an essential pathophysiologic role for ET in the development of lung 
inflammation in asthma and highlighting the potential of ET antagonists for the 
treatment of this disease.  
 
1.8.3. Chronic obstructive pulmonary disease (COPD) 
COPD is a common multifactorial disease with a heterogeneous 
pathogenesis, and is defined according to the recently updated GOLD guidelines as 
a chronic lung disease characterized by airflow limitation that is not fully reversible. 
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The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response in the airways and the lungs to noxious particles and gases. 
The characteristic symptoms of COPD are breathlessness, chronic cough, wheezing 
and excessive mucus production. The disease is characterized by an accelerated 
decline in lung function, progressive impairment of physical performance and an 
increased quality of life impairment (Godtfredsen et al., 2008).  
Pathologic changes feature of COPD are found at different levels and compartments 
in the lungs of COPD patients: peripheral airways, proximal airways, lung 
parenchyma and pulmonary vasculature (Barnes, 2000b; Saetta et al., 2001). These 
changes are present to differently extend in the affected individual. Cigarette 
smoking is by far the most important environmental risk factor for developing COPD, 
however there are many other risk factors including, gene/environment interactions, 
respiratory infections, occupational exposure and lung growth that may contribute 
separately or in combination to the development of COPD (Snider, 1989; Barnes, 
2000a; Yoshida et al., 2007). COPD is the greatest risk factor for lung cancer among 
smokers and is found in 50–90% of patients with lung cancer (Young et al., 2009). 
The cellular inflammatory response in COPD is characterized by an increase in 
macrophages, neutrophils and CD8+ lymphocytes in different parts of the lung (Di 
Stefano et al., 1998; Pesci et al., 1998; Saetta et al., 2001; Hogg et al., 2004). In 
addition, elevated bronchial deposition of ECM components including collagens and 
fibronectin have also been reported in patient with COPD (Kranenburg et al., 2006) 
and may contribute to the decline in lung function and airway remodelling. The 
inflammatory mediators involved in COPD are less well defined than those in 
asthma, however significantly elevated levels of leukotriene B4 (chemotactic for 
neutrophils, LTB4), IL-6, IL-8, TNF-α and TGF-β have been reported in the sputum 
of patients with COPD (Keatings et al., 1996; Crooks et al., 2000; Bergeron et al., 
2006; Perera et al., 2007). 
Several studies demonstrated that ET-1 plays an important role in the 
pathophysiological features of COPD including, mucus secretion stimulation, airway 
oedema, smooth muscle mitogenesis, and bronchial hyperresponsiviness, as well as 
ET-1 has also essential proinflammatory effects in the airways (Mullol et al., 1996; 
Hay, 1999). Sputum and bronchoalveolar lavage ET-1 levels significantly increase 
during exacerbation of COPD (Roland et al., 2001; Bacakoglu et al., 2003) and this 
increase in sputum ET-1 levels correlated with the elevation in plasma ET-1 levels 
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and sputum IL-6 levels (Roland et al., 2001; Trakada et al., 2001; Spiropoulos et al., 
2003).  
 
1.8.4. Pulmonary hypertension 
Pulmonary hypertension (PH) is a progressive and fatal disease, 
characterized by vasoconstriction, pulmonary vascular proliferation and remodeling 
associated with raised pulmonary arterial pressure leading to right ventricular failure 
(Humbert et al., 2004; Pietra et al., 2004; McLaughlin et al., 2009).  
ET-1 serum level is elevated in patients with pulmonary hypertension, and 
associated with the disease severity and prognosis (Allen et al., 1993; Rubens et al., 
2001). In addition, ET-1 clearance in the pulmonary vasculature is decreased in PAH 
(Stewart et al., 1991). This phenomenon may represent increased ET-1 production 
and/or reduced clearance by the lung. Furthermore, pulmonary vascular remodeling 
caused by hyperproliferation of fibroblasts and smooth muscle cells as well as 
endothelial cells within the pulmonary arterial wall is considered to be one of 
numerous essential pathophysiologic mechanisms involved in PAH (Humbert et al., 
2004; McLaughlin et al., 2009). These cellular processes are associated with over-
expression of the vasoconstrictor ET-1 along with a reduction in the vasodilators 
such as nitric oxide and prostacyclin (Rubin et al., 2002; Budhiraja et al., 2004; 
Humbert et al., 2004; Racké et al., 2014). Accordingly, and as mentioned previously 
the potential role of ET receptors in these cellular events, ET receptor antagonists  
may represent a major advance in the treatment of this disease. 
 
1.9. Aims of the study 
ET-1, in addition to its role as vasoconstrictor, also appears to contribute to 
inflammation and fibrosis during various pathological processes. There is 
accumulating evidence that ET is involved in the pathogenesis of several lung 
diseases like pulmonary hypertension, lung fibrosis and fibrotic remodeling 
processes associated with chronic inflammatory and obstructive airway diseases 
such as bronchial asthma and COPD.  
The lung fibroblasts are connective tissue cells that play an essential role in 
remodling processes, as a long-term consequence of chronic respiratory diseases. 
They are the main cells responsible for the synthesis, deposition and remodeling of 
ECM. Through an increase of proliferation, migration into connective tissues and 
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synthesis of the ECM components, pulmonary fibroblasts significantly participate in 
airway remodling processes. Hyper-activation of pulmonary fibroblasts as a result of 
inadequate control of inflammation, which occurs in chronic respiratory diseases, 
leads to excessive connective tissue formation, and thereby could contribute to 
airway fibrosis. The mechanisms underlying the pathophysiology of fibrosis are 
poorly understood and there are currently no satisfactory therapeutic options 
available to reverse or prevent excessive fibrosis.  
Although there are several reports describing pro-fibrotic effects of ET-1 in rat and 
human pulmonary fibroblasts, a detailed analysis of the expression of ET isoforms 
and ET receptors and their potential regulation in human pulmonary fibroblasts as 
well as a detailed pharmacological characterization of their functions are still missing. 
Therefore, in the present study, human lung fibroblasts were used as in vitro cell 
model to study whether and to what extent the increased activity of the 
endothelinergic system might be involved in structural remodelling processes in the 
context of chronic inflammatory and obstructive airway diseases, including cellular 
proliferation, differentiation and collagen synthesis, and whether the use of ET 
receptor antagonists could have beneficial effects on these processes. For this 
purpose, the following approaches were performed: 
1- To determinate the expression pattern and release of ET isoforms and the 
expression of ET receptors in human lung fibroblasts. 
2- To investigate the molecular mechanisms regulating expression and release 
of ET-1 and its functional significance. 
3- To explore the potential effects of TGF-β on the expression and release of ET 
isoforms and the expression of ET receptors in human lung fibroblasts.  
4- To investigate whether the expression of ET-1 in human lung fibroblasts is 
regulated by muscarinic and/or β-adrenergic mechanisms, and if so, to 
elucidate the intracellular signaling pathways entailed. In addition, possible 
functional consequences of an altered ET-1 expression were explored. 
5- To investigate whether human lung fibroblasts proliferation and differentiation 
into myfibroblasts are regulated by endothelinergic mechanisms and if so, to 
elucidate the intracellular signaling pathways entailed. 
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6- To investigate whether endothelinergic mechanisms are involved in the 
regulation of collagen synthesis in human lung fibroblasts and if so, which 
intracellular signaling pathways are involved. 
  Materials and Methods 
39 
 
2. Materials and methods 
2.1. Materials 
2.1.1. Chemicals  
Acetic acid       Merck, Germany 
Boric acid        Roth, Germany 
Bovines serum albumin (BSA)    Bio-Rad, Germany  
Calcium chloride       Merck, Germany 
Chemiluminescence blotting substrate (POD)   Bio-Rad, Germany 
Developing solution Adefo-Chemie GmbH,  
(Entwicklerkonzentrat T-Matic) Germany 
Dimethylsulfoxid (DMSO)      Merck, Germany 
Disodium hydrogen orthophosphate (Na2HPO4)  Merck, Germany  
Dried milk powder, fat free     Heirler, Germany 
Ethanol, absolut       Merck, Germany 
Ethylene diamine tetraacetic acid (EDTA)  Sigma-Aldrich 
Fixing solution (Fixierkonzentrat T-Matic)   Adefo-Chemie GmbH, 
Germany      
Fetal Calf Serum (FCS)      Biochrom, Germany  
Glycin        Roth, Germany 
Hydrochloric acid 32% (conc. HCl)    Merck, Germany 
Kaleidoscope Marker Sigma-Aldrich, Germany  
Leupeptin    Sigma-Aldrich, Germany  
Lumasafe plus scintillation liquid     Lumac LSC,Netherland 
Magnesium chloride hexahydrate (MgCl2 x 6 H2O)  Merck, Germany 
Non Essential Amino Acids (100 x)    PAA, Germany  
β-Mercaptoethanol       Sigma-Aldrich, Germany  
Methanol        Roth, Germany 
MOPS SDS running-buffer (20x)     Invitrogen, Germany 
Nonidet P-40       Sigma-Aldrich, Germany  
Penicillin/Streptomycin solution    Sigma-Aldrich, Germany 
(10000 U/ml, 10 mg/ml) 
Pepstatin A        Sigma-Aldrich, Germany 
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Phenylmethylsulphonylfluoride (PMSF)    Sigma-Aldrich, Germany  
phosphoric acid 85% (H3PO4)     Roth, Germany 
Ponceau S        Sigma-Aldrich  
Potassium chloride (KCl)     Merck, Germany 
Potassium dihydrogenphosphate (KH2PO4)   Merck, Germany  
Roti-Load 1        Roth, Germany  
Sodium chloride (NaCl)      Roth, Germany  
Sodium deoxycholate      Sigma-Aldrich, Germany 
Sodium dodecyl sulfate (SDS)     Sigma-Aldrich, Germany 
Sodium fluoride (NaF)     Merck, Germany 
Sodium hydroxide pellets (NaOH)    Merck, Germany  
Sodium orthovanadate (Na3VO4)    Sigma-Aldrich, Germany 
Sodium pyrovate solution (SPS) 100mM   PAA, Germany  
Sulfanilamide       Merck, Germany 
Sulfuric acid 95% (conc. H2SO4)     Merck, Germany 
Trichloro-acetic acid crystals (TCA)    Merck, Germany  
Tris-(hydroxymethyl)-aminomethane (Tris)   Roth, Germany 
Tris-(hydroxymethyl)-aminomethane-    Boehringer Ingelheim,  
hydrochloride (Tris HCl)     Germany 
Triton X-100        Boehringer Ingelheim,  
Germany 
Trypsin-EDTA solution (10x)    Sigma-Aldrich, Germany 
Trypthan blue stain (0.4 %)     Sigma-Aldrich, Germany  
Tween 20        Sigma-Aldrich, Germany 
 
2.1.2. Radio-active chemicals 
[3H]-Proline (specific activity = 1.813 TBq/mmol)  Perkin Elmer, USA 
[3H]-Thymidine (specific activity = 37 MBq/ml)  Perkin Elmer, USA 
 
2.1.3. Markers and Nucleotides  
Kaleidoscope Marker proteins    Bio-Rad, Germany 
Oligonucleotide (dT)18 primer Eurofins MWG Operon,    
Germany  




DNase (RNase free DNase Set)     Qiagen, Germany 
Omniscript reverse transcriptase     Qiagen, Germany 
RNase Inhibitor RNasin Plus (40 U/μl)    Fermentas, Germany  
 
2.1.5. Kits for molecular biology 
BM Chemiluminescence Blotting Substrate (POD)  Roche, Germany 
DC (Detergent compatible) Protein assay kit   Bio-Rad, Germany 
ELISA kits        Stressgen, Enzo Life 
Sciences, Germany  
RNeasy Mini Kit       Qiagen, Germany  
Omniscript RT Kit       Qiagen, Germany 
NucleoSpin® RNA II kit      Macherey-Nagel 
QuantiTect® SYBR® Green PCR     Qiagen, Germany 
QuickZyme Soluble Collagen Assay kit  QuickZyme 
BioSciences, Netherlad 
 
2.1.6. Culture medium 
Minimal Essential Medium Eagle (MEM)   PAA, Germany 
with Earle’s Salt and L-glutamine 
 
2.1.7. Test substances 
Actinomycin (30 μM)     Sigma-Aldrich, Germany 
Stock solution prepared in methanol 
 
Big-endothelin (1 nM-100 nM)    Bachem, Germany 
Stock solution prepared in sterile water       
6-Bnz-cAMP (500 µM)     Biolog life science,Germany 
PKA agonist: N6-benzyladenosine-30,50-phosphate 
Stock solution prepared in sterile water 
Bosentan (10 µM)      Actelion, Germany 
Stock solution prepared in preheated sterile water 
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BQ-123 (1 μM)      Bachem, Switzerland 
Selective ET-A antagonist: Cyclo (D-Trp-D-Asp-Pro-D-Val-Leu) 
Stock solution prepared in sterile water 
BQ-788 (0.1 μM)      Bachem, Switzerland 
N-cis-2,6-dimethylpiperidinocarbonyl-β-tBu-Ala-D-Trp(1-methoxycarbonyl)-D-Nle-OH 
Selective ET-B antagonist: Cyclo (D-Trp-D-Asp-Pro-D-Val-Leu) 
Stock solution prepared in DMSO 
8-CPT-2`-O-Me-cAMP (100 µM)    Biolog life science,Germany  
Epac agonist: 8-(4-chloropheylthio)-20-O-methylaldenosine-cAMP 
Stock solution prepared in sterile water 
Cycloheximide (30 μM)     Sigma-Aldrich, Germany 
Stock solution prepared in DMSO 
CGP 20712 (3 µM)      Biozol, Germany  
1-[2-((3-carbamoyl- 4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl- 
2-imidazolyl)phenoxy]-2-propanol dihydrochloride 
Stock solution prepared in sterile water 
Enodthelin-1 (0.1-100 nM)     Actelion, Germany 
Stock solution prepared in sterile water 
ICI 118,551 (1 µM)      Biozol, Germany 
(±)-1-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino] 2-
butanolhydrochloride  
Stock solution prepared in sterile water 
Olodaterol (1-10 nM)    Boehringer Ingelheim, Germany 
Stock solution prepared in sterile water 
Oxotremorine M (10 µM)     Sigma-Aldrich, Germany 
Stock solution prepared in sterile water 
PD 98059 (10-30 µM)     Sigma-Aldrich, Germany 
Stock solution prepared in DMSO 
Pertussis toxin (50-100 ng/ml)    Sigma-Aldrich, Germany 
Stock solution prepared in sterile water 
TGF-β human recombinant (0.1-5 ng/ml)  Sigma-Aldrich, Germany 
Stock solution prepared in sterile 0.1% BSA in 4 mM HCl, further dilutions were done 
with sterile culture media 
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Tiotropium bromide monohydrate (100 nM)  Boehringer Ingelheim, Germany  
Stock solution prepared in sterile water 
SIS3 (10 µM)      Calbiochem, Germany 
Smad3 inhibitor: (6,7-dimethoxy-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b] 
pyridine-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline. 
Stock solution prepared in sterile water 
Y-27632 (1-10 µM)      Tocris, Germany 
Rho kinase inhibitor: trans-4-[(1R)-1-aminoethyl]-N-(4-pyridinyl) 
cyclohexanecarboxamide dihydrocholiride. 
Stock solution prepared in sterile water 
 
2.1.8. Antibodies  
2.1.8.1. Primary antibody 
The following primary antibodies were utilized for Western blot analysis. 
Antibody Origin Dilution Supplier 
ET-A receptor Rabbit polyclonal antibody 1:200 Santa Cruz 
Biotechnology 







α-Tubulin Mouse monoclonal 
antibody 
1:1000 Cedar Lane 
p42/44 Rabbit polyclonal antibody 1:1000 Cell Signaling 
Technology 
ERK 2 Rabbit polyclonal antibody 1:500 Santa Cruz 
Biotechnology 
 
2.1.8.2. Secondary antibody 
The following secondary antibodies are conjugated with horseradish peroxydase 
(HRP) and used for Western blot analysis. 
Antibody Origin Dilution Supplier 
Anti-mouse 
Ig 
Goat, HRP linked polyclonal 
antibody 
1:5000 Santa Cruz 
Biotechnology 
Anti-rabbit Ig  Goat, HRP linked polyclonal 
antibody 
1:2667 Bio Rad 
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2.1.9. Equipment  
Analytical balance BP221 D, 2258    Sartorius, Netherland 
Autoclav 80230       Webeco, Germany 
CASY® Cell counter and Analyzer system  Innovatis, Germany 
Cell culture incubator, HeraCell 150   Heraeus, Germany  
Centrifuges: 54115 C, 5804 R cooled centrifuge Eppendorf, Germany  
Mini-centrifuge MCF 2360     LMS, USA 
Electrophoresis- and blotting chamber: NuPAGE Invitrogen,Germany 
Electrophoresis power supply    Bio Rad, Germany 
Film processor, CP100     Agfa, Germany 
Fluorescence Microplate Reader Fluorometer   Fluostar OPTIMA, BMG,  
Germany 
Hyperfilm ECL      Amersham, USA 
Laminar air flow, HeraSafe     Heraeus, Germany  
Liquid scintillation Analyzer, Tri-Carb2100 TR  Packard, Germany 
Microscope IMT2-RFL     Olympus, Germany 
Mycycler Thermal Cycler System     Bio-Rad, Germany  
Neubauer counting chamber    Labomedic, Germany  
4-12% Nu PAGE® Bis-Tris Gel     Invitrogen, Germany 
PH-Electrode SenTix 81      WTW GmbH, Germany 
PH-Meter inoLab 1       WTW GmbH, Germany 
PVDF Blotting membrane     Millipore, Germany 
Real time PCR machine, MAX3000P   Stratagene, USA 
Multiplex Quantitative PCR System 
Spectophotometer, SmartspecTM plus   Bio Rad, Germany 
Therommixer compact     Eppendorf, Germany 
2.1.10. Tools for statistical analysis  
 GraphPad Software  
Graph Pad Prism 5 software was used for performing biostatistics, graph fittings 
and scientific graphing. All values are presented as means ± standard error of the 
mean (SEM) of n experiments. The Student’s t-test was performed to compare two 
groups. Statistical significant of differences among more than two groups were 
evaluated by ANOVA (analysis of variance) followed by Dunnet’s or Bonferroni’s 
test. P value of < 0.05 was accepted as statistically significant. 




MxPro software was used for evaluation of real-time PCR 
 RFLPscan 2.01  
RFLPscan software was utilized for semiqauntitatively measured of optical 




2.2.1. Cell culture  
 Most of this work was carried out on MRC-5 human lung fibroblast cell line, 
but also on some experiments were carried out on primary human lung fibroblasts 
(phLFb). Both cell types (MRC-5 and phLFb) were grown in Minimum Essential 
Medium Eagle (MEM with Earle's Salts; PAA) supplemented with 2 mM L-glutamine, 
non-essential amino acids (NEAA), sodium pyruvate (SPS), penicillin and 
streptomycin and different amount of FCS (0-15%) depending on the experimental 
conditions. All cells were cultured in an incubator (Heraus, Heracell 150) with 
humidified air (95%) and CO2 (5%) at 37°C.  
 MRC-5 human lung fibroblast  
MRC-5 human lung fibroblast cell line was developed in 1966 from normal 
human lung tissue of an aborted 14 week old male fetus. MRC-5 cells, which grew 
adherently in culture and exhibit fibroblast morphology, they are capable of 42-46 
population doublings before the onset of senescence. American Type Culture 
Collection number ATCCL-171. 
 Primary human lung fibroblasts (phLFb) 
Cell culture of phLFb were established from histologically normal areas of 
surgically resected lung tissue, either central or peripheral region of the lung, which 
was obtained via thoracotomies from lung cancer patients. Tissue was stored until 
the culture in cold (4°C) 1x PBS. Under the laminar flow, about 4x6 cm piece of lung 
tissue was sliced into tiny pieces. The resulting  tissue pieces were then treated with 
pronase (1mg/ ml in fibroblast medium with 10% FCS) at 37oC for 30 minutes, 
thereafter washed twice with 1X BPS and were then placed in cell culture plates, and 
incubated in human fibroblast medium with 15% FCS. The first medium was 
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changed after 24 hours of incubation and then twice weekly. After two weeks, 
fibroblasts had grown out from the tissue, the slices were removed and the cells 
were allowed to reach confluence. Confluent cells (about 80-90% of confluency) 
were then passaged by trypsinization further and used for the experiments. The 
protocol for obtaining human tissue was approved by the local ethics review board 
for human studies (Ethics Committee, Medical Faculty, University of Bonn, Bonn, 
Germany), and informed consent was obtained from the patients. 
In addition, commercially available primary human lung fibroblasts from healthy 
Caucasian donors were purchased from PromoCell (Heidelberg, Germany). 
 
2.2.2. Culture of human lung fibroblasts 
The frozen cryo-preserved human lung fibroblast culture was thawed rapidly 
in a water bath at 37°C. Afterward, the cell suspension was transferred to 175 cm2 
culture flask which was pre-incubated in a humidified incubator at 37oC and 5% CO2 
previously for short time to equilibrate the FCS-containing medium (10% FCS). After 
24 hours of incubation the cells were seen to have attached to the flask and, to 
prevent cell damage, the medium was replaced with 10 ml of fresh 10% FCS culture 
medium to remove any residue from the cryoprotective agent DMSO. The cells were 
then allowed to grow and the culture medium was changed twice per week. After the 
cells reaching confluence, they could be seeded and passaged further. 
For cell passage and cultivation, culture medium was aspirated out from the culture 
flask and the cells were washed with pre-warmed (37°C) sterile 1X BPS. Then, pre-
warmed sterile 1X Trypsin/EDTA solution was added to cover the surface of the flask 
bottom and incubated for approximately 30-45 seconds. Trypsin is a proteolytic 
enzyme which helps in breaking cell-cell adhesion, thus facilitating the detachment of 
the adherent cells from the surface of the flask whereas EDTA is a chelator that 
binds divalent cations such as calcium and magnesium present between the cells 
allowing trypsin access to the cell-cell and cell-substrate bonds. The tyrpsin was then 
aspirated out and the detached cells were re-suspended in pre-warm medium 
containing 10% FCS. Thereafter, the cell suspensions were transferred into a sterile 
tube and centrifuged for 5 minutes at 1000 RMP. The supernatant was discarded 
and the cells pellet was resuspended in a known amount of 10% FCS medium. Cell 
count was carried out in a Neubauer counting chamber using 0.15% trypthan blue. 
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The counting chamber was filed with mixed solution of 1 part of cell suspension and 
4 parts of 0.15% trypthan blue (1:5) and the cells were counted under the 
microscope. The total number of the cells in whole suspension then can be 
determined by using chamber factor calculation. Required number of cells were 
seeded further in a 175 cm2 culture flask with medium containing 10% FCS or 
seeded into culture plates to continue cell culture experiments.  
To store cells for longer periods of time, cell pellets were resuspended in freezing 
medium in a ratio of 1:10 (1 part dimetyl sulphoxide, DMSO and 9 parts culture 
medium with 10% FCS) and transferred to cryogenic vials. The cryogenic vials were 
frozen to -80oC before being stored in liquid nitrogen (-196°C).  
Standard fibroblast culture medium  
Basismedium EARLE`S MEM (with L-Glutamine) 
FCS        0-15% (v/v)  
Penicillin/Streptomycin     100 U/ml / 100 μg/ml  
Non Essential Amino Acids = NEAA   1x  
Sodium Pyrovate Solution = SPS   1 mM 
Buffers and solutions for cell culture  
 10x PBS (Phosphate buffered saline) pH 7.4-7.5 
KCl        27 mM  
KH2PO4       15 mM  
NaCl        1.38 M  
Na2HPO4 x H2O      81 mM  
Distilled water  
 1x PBS-Buffer pH 7.4-7.5  
10x PBS 
1:10 dilution with distilled water 
 1x Trypsin-EDTA-solution  
10x Trypsin-EDTA      1:10  
dilution with1x sterile PBS-Buffer 
 0.15% Trypthan blue staining dye  
0.4% Trypthan Blue Stain     3:8  
dilution with 1x PBS-Buffer 
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2.2.3. Detection and analysis of RNA and cDNA 
2.2.3.1. RNA extraction  
Total RNA extraction was performed at room temperature by using either a 
RNeasy Mini kit provided by Qiagen along with an additional DNase digestion step to 
avoid any contamination by genomic DNA, or with NucleoSpin® RNA II kit provided 
by Macherey-Nagel, according to the manufacturer’s instructions.  
Both procedures (RNeasy and NucleoSpin® RNA II) for RNA purification combine the 
selective binding characteristics of a silica based membrane with the speed of 
microspin technology. A specialized high salt buffer system assists the binding of 
RNA to the silica based membrane.  
0.2 - 0.5 Mio fibroblasts were seeded in a 35 mm cell culture dishes or 6 well culture 
plates, and 2 ml culture medium was added. Depending on the protocol, the cells 
were incubated in presence or absence of test substances. At the end of incubation 
period, the medium was aspirated out and the cells were lysed by addition of 350 μl 
RLT (Qiagen) or 350 μl RA1 (Macherey-Nagel) lysis buffer that was previously 
treated with β-mercaptoethanol 1:100. The cells lysate was homogenized by 
centrifugation with the QIA shredder (Qiagen), or with the NucleoSpin filter 
(Macherey-Nagel), for 2 minutes at speed of 13000 RPM at room temperature and 
the filtrate was collected in collection tube (2 ml). Ethanol (70%) was then added to 
the homogenized lysate and mixed thoroughly by pipetting to provide appropriate 
binding conditions, thereafter the sample was applied to an RNeasy spin column 
(Qiagen) or NucleoSpin column (Macherey-Nagel), centrifuged at 10000 RPM for 30 
seconds. The flow-through was discarded and the spin column was placed on a new 
collection tube. The wash buffer RW1 (700 μl, Qiagen) or the membrane desalting 
buffer (350 μl MDB, Macherey-Nagel) was added on the spin column and centrifuged 
for 30 seconds at 10000 RPM. The flow-through was discarded and the spin column 
was placed on a new collection tube. In order to remove possible genomic DNA 
contamination and to enhance PCR quality, an additional DNase treatment step was 
performed by adding 80μl DNase (10 μl DNase + 70 μl RDD buffer, Qiagen),or 95 μl 
DNase (10μl DNase + 90 μl reaction buffer for rDNase, Macherey-Nagel) directly 
onto the spin column and incubating it at room temperature for 15 minutes. After 
incubation, 500 μl RPE buffer (Qiagen) or 200 μl of RA2 buffer (Macherey-Nagel) 
was added on the spin column and centrifuged at 10000 RPM for 30 seconds. The 
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RPE (Qiagen) or RA2 (Macherey-Nagel) buffer wash step was repeated with an 
extended centrifugation time of 2 minutes. The flow-through was discarded and the 
spin column was spun dry at 10000 RPM for 30 seconds. The spin column was then 
transferred onto a new collection tube for the elution, which was done by adding 30-
40μl of RNase free water on the spin column and centrifuged at 10000 RPM for 1 
minute. To obtain a higher total RNA concentration, the elution step may be 
repeated. The RNA sample preparation was stored at -80oC. 
Each step of the RNA extraction and purification were carried out with RNase free 
material and solutions to prevent RNA degradation and to get a high quality of RNA 
preparation. 
 
2.2.3.2. Determination of RNA concentration 
The concentration of RNA in the collected samples was determined photometrically 
by measuring the absorption at wavelenght of 260 nm. In addition, the absorption of 
blank was measured at wavelenght of 280nm. The ratio of the absorbance at 260 nm 
to the blank absorbance at 280 nm gives an estimate of the purity of each RNA 
preparation. The determination was carried out with the SmartSpecTMPlus 
photometer (BioRad), using quartz cuvettes for measurement. Firstly, the 
photometer was calibrated with the solvent (RNase-free water) and the samples 
were then measured in a 1:40 or 1:20 dilution. The RNA concentration was 
calculated from the absorbance at 260 nm, the dilution factor and a multiplication 
factor for RNA which is 40. Since 40 µg / ml RNA exhibits an absorbance value of 1 
at a wave length of 260 nm.  
(A260 nm x 40 x Dilution Factor = RNA concentration in μg/ml) 
2.2.3.3. Reverse transcription  
 Reverse transcription is the process by which complementary DNA (cDNA) is 
synthesized from an RNA template by means of the enzyme reverse transcriptase. 
For this purpose, Omniscript Reverse Transcriptase enzyme was used (Qiagen). 
For the reaction, an amount equivalent to 1 μg of total RNA was employed as a 
starting template, making up the volume to 12.5 μl with RNase free water. The RT-
Master mix containing 5 mM dNTP-Mix, 1 μM Oligo (dT) 18 primer, 0.25 U RNase 
inhibitor and 4 U omniscript reverse transcriptase was added to the probe making up 
volume to 20 μl/probe. The probes were then incubated at 37oC for 1 hr followed by 
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5 minutes at 93oC, and quickly chilled on ice. Following which the probes were briefly 
centrifuged and 80 μl of bidest water was then added per probe. The synthesized 
cDNA were stored at -20oC until further used as the template for the real time PCR 
reaction. 
To prevent RNA degradation care was taken by using RNase free material and all 
reaction steps were performed on the ice.  
RT-Master-Mix  
Reagents        Volume per probe  
10x RT-buffer         2 μl  
1 μM Oligo (dT) 18 primer       2 μl  
5 mM dNTP-Mix         2 μl  
10 U/μl RNase inhibitor       0.5 μl  
(40 U/μl RNase inhibitor RNasin Plus 1:4 dilution with 1x RT-buffer) 
Omniscript reverse transcriptase       1 μl  
Total volume         7.5μl 
 
2.2.3.4. Real-time PCR  
Real time polymerase chain reaction is a quantitative PCR (qPCR), an in vitro 
method used to amplify and simultaneously quantify messenger RNA (mRNA). The 
result obtained by qPCR is sensitive, quantitative, accurate and reliable, wherein 
data are collected throughout the PCR process as it occurs (in real time), thus 
combining amplification and detection into a single step. 
In principle in qRT-PCR syber green binds to all double-stranded DNA during PCR, 
causing a fluorescent signal. Determining the quantity of a product is carried out 
indirectly by the measurement of a fluorescent dye, the signal intensity is 
proportional to the amount of DNA. The quantification is done in the exponential 
phase of the PCR, as only in this stage, the PCR efficiency is constant (Pfaffl, 2001). 
At the exponential phase, the Ct value (Threshold Cycle) is used to calculate the 
experimental results, at which the fluorescent intensity is significantly above the 
background fluorescence signal. In addition, because knowing of the PCR efficiency 
is critical to accurate data interpretation, PCR efficiency was determined for all 
primers that were used. Under optimal condition, the PCR efficiency (E) reached E = 
2 (100%), in which the amount of PCR product doubles during each cycle. The slope 
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of a standard curve provides an indication of the efficiency of real time PCR. For this 
purpose, various dilution of known concentration cDNA is measured (1:3 to 1:300) 
and the Ct values were then plotted against the logarithm of the relative 
concentration. From the linear regression slope, the PCR efficiency can be 
determined and this may differ only by 10% from optimal efficiency (slope values 
correlate to amplification efficiencies between 90% (1.9) and 110% (2.1)). In order to 
quantify the relative expression of a target gene, an internal standard is required for 
normalization (Vandesompele et al., 2002), which used to compensate for any 
difference in concentration between the samples that occur in the analysis of cDNAs. 
The gene that was used as internal standard, whose expression is independent of 
cell type, cell stage and external influences (housekeeping genes). For this purpose 
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used. 
To avoid any contamination all the apparatus used were autoclaved and sterile 
pipette tips were used. For the real-time PCR, the cDNA was diluted 1:3 with RNase-
free water. 5 µl diluted cDNA was used as the template mixed with PCR Master Mix, 
making up the volume to 15 µl. The master mix containing 7.5 µl QuantiTect SYBR 
Green PCR Master Mix kit supplied from Qiagen, 0.45 µl sense primer, 0.45 µl 
antisense primer and 1.6 µl RNase-free water. All samples were run in triplicate for 
both target genes and housekeeping genes (GAPDH). The real-time PCR was 
carried out using the Mx3000P Multiplex Quantitative PCR System (Stratagene; 96-
well format) using the following specific primer combinations (based on human 
EMBL sequences):  
Primers for real time-PCRs 
Primer     Sequence  
ppET-1 sense   5′-TTATCAGCAGTTAGTGAGAGG-3′   
ppET-1 antisense    5′-GAAGGTCTGTCACCAATGTG-3′                    
ppET-2 sense   5′-TGAGGGACATTTCCACAGTCAAG-3′   
ppET-2 antisense   5′-CGGTTGCTCCTGGTTTGTAGC-3′   
ppET-3 sense   5′-TATCGGCCTGGTGTCTATAC-3′    
ppET-3 antisense   5′-AGTGGACTCCAAGCTAACTC-3′             
ET-A receptor sense  5′-GCTCTTTGCTGGTTCCCTGTT-3′            
ET-A receptor reverse  5′-GGTCATCAGACTTTTGGACTGG-3′              
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Primer     Sequence  
ET-B receptor sense   5′-TCTTTTGCCTGGTCCTTGTCT-3′             
ET-B receptor antisense  5′-GCAGTTTTTGAATCTTTTGCTCAC-3′  
Collagen I-α1 sense  5′-TGCTGGTCCCAAAGGTGCTGATG-3′  
Collagen I-α1 antisense  5′-GACCAGGCTCACCACGGTCT-3′       
GAPDH sense   5′-CTGCACCACCAACTGCTTAGC-3′      
GAPDH antisense   5′-GGCATGGACTGTGGTCATGAG-3′ 
The cycling conditions were 10 min polymerase activation at 95°C (activation of 
HotStarTaq® DNA Polymerase) and 35-45 cycles at 95°C for 30 sec (Denaturation), 
55-58°C (depending on the primers) for 30 sec (Annealing) and 72°C for 30 sec 
(Elongation). The threshold was automatically set by the software. Fluorescence 
data from each sample were analysed with the 2-[∆∆Ct] method: fold induction = 2-
[∆∆Ct], where ∆∆Ct = [Ct GI (unknown sample) - Ct GAPDH (unknown sample)] - [Ct 
GI (calibrator sample) - Ct GAPDH (calibrator sample)], GI is the gene of interest. 
Furthermore, ∆Ct = 35 was set as detection limit, and the fold expression over 
detection limit (235-∆Ct) was used as a measure of the expression levels. 
 
2.2.4. Enzyme linked immunosorbent assay (ELISA)  
The concentrations of ET-1 in cell culture supernatants were measured by 
ELISA using commercially available ELISA kits (Stressgen, Enzo Life Sciences 
GmbH, Lörrach, Germany). 
Enzyme linked immunesorbent assay (ELISA) also called enzyme immunoassay 
(EIA) is a biochemical technique used as analytic and diagnostic tools to detect the 
presence of antibodies or antigens in a sample. The basic principle of an ELISA is to 
use an enzyme to detect the binding of antigen (Ag) antibody (Ab). The enzyme 
converts a colorless substrate (chromogen) to a colored product, indicating the 
presence of Ag:Ab binding. An ELISA can be used to detect either the presence of 
Ags or Abs in a sample, depending on how the test is designed.  
MRC-5 cells were cultured for 24 h in presence of 10% FCS, followed by 48 h in 
presence of 1% FCS, and absence or presence of TGF-β. Thereafter, the medium 
was changed and cells incubated for a further 1 to 8 h. The supernatant were then 
collected for ET-1 determination by a highly sensitive (detection limit 0.41 pg·mL-1) 
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and specific cross-reactivity for ET-1 100%, ET-2 21%, ET-3 3.6%, human big-ET-1 
< 0.1%, using commercially available ELISA kit (Stressgen, Enzo Life Sciences 
GmbH, Lörrach, Germany). Preparations were performed according to the 
manufacturer’s instructions. The kit contains a polyclonal antibody for human ET-1 
and was immobilized on a microtiter plate to bind the ET-1 to the standards or 
samples. A recombinant human ET-1 protein was used as standard. After a short 
incubation the sample or standard with ET-1 antibody was washed out and a 
monoclonal antibody to human ET-1 labeled with the enzyme Horseradish 
peroxidase was then added. This labeled antibody binds to the human ET-1 
captured on the plate. After a short incubation the excess labeled antibody was 
washed out and MTB substrate solution was added. The substrate reacts with the 
labeled antibody bound to the human ET-1 captured on the plate. After a short 
incubation, the enzyme reaction was stopped and the color generated was read at 
450nm. The measured optical density was directly proportional to the concentration 
of human ET-1 in either standards or samples.  
Assay procedure  
All reagents of the kit were allowed to warm at room temperature for at least 30 
minutes prior to opening and all necessary buffers and solutions were prepared 
according to the manufacturer’s instructions. To ensure reproducibility of the results, 
on each ELISA plate all standard curve dilutions and samples were run in duplicate 
and results pooled.  
For the preparation, wash buffer was prepared by adding 50 mL of wash buffer 
concentrate to 950 mL of sterile water. And antibody was prepared by diluting 10 μL 
of the supplied antibody concentrate with 1 mL of antibody diluent for every mL of 1X 
needed. The diluted antibody must be used within 8 hours. In the meantime, 
standard curve was prepared in Eppendorf tubes. The fallowing dilutions were made 
to produce the standard curve to achieve a range of concentrations from 0.78 to 100 
pg/ml: eight 1.5 Eppendorf tubes were labled #1 through #8. 450 μL of the assay 
buffer was then piptted into tube # 1, and 250 μL into tubes #2 through #8. 
Thereafter, 50 μL of the 1.000 pg/mL standard stock was added into tube number1 
and vortexed thoroughly. 250 μL of tube #1 to tube #2 was added and vortexed 
thoroughly, and this was continued for tubes #3 through #8. Diluted standards should 
be used within 30 minutes of preparation. The concentration of ET-1 in tubes #1 
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through #8 will be 100, 50, 25,12.5, 6.25, 3.13,1.56 and 0.78 pg/ml respectively.    
For the handling of the sample, an equal volume of 20% acetic acid (AA) was added 
to the sample and centrifuged at 3000 x g for 10 minutes at 4°C to clarify. The pellet 
was discarded and the supernatant transferred into a new tube. 200 mg C18 
Sep‐Pak column equilibrated with one column reservoir volume (CV) 100% methanol 
(MeOH), followed by one CV water and one CV 10% MeOH. The supernatant was 
applied to the Sep‐Pak column and washed with one CV 10% AA and the washes 
were then discarded. Thereafter, the column was washed with CVs ethyl acetate. 
Finally, the sample was eluted slowly by applying 3 mL 100% MeOH/ 0.05 M 
ammonium bicarbonate (80/20 v/v) and the eluant was collected in a new tube. If 
samples cannot be assayed immediately, store at ‐20°C. For the measurement, the 
eluant was reconstituted with at least 250 μL of the assay buffer and measured 
immediately. Before beginning the procedure of the assay, the microplate was 
washed twice by adding 400 μL of wash solution to each well. Thereafter, 100 μL of 
Assay Buffer was pipetted into the S0 (0 ng/mL Standard) well followed by 100 μL of 
Standards #1 through #8 into the appropriate wells. 100 μL of the samples was then 
added into the appropriate wells, the plate is sealed and incubated at room 
temperature for 1 hour. At the end of incubation, the content of the wells was 
emptied and washed for total of five times by adding 400 μL of wash solution to 
every well. After the final wash, to remove any remaining wash buffer, the plate was 
firmly tapped on a lint free paper towel. Thereafter, 100 μL of the diluted antibody 
was pipetted into each well, except the blank, and the plate is sealed and incubated 
at room temperature. The plate was washed again for total of 5 times as described 
above and 100 μL of the substrate solution (a solution of 3,3’,5,5’ 
tetramethylbenzidine (TMB) and hydrogen peroxide) was added to each well 
followed by incubation at room temperature for 30 minutes. Later, 100 μL of stop 
solution was added to each well and the plate was read immediately by placing it in a 
microplate (ELISA) reader. After blanking the plate reader against the substrate 
blank, absorbance of each well was read at a wavelength of 450 nm using 
FluoStarTM OPTIMA photometer. The concentration of ET-1 in the tested samples 
was estimated using the standard curve obtained from the assay procedure.  
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2.2.5. Determination of cell proliferation and viability 
 
2.2.5.1. [3H]-Thymidine incorporation Assay 
Cell proliferation was measured by determining the uptake of [3H]-thymidine 
into DNA. [3H]-Thymidine incorporation method is the classical and reliable method 
to measure the newly synthesized DNA (Naito et al., 1987). Cell proliferation assays 
measure the incorporation of a radiolabeled DNA precursor, [3H]-thymidine, into the 
replication strands of DNA produced during cell division. Measurement of tritiated 
thymidine ([3H]-thymidine) incorporation as cells enter S phase is considered to be 
one of the most familiar and widely used methods for quantifying cell proliferation. 
Cells incorporate the labeled DNA precursors into newly synthesized DNA, such that 
the amount of incorporation, measured by liquid scintillation counting, is a relative 
measure of cellular proliferation. 
Human lung fibroblasts cells (MRC-5 or phLFb) were cultured as previously 
described in section 2.2.2. Cells were then trypsinized, harvested, and seeded into 
12-well cell culture plates at a density of 4 x 104  or 7.5 x 104 or 2 x 105 cells per well 
depending on the protocol being proceeded. Three different sets of protocols were 
tested to discover under which conditions endothelinergic effects might be 
particularly prominent on the proliferation rate.  
In the first set which was applied in most experiments, cells were seeded into 12-well 
cell culture plates at a density of 4 x 104  cells per well. Cells were initially cultured for 
24 hours in the presence of 10% FCS, followed by an additional 18-24 hours under 
FCS-free conditions. Thereafter, test substances were added and present for 30 
hours under FCS-free conditions, and [3H]-thymidine (37 MBq/ml) was present 
during the last 24 hours (i.e. it was added 6 hours after the addition of test 
substances).  
In a second set of experiments, cells were seeded into 12-well dishes at a density of 
5×104 cells per well and cultured for 5 hours in the presence of 10% FCS. 
Subsequently, cells were starved overnight in serum free medium, subsequently test 
substances were added and present for 30 hours under FCS-free conditions, and 
[3H]-thymidine (37 MBq/ml) was present during the last 24 hours.  
In a third set of experiments, cells were seeded at a density of 2 x 105 per well and 
cultured under FCS-free conditions from the onset in presence of test substances for 
30 hours. [3H]-Thymidine (37 MBq/ml) was present during the last 24 hours.  
  Materials and Methods 
56 
 
After the end of the incubation period, the culture supernatants were aspirated out 
and the adherent cells were washed with ice-cold 1X PBS, followed by a 
denaturation in 5% trichloro-acetic acid (TCA) for 10 minutes at 37oC. Thereafter, 
TCA was aspirated out and the cells were washed once again with ice-cold 1X PBS 
and the fixed cells were lysed by incubating with 1 ml 0.1 mol/l NaOH at 37oC for 1 
hour, subsequently neutralized with 200 µl Tris HCl (PH 7.4). An equal portions 300 
µl of samples were combined with 3 ml of scintillation cocktail, and DNA incorporated 
radioactivity in the lysates was measured by liquid scintillation spectrometry in a 
Packard 2100 TR liquid scintillation analyzer. 300 µl of a mixture of 1 ml 0.2 M NaOH 
with 200 µl 0.2 M HCl in 3 ml of scintillation cocktail was performed as blank reading 
to correct for counting efficiency. The results of the incorporated [3H]-thymidine into 
the DNA were expressed either in absolute terms, disintegrations per minute (d.p.m) 
or as a percentage of the mean value of the controls group of each series of 
experiments. 
Buffers and solutions for proliferation assay  
 Trichloro-acetic acid  5 % (w/v) in bidest H2O  
 NaOH     0.1 M in bidest H2O 
 1 M Tris-HCl pH 7.4   Tris-HCl 1 M  
Bidest water  
Adjust to PH 7.4 with HCl (conc) 
 1x PBS, pH 7.4-7.5  
 
2.2.5.2. Cell counting 
MRC-5 human lung fibroblasts were cultured as previously described in 
section 2.2.2. Cells were then trypsinized, harvested, and seeded into 12-well cell 
culture plates at a density of 7.5 x 104 cells per well and cultured under FCS-free 
conditions from the onset in absence or presence of test substance for 28 or 48 h. At 
the end of the incubation period cells were trypsinized and resuspended in medium. 
200 mL of cell suspension were diluted into 10 mL of a ready-to-use isotonic saline 
solution (CASYton®). This dilution was counted immediately in a 
CASY®CellCounter+Analyzer System (Innovatis, Bielefeld, Germany). Cell count is 
expressed as a percentage of the mean value of the controls of each cell 
preparation. 
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2.2.6. Determination of collagen synthesis 
2.2.6.1. [3H]-Proline incorporation assay 
[3H]-Proline incorporation is a method to detect new collagen synthesis and 
deposition into the extracellular matrix. The method was originally developed in 1971 
by Peterkofsky and Diegelmann and subsequently used in many studies and 
optimized (Trevisan et al, 1997; Eickelberg et al, 1999; Goulet et al, 2007), and 
established also in our laboratory (Haag et al., 2008a). 
Human lung fibroblast cells (phLFb or MRC-5 cell lines) were cultured as previously 
described in 2.2.2. Cells were then trypsinized, harvested, and seeded into 12-well 
dishes at a density of 105 per well human lung fibroblasts (phLFb or MRC-5 cell 
lines) were seeded into 12 or 24 well cell culture plates. Cells were initially cultured 
for 24 hours in presence of 10% FCS, followed by an additional 18-24 hours under 
FCS-free conditions. Subsequently, [3H]-proline (37 MBq/ml) was added alone or in 
combination with the test substances, to the near-confluent fibroblast cultures, since 
fibroblasts synthesised under confluent conditions considerably more collagen than 
under sub-confluent conditions (Shen and Strecker, 1975). The Incorporation phase 
lasted for further 24 hours. After the end of the incubation period the medium was 
removed and the cells were washed twice with 4°C cold 1X PBS, followed by 1–2 h 
incubation in 1 mL 20% trichloro-acetic acid (TCA) at 4°C. Denaturated cells were 
scraped off, transferred into a reaction tube and centrifuged at 13000 RPM for 10 
min. The supernatant was removed and discarded and the resulting pellet was 
washed with 1 ml of 10% TCA and centrifuged again at 13000 RPM for 5 min. After 
the wash steps, the pellet was solubilised by incubating with 300 µl 0.2M NaOH at 
room temperature for 1 hour, then  neutralized with  300 µl 0.2M HCl. An equal 
portion 300 µl of samples were combined with 3 ml of scintillation cocktail, and 
radioactivity was measured by liquid scintillation spectrometry in a Packard 2100 TR 
liquid scintillation analyzer. 300 µl of a mixture of 150 µl 0.2 M NaOH with 150 µl 0.2 
M HCl in 3 ml of scintillation cocktail was performed as blank reading to correct for 
counting efficiency. [3H]-Proline incorporation was expressed either in absolute term, 
disintegrations per minute (d.p.m.) or as percentage of the mean value of the 
controls group of each series of experiments.  
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Buffers and solutions for proline assay  
 Trichloro-acetic acid   10/20 % (w/v) in bidest.H2O 
 NaOH     0.2 M in bidest.H2O 
 HCl     0.2 M in bidest.H2O 
 1x PBS, pH 7.4-7.5  
 
2.2.6.2. QuickZyme collagen assay 
Collagen synthesis was additionally assessed by QuickZyme Soluble 
Collagen Assay (QuickZyme BioSciences, Netherlands). This method is colorimetric 
assay, which is based on specific binding of the dye Sirius Red to collagen. 
Following binding of the dye, the collagen-dye complex precipitates, resulting in a 
coloured pellet. This colour can be released in an alkaline solution.  
Cells were cultured for 24 h in presence of 10% FCS, followed by an additional 24 h 
under FCS-free conditions in absence or presence of test substances. At the end, 
culture medium was removed, and cells were washed with 4°C cold PBS followed by 
overnight incubation in 500 µL 0.5 M acetic acid at 4°C. Denaturated cells were 
scraped off, and the extract centrifuged at 3000 x g for 10 min. The supernatant was 
analysed according to the manufacturer’s instructions. 
Standard preparation 
All reaction steps were performed on the ice to prevent collagen denaturation, and all 
samples and standards be assayed in duplicate. 
Diluted collagen stock was prepared by adding 120 μl of collagen standard solution 
(714 μg/ml  in 20 mM acetic acid ) to 1080 μl dilution buffer, resulting in 1200 μl of 
the 10-fold diluted collagen stock (71.4 μg/ml). The standard curve was made to 
achieve a range of concentrations from 0 to 10 μg collagen /well, which was 
prepared as follows: eight Eppendorf tubes were labled #1 through #8. 350 μL of 10-
fold diluted collagen stock (71.4 μg/ml) was piptted into tube # 1, 280 μL tube # 2, 
210 μL tube # 3 , 140 μL tube #4, 70 μL tube #5, 35 μL tube #6, and 17.5 μL tube 
#7, followed by piptted 70 μL of addition buffer into tube # 2, 140 μL tube # 3 , 210 
μL tube #4, 280 μL tube #5, 315 μL tube #6, 332.5 μL tube #7 and 350 μL tube #8. 
Assay procedure: 
140 μL of standard was pipetted into appropriate wells of the assay microplate (V-
shaped plate) , 140 μL of dilution buffer into appropriate wells for use as blank, and 
140 μL of μl of unknown samples into the appropriate wells followed by 60 μL of dye 
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solution to each well and then was mixed thoroughly by pipetting up and down. The 
plate is sealed and incubated for 10 min on ice. At the end of incubation, the plate 
was centrifuged at 3000 x g for 1 hour at 4°C. Thereafter, 100 μl washing solution 
was added to each well, the supernant and washing solution (unbound dye) was 
removed by placing the plate at a 45o angle on a (5 cm thick) stack of paper towels. 
If the solution doesn’t easily flow out of the plate, gently move the plat. 250 μl 
washing solution was added to each well and this solution was removed by placing 
the plate at a 45o angle on a stack of paper towels as described above and this 
washing step was repeated. The plate was placed upside down on a paper towel for 
at least 5 minutes to remove remainder of wash buffer, followed by addition of 150 μl 
detection solution to the pellets and mixed thoroughly by pipetting up and down. 
Finally, 100 μl of the coloured solution is transferred to the reading microplate (flat 
bottom), and the absorbance of each well was read at wavelength of 540 nm using a 
photometer FluoStarTM OPTIMA. 
 
2.2.7. Detection and analysis of proteins  
2.2.7.1. Total protein preparation from adherent cell culture  
For protein expression analysis, MRC-5 fibroblasts were seeded into 55mm 
culture dishes or into 6 well plates at a density of 1x105 per dish, or 1x103 per well, 
respectively, and grown in humidified incubator at 37 oC and 5% CO2. Cells were first 
cultured for 24 hours in the presence of 10% FCS, followed by an additional 18–24 
hours under FCS-free conditions. Cells were then incubated with or without test 
substances for the times indicated. In inhibitor studies, cells were pre-incubated with 
vehicle or inhibitor for 30 min prior to stimulation. Culture dishes or plates were then 
maintained on ice. The medium was aspirated out and the cells were washed with 
ice cold 1XPBS. The adherent cells were then lysed with 200 µl of 4oC lysis/protein 
extraction buffer (radioimmunoprecipitation (RIPA)-buffer) containing protease 
inhibitor (PI). In the case of protein extracts being immunoblotted to test for activated 
phospho-protein, phosphatase inhibitors (PhI) were added to the lysis buffer in 
addition to protease inhibitor (PI), to prevent dephosphorylation of the proteins after 
extraction. Cells were scraped with a cell scraper and lysates. The contents of each 
well were transferred to 1.5 ml sterile reaction tubes on ice and then centrifuged at 
13000 RPM for 15 minutes at 4°C. The supernatants were placed into new tubes 
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and any debris was discarded. Samples were either frozen at -20°C or directly 
determined the protein concentration of the supernatant and subjected to SDS-
PAGE. 
Buffers for protein detection  
 RIPA Lysis Buffer  
TrisHCl     10 mM pH 7.4 
NaCl      150 mM 
NP-40      1% 
Desoxy-cholic acid-Na   1%    
Sodium dodecyl sulphate (SDS)  0.1% 
 PI  
0.1 M EDTA, PH 8    2 Mm 
125 μg/ml Pepstatin A   0.7 μg/ml (1 μM) 
100 mM PMSF    170 μg/ml (1 mM) 
10 μg/ml Leupeptin     0.5 μg/ml (1 μM) 
 PhI 
1.75 mM NaF     35 mM 
20 mM Na3VO4     1 mM 
 
2.2.7.2. Quantification of protein concentrations 
The protein concentration was measured using Lowry protein assay. This 
method is colorimetric assay, which is based on the combination of biuret reaction 
and Folin-ciocalteau phenol reagent and is referred to as the lowry assay, in which 
the proteins react with an alkaline copper tartate solution (biuret reaction) and 
subsequently the copper-treated proteins reduce Folin reagent giving rise to a 
characteristic blue colour which can be measured colorimetrically by absorbance at 
wave length 750 nm. The amount of color produced is proportional to the amount of 
protein. The reagents are from the DC protein assay kit was supplied by Bio Rad and 
they have been used according to the manufacturer’s instructions. 
For the assay, 5 μl of the supernatant previously extracted was mixed with 45 μl of 
0.1% Tris-Triton-X 100. Then 100 μl of freshly prepared Working solution A (1% 
reagent S in reagent A) was added to the probe followed immediately by 800μl 
Reagent B. Likewise 50 μl bovine serum albumin (BSA) standards in the 
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concentration of 50, 100, 300, 700, 1100, and 1500 μg/ml in 0.1% Triton X100 were 
mixed with 100 μl of Working solution A and 800μl of Reagent B was added to each 
probe. For the blank reading, 5 μl of the lysis buffer was treated in a similar fashion. 
The probes were subsequently vortexed and incubated at room temperature for 15 
min. After the incubation, the absorbance was measured spectrophotometrically at a 
wave length of 750 nm, and the concentration of protein samples was interpolated 
from the regression line of the standards. 
 
Solutions for protein detection  
 BSA-Standard solution   4 mg/mL BSA  
0.1% Tris/Triton X-100 solution  
 
 1% Tris/Triton X-100 solution  100 M of 1M Tris-HCL-solution, pH 7.4  
1% (v/v) Triton X-100  
Distilled Water  
 
 Reagent A     1% (v/v) Reagent S  
99% (v/v) Starting Reagent A  
 
2.2.7.3. SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) 
Protein samples were analysed using SDS-PAGE (Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis), which is the most widely used analytical method 
for separating proteins according to their size (molecular weight) from a mixed 
protein sample in an electric field, which was performed under denaturating 
conditions. SDS is an anionic detergent that denatures secondary and non 
disulphide linked tertiary structures of the proteins by breaking hydrogen bonds and 
unfolding protein, it binds to the proteins at a constant ratio of 1.4gm SDS per gram 
of protein, and applies an evenly distributed negative charge to each protein in 
proportion to its relative molecular mass enabling migration towards the positive pole 
when run through a polyacyrlamide gel placed in an electric field. 
Protein gel electrophoresis was carried out using Nu PAGE® novex® system for 
western blot supplied by Invetrogen. This system is based upon a Bis-Tris-HCl 
buffered gel polyacrylamide gel that operates at neural PH (PH 7), that minimizes 
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protein modifications. To optimize the separation of small to medium-sized of 
proteins under denaturing conditions, polyacrylamide gradient gels (4-12% Nu 
PAGE® Bis-Tris Gel, Invitrogen) were used. Protein samples to be analysed were 
first mixed with reducing agents 1:4 (4x loading buffer, Roth) and then heated for 10 
min at 70°C to further denature the proteins by reducing disulphide bonds, thus 
overcoming some forms of tertiary protein folding, and breaking up quaternary 
protein structures. The samples were thereafter centrifuged at 1000 rpm for 30 
seconds to allow all the contents of each eppendorf tube to collect at the bottom. An 
equal amount of protein samples were loaded on gradient 4-12% Nu PAGE® Bis-Tris 
Gel (Invitrogen). 5 μl of the Kaleidoscope marker proteins (Bio-Rad) were loaded as 
molecular size standards for determines molecular size of other proteins on the gel. 
The gel electrophoresis run was performed in 1xNu PAGE® MOPS-SDS running 
buffer (Invitrogen) at a constant voltage of 200 V at approximately 80-90 mA current 
for about 90 minutes.  
 
2.2.7.4. Western blot analysis 
Western blot analysis, also referred to as immunoblot, is a technique used to 
detect specific proteins in a complicated mixture of different proteins by polyclonal or 
monoclonal antibodies that is specific to that particular protein. First, proteins are 
separated by SDS-PAGE and then electrically transferred onto a polyvinylidine 
diflurid (PVDF) membrane. Proteins on the membrane can be visualized by 
immunodetection reagents. 
 
2.2.7.5. Protein blotting 
The immunoblot was performed using XCell IITM Blot-Module (Invitrogen). 
Prior to the completion of the gel run, the PVDF membranes were moistened with 
methanol for a few seconds and washed with distilled water, then equilibrated in the 
transfer buffer for about 20 min. After separating the proteins by SDS-PAGE, the 
SDS gel was washed with distilled H2O to remove any adhering salts and detergents 
and then equilibrated with 1x transfer buffer for 5 min. At the end of the equilibration 
period the gel was placed on a sheet of Whatman paper soaked in a transfer buffer. 
The PVDF membrane was then placed on the top of the gel and the membrane was 
covered with another sheet of Whatman paper soaked in a transfer buffer, ensuring 
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that there were no air bubbles which would prevent the transfer of the proteins. The 
assembly was then covered with sponges soaked in transfer buffers on both sides. 
This sandwich was then placed in a XCell IITM Blot Module. The blot module was 
placed inside the XCell Sure Lock and then filled with a 4°C transfer buffer. Water 
was placed in the XCell Sure Lock around the outside of the blot module. The 
transfers were carried out at constant current of 250 mA, 100V for 90 min. 
 
2.2.7.6. Immuno-detection of blots  
Following the protein transfer onto membranes, the membrane was removed 
from the blot module and placed protein side up in a flat container on a rocker. 
Following this, the membrane was stained with 0.2% w/v ponceu S (Sigma) for 
visualizing the protein bands, and to confirm efficient transfer of protein onto the 
membrane and the lanes were then marked. Next, the stain was removed by 
washing with water followed by washing with TBS on a shaking platform for 2-3 
minutes until the stain was removed. Afterwards, the unspecific binding sites on the 
membrane were saturated by 5% blocking solution (dried milk powder in 0.05% 
TBST) over night at 4oC. 
The next step, the membrane was incubated for 90 minutes with an appropriate 
dilution of the primary antibody in 3% blocking solution at room temperature on the 
rocker. After antibody incubation, the unbound antibody was washed twice for 10 min 
with 0.1% TBST and blocking twice for 10 min with 3% blocking solution on a rocker. 
The membrane then was incubated for 45 minutes with appropriate dilution of a 
horseradish peroxidase (HRP)-conjugated secondary antibody in 3% blocking 
solution at room temperature on the rocker. Later, the membrane was washed again 
with 0.1% TBST for four 15 minutes periods on a platform rocker.  
In the meantime, the chemiluminescene detection solution was prepared, using BM 
chemoluminescence blotting substrate peroxidise (POD) kit (Roch) and kept at room 
temperature. At the end of the final washing step, TBST solution was decanted and 
the detection solution was added to the protein side of the membrane for 1 min. 
Finally, the membrane was wrapped into a plastic foil and fixed in an 
autoradiography cassette and exposed to an X-ray film in a dark room for 5 sec to 5 
min depending on the signal intensity. The film was developed by an automatic 
photo developer (CP-100, Agfa). The developed films were then scanned and RFLP 
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scan software was used to perform the densitometric analysis of the blots. The 
results are expressed as arbitrary units related and normalized to the signal of house 
keeper. 
Buffers and solutions for protein gel electrophoresis and immunoblot  
 Running Buffer 
1x NuPAGE MOPS SDS   5% (v/v) 20x NuPAGE MOPS SDS  
      running buffer 
      Distilled Water 
 Transfer Buffer  
Tris      25 mM  
Glycine     192 mM  
Methanol     20% (v/v)  
Distilled water  
 Ponceau S solution  
Ponceau S     0.2% (w/v)  
Tris-HCl     3% (w/v)  
Distilled water  
 Tris Buffered Saline (TBS) solution pH 7.5  
Tris      50 Mm  
NaCl      150 mM  
Distilled water   
 TBST 0.1% (v/v) 
Tween 20      1 mL  
TBS       1000 mL  
 TBST 0.05% (v/v) 
TBS      500 mL  
TBST 0.1% (v/v)     500 mL  
 3 and 5% Blocking solution  
Dried fat-free milk powder   3 or 5 gm  
Distilled water    100 ml  
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 Chemiluminiscence solution  
Starting solution    1% (v/v)  
Blotting substrate  
 
2.2.7.7. Stripping of the membranes 
The stripping of the membranes was performed to remove primary and 
secondary antibodies from a western blot membrane and to allow the same 
membrane to be probed for different proteins with another antibody. In this regard, 
the membrane was soaked in methanol followed by washing with distilled water for 5 
min. 0.2% NaOH solution was then added onto the membrane for 5 minutes over a 
shaker platform followed by washing the membrane with distilled water for 5 min. 
Then the membrane was blocked with a 5% blocking solution overnight at 4oC. This 
was also followed by the addition of another primary antibody in a 3% blocking 
solution and the remaining protocol for the immunoblotting was similar to what was 
described previously. 




3.1. Expression of endothelins and their receptors in human lung fibroblasts 
3.1.1. Expression of ET isoforms  
To characterize the expression level of mRNA encoding for the different ET 
isoforms (ET-1, ET-2 and ET-3) in primary human lung fibroblasts (phLFb) and in the 
MRC-5 human lung fibroblast cell line, quantitative real time PCR was used. As 
shown in figure 3-1, under basal, un-stimulated conditions, phLFb, and MRC-5 
fibroblasts, clearly express mRNA encoding ppET-1 and ppET-2, but phLFb 
expressed lower levels for ppET-1 and ppET-2 than MRC-5 cells. ppET-1 mRNA 
was found to be the major ET isoforms expressed, with mRNA levels about 100 
times higher than those for ppET-2 in both cell types (Fig. 3-1). mRNA for ppET-3 










Figure 3-1: Expression of pp-ET-1, -2 and -3 in MRC-5 and primary (phLFb) human lung 
fibroblasts. Cells were grown in presence of 10% FCS in 35 mm culture dishes to 
confluency. Total RNA was isolated, treated with DNase and used for quantitative real time 
PCR with primers specific for the respective human sequences. Height of columns: mRNA 
expressed as n-fold over detection limit (2(35-ΔCt)), given are means + S.E.M of n>6 
independent experiments. Significance of differences: ***P<0.001 vs ET-2; +P<0.05; ++P<0.01 
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3.1.2. Expression of ET receptor subtypes   
ET-1 may act in an autocrine and paracrine fashion through binding to the 
GPCR (ET-A and ET-B) receptors. Thus, it was important to determine whether 
phLFb and MRC-5 fibroblasts express these receptors. Therefore, quantitative real 
time PCR was performed to determine the expression level of mRNA encoding for 
the two ET receptors subtypes (ET-A and ET-B) in phLFb and MRC-5 cells. As 
shown in figure 3-2, under basal, un-stimulated condition, mRNA encoding ET-A and 
ET-B receptors were clearly expressed in phLFb and in MRC-5 cells. In phLFb, the 
levels of mRNA for ET-B receptors were found to be significantly higher than those 
for ET-A receptors. However, there were no significant differences in the expression 
level of mRNA encoding ET-A and ET-B receptor in MRC-5 cells.  
In addition, to provide evidence for the expression of ET-A and ET-B 
receptors at the protein levels, Western blot analysis was performed, using specific 
commercially available polyclonal antibodies for ET-A and ET-B receptors. As shown 
in figure 3-2B, the immunoblot result demonstrated one band for ET-B receptor of 
about 70 kDa, which is in the range of the expected molecular weight, and an 
additional protein band, with a lower molecular weight, was also detected. This 
additional protein band probably reflects a cellular degradation product which is 
recognized by the antibody. The immunoblot for ET-A receptor demonstrated also 
two bands, both with molecular weights lower than what was expected. Nonetheless, 
the larger band seems to be an ET-A receptor signal as it corresponds to a specific 
band of about 45 kDa seen in ET-A receptor transfected cells (antibody reference 
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Figure 3-2: Expression of ET-A and ET-B receptors in MRC-5 and primary (phLFb) human 
lung fibroblasts. Cells were grown in presence of 10% FCS in 35 mm culture dishes to 
confluence. Either total RNA was isolated, treated with DNase and used for quantitative real 
time PCR with primers specific for the respective human sequences (A) or proteins were 
extracted and used for immunoblot analysis using commercially available antibodies against 
ET-A and ET-B receptor protein (B). A, Height of columns: mRNA expressed as n-fold over 
detection limit (2(35-ΔCt)), given are means + S.E.M of n>6 independent experiments. 
Significance of differences: **P<0.01 vs respective value in MRC-5 cells; +++P<0.001 vs ET-A 
(in phLFb). B: Representative samples of SDS PAGE of 4 similar experiments. 
 
3.2. Regulation of ET expression and release in human lung fibroblasts 
3.2.1. Effect of TGF-β on ET expression  
In order to investigate whether the ET-1 gene expression in phLFb and MRC-
5 cells is regulated by TGF-β, the effect of TGF-β on the expression of ppET-1 
transcription was studied. As depicted in figure 3-3A, TGF-β induced in 
concentration-dependent manner a strong, sustained and selective increase in 
ppET-1 mRNA expression in both phLFb and MRC-5 cells. Furthermore, 5 ng/ml 
TGF-β did not exhibit any stronger effect than that obtained with 1 ng/ml TGF-β, as 
maximum effective concentration on the expression of ppET-1 in human lung 
fibroblasts. A marked stimulatory effect of TGF-β on ppET-1 transcription was 
already observed within one hour (Fig. 3-5A and 3-5B) and remained unchanged 
until one week of exposure (Fig. 3-3A). On the other hand, after 24 hours treatment 
of phLFb and MRC-5 cells with 1 ng/ml TGF-β, ppET-2 mRNA expression was 
decreased (Fig. 3-3B) and ppET-3 mRNA expression remained below detection limit 







































































































Figure 3-3: Effects of TGF-β on expression of ppET-1 and ppET-2 in MRC-5 and primary 
(phLFb) human lung fibroblasts. After dissemination, cells were cultured for 24 h in presence 
of 10% FCS followed by 24 or 72 h  or 7 d (A, as indicated) or 24 h (B) in presence of 1% 
FCS and absence or presence of TGF-β (0.1 - 5 ng/ml). Thereafter, total RNA was isolated, 
treated with DNase and used for quantitative real time PCR. Height of columns: ppET-1 or -2 
mRNA (ΔCt over GAPDH) expressed as % of the control of the individual cell preparation, 
given are means + S.E.M of n≥6 independent experiments. Significance of differences: 
*P<0.05; **P<0.01; ***P<0.001 vs respective value in absence of TGF-β. 
 
3.2.2. Effect of TGF-β on ppET-1 mRNA stability and/or transcription  
In order to examine whether TGF-β has an effect on ppET-1 mRNA stability 
and/or transcription, transcription inhibitor actinomycin D (Act, 30 µM) was used to 
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of ppET-1 mRNA. MRC-5 fibroblasts were incubated for 0 to 120 min with 30 µM of 
Act alone, or Act and TGF-β (1 ng/ml) in combination. As shown in figure 3-4A, after 
inhibition of de-novo RNA synthesis by 30 µM actinomycin D, ppET-1 mRNA showed 
a rapid decline, with a half life of about 30 min. Furthermore, the stimulatory effect 
induced by a 60 minute exposure to 1 ng/ml TGF-β on ppET-1 mRNA was prevented 
by pre-treatment with 30 µM Act (Fig. 3-4B). This suggests that TGF-β had no effect 
on the rate of decay of ppET-1 transcripts. 












Figure 3-4: Time-dependent effects of actinomycin D (30 µM, A) and effect TGF-β (1 ng/ml, 
1 h) in absence and presence of actinomycin D (Act, present 15 min before TGF-β, B) on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 h in presence of 10% FCS followed by up to 4 h in presence of 1% FCS and 
absence or presence test drugs. Thereafter, total RNA was isolated, treated with DNase and 
used for quantitative real time PCR. Ordinate (A) and height of columns (B): ppET-1 mRNA 
(ΔCt over GAPDH) expressed as % of the Ctr. of the individual cell preparation, given are 
means + S.E.M of n≥4 independent experiments. Significance of differences: ***P<0.001 vs 
Ctr.; +++P<0.001 vs value in presence of TGF-β alone; ns, not significant vs Act alone. 
 
In a further series of experiments, cycloheximide, a protein synthesis inhibitor, 
was used to assess whether ppET-1 mRNA stimulation by TGF-β is induced through 
de-novo cellular protein synthesis. As shown in figure 3-5A, cycloheximide induced a 
rapid and strong up-regulation of ppET-1 mRNA expression of about tenfold within 
one and a half hours and more than fourteen-fold after four and a half hours. 
Strikingly, the stimulatory effect of TGF-β was highly augmented in the presence of 
30 µM cycloheximide, resulting in a more than thirty five-fold increase in ppET-1 





















































































Figure 3-5: Effects of cycloheximide (CHX, A) or TGF-β in absence or presence of CHX (B) 
on expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 hours in presence of 10% FCS followed by 1.5 or 4.5 hours in presence of 
1% FCS and absence or presence of CHX (30 µM) or 1 hour and 4 hours TGF-β (1 ng/ml) 
and/or CHX (30 µM, 1.5 h and 4.5 h, i.e. present 30 minute before TGF-β). Thereafter, total 
RNA was isolated, treated with DNase and used for quantitative real time PCR. Height of 
columns: ppET-1 mRNA (ΔCt over GAPDH) expressed as % of the Ctr. of the individual cell 
preparation, given are means + S.E.M of n≥6 independent experiments. Significance of 
differences: **P<0.01 ***P<0.001 vs respective Ctr.; ++P<0.01, +++P<0.001 vs respective 
value in presence of TGF-β or CHX alone. 
 
3.2.3. Role of ET receptors in TGF-β-induced ppET-1 mRNA expression  
In order to determine the role of ET receptors in TGF-β mediated up-
regulation of ppET-1 mRNA expression in MRC-5 cells, interaction experiments with 
two selective ET-receptor antagonists BQ-123 (ET-A) (Ihara et al., 1992) and BQ-
788 (ET-B) (Ishikawa et al., 1994), and a non-selective ET receptor antagonist 
(bosentan) (Clozel et al., 1994) were performed. The effects of ET receptor 
antagonists on TGF-β induced up-regulation of ppET-1 mRNA expression were 
studied at two time points (24 hours and 72 hours). As shown in figures 3-6A, B and 
C, none of the ET-1 antagonists had any effect on the basal levels of ppET-1 mRNA 
expression in MRC-5 cells, neither after 24 hours nor 72 hours of exposure. 
However, the stimulatory effect caused by 24 hours exposure to a sub-maximally 
effective concentration of TGF-β (0.3 ng/ml) was inhibited by pre-treatment with 10 
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antagonist (120 % of controls, n=6, Fig. 3-6B), whereas it was not affected by the 
selective ET-B antagonist (BQ-788, 100nM, Fig. 3-6C). The increase in pp-ET-1 
mRNA expression caused by 1 ng/ml TGF-β, a maximally effective concentration, 
was neither significantly affected by the selective ET-A antagonist BQ-123 (1 µM, by 
about 800%, n=11), nor by the selective ET-B antagonist (BQ-788, 100 nM, to about 
850%, n=6 (Fig. 3-6B and C)). Furthermore, the up-regulation of ppET-1 transcription 
induced by 0.3 ng/ml TGF-β at 72 hours exposure of MRC-5 cells was strongly 
inhibited by 10 µM bosentan and BQ-123 (1 µM) but was not affected by BQ-788 
(100 nM). The increase in ppET-1 mRNA expression caused by 1 ng/ml TGF-β at 72 
hours exposure was neither affected by BQ-123 (1 µM, by about 900%) nor BQ-788 










































































































































Figure 3-6: Effects of TGF-β in absence and presence of bosentan (Bos), the ET-A (BQ123) 
or ET-B (BQ-788) receptor selective antagonist on expression of ppET-1 mRNA in MRC-5 
human lung fibroblasts. After dissemination, cells were cultured for 24 h in presence of 10% 
FCS followed by 24 or 72 h in presence of 1% FCS and absence or presence of 0.3 or 1 
ng/ml TGF-β and/or 10 µM Bos, 1 µM BQ-123 or 100 nM BQ-788. Thereafter, total RNA was 
isolated, treated with DNase and used for quantitative real time PCR. Height of columns: 
ppET-1 (ΔCt over GAPDH) expressed as % of the Ctr. of the individual cell preparation, 
given are means + S.E.M of n≥6. Significance of differences: **P<0.01, ***P<0.001 vs Ctr.; 
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3.2.4. Effects of TGF-β and ET receptor antagonist on ET-1 release 
In order to confirm that the induction of ET-1 mRNA by TGF-β results in 
increased synthesis and release of ET-1, the levels of ET-1 in the culture medium of 
MRC-5 cells was measured by a specific ELISA. Under controlled conditions, ET-1 
accumulation in the culture medium of MRC-5 cells amounted to 6.8 ± 0.3 pg/ml (≈ 3 
nM) at the end of a 6 hours incubation period, corresponding to 44.8±2.6 pg/mg 
protein (n=74). Addition of TGF-β evoked in a concentration-dependent manner, a 
strong increase in ET-1 accumulation (Fig. 3-7A), resulting in a maximal 
accumulation of 34 ± 7 pg/ml ET-1 (≈ 15 nM) in presence of 0.3 ng/ml TGF-β (n=17). 
The maximum effect on ET-1 accumulation caused by 0.1 - 0.3 ng/ml TGF-β was a 
three- to fourfold increase. Thus, the TGF-β-induced increase in expression of ET-1 
mRNA was accompanied by an increase in ET-1 synthesis and release. 
Interestingly, the concentrations of TGF-β (0.1-0.3 ng/ml), that caused maximal 
increase in ET-1 accumulation were lower than those required for maximal effect on 
ppET-1 mRNA expression (1 ng/ml, Fig. 3-3). In other words, the further substantial 
increase in mRNA seen at 1 ng/mg TGF-β did not result in an equivalent further 
increase in ET-1 accumulation. Nonetheless, in line with observations on mRNA 
levels, the up-regulation of ET-1 accumulation by a sub-maximally effective 

























































Figure 3-7: Concentration-dependent effects of TGF-β (A) and effect of 0.03 ng/ml TGF-β in 
absence and presence of bosentan (Bos, 10 µM) (B) on release of ET-1 by MRC-5 human 
lung fibroblasts. After dissemination, cells were cultured for 24 hours in presence of 10% 
FCS followed by 48 hours in presence of 1% FCS and absence or presence of test 
substances as indicated. The last medium change was performed 6 hours before the 
supernatant were collected for ET-1 determination by ELISA. ET-1 accumulation expressed 
as % of the Ctr. of the individual cell preparation, given are means + S.E.M of n≥12 
independent experiments. Significance of differences: ***P<0.001 vs respective Ctr.; 
+++P<0.001 vs respective value in presence of TGF-β or Bos alone. 
 
In order to test whether ET converting enzyme activity could have been a 
limiting factor for the accumulation of ET-1 under the present culture conditions, the 
conversion of big-ET-1 into ET-1 was studied. Addition of big-ET-1 to confluent cell 
cultures resulted in concentration- and time-dependent accumulation of ET-1 in the 
supernatant. Maximal rate of conversion appears to occur at a concentration of 100 
nM big-ET-1, and steady-state conditions (where formation and degradation might 
be balanced) appear to be reached in 6 hours (Fig. 3-8). Notably, the ET-1 
concentrations during 6 hours incubation with 100 nM big-ET-1 were about 40 times 
higher than those observed during a 6 hour collection period after exposure to 
maximally stimulating concentrations of TGF-β. Pre-treatment of the cells with TGF-β 
(0.3 ng/ml for 48 hours) did not affect the accumulation of ET-1 during 3 or 6 hours of 

























































Figure 3-8: Time- and concentration-dependent conversion of big-ET-1 into ET-1 by MRC-5 
human lung fibroblasts in culture. Big-ET-1 at the concentrations given was added to nearly 
confluent cultures in absence of FCS for 1 to 8 hours, as indicated, followed by 
determination of ET-1 accumulation in the supernatant. Given are means of n≥6 
independent experiments, for clarity of the figure without S.E.M, which were between 5 and 
15% of the respective mean value. 
 
3.2.5. Role of canonical (Smad) and non-canonical (MAPK, Rho G-protein) 
signaling in TGF-β-induced ppET-1 mRNA expression 
3.2.5.1. Role of Smad3 in TGF-β-mediated ppET-1 mRNA expression  
To investigate the role of Smad3 pathway in TGF-β-mediated increases in 
ppET-1 mRNA expression in MRC-5 fibroblasts, interaction experiments with a 
specific inhibitor of the canonical TGF-β effector Smad3, Smad3 inhibitor (SIS3) 
were performed. MRC-5 fibroblasts were cultured for 1 and 4 hours in presence of 
1% FCS and in absence or presence of 1 ng/ml TGF-β and/or 10 µM SIS3. Real 
time PCR analysis revealed that TGF-β (1 ng/ml, a maximally effective 
concentration) induced a rapid and strong increase in ppET-1 mRNA expression 
within one and four hours by about 570% and 470%, respectively (Fig. 3-9A and B). 
Whereas the Smad 3 inhibitor (SIS3) provoked a strong reduction of the basal level 
of ppET-1 mRNA expression by about 65% and 75% after 1 and 4 hour, respectively 
(Fig. 3-9A and 5B). Moreover, the increase in ppET-1 mRNA expression induced by 
1 and 4 hours exposure to 1 ng/ml TGF-β was largely attenuated by SIS3 (Fig. 3-9A 
and B).  






















































Figure 3-9: Effects of TGF-β in absence or presence of the smad3 inhibitor (SIS3) on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 h in presence of 10% FCS followed by 1 h or 4 h in presence of 1% FCS and 
absence or presence of 1 ng/ml TGF-β and/or 10 µM SIS3 (present 30 min before TGF-β). 
Thereafter, total RNA was isolated, treated with DNase and used for quantitative real time 
PCR. Height of columns: ppET-1 (ΔCt over GAPDH) expressed as % of the Ctr. of the 
individual cell preparation, given are means + S.E.M of n≥5. Significance of differences: 
***P<0.001 vs Ctr.; +++P<0.001 vs value in presence of SIS3 or TGF-β alone. 
 
3.2.5.2. Role of the ERK MAPK pathway in TGF-β-induced ppET-1 mRNA            
            expression  
In order to investigate the role of ERK MAPK pathway in TGF-β-mediated 
increases in ppET-1 mRNA expression in MRC-5 fibroblasts, interaction experiments 
with PD 098059, a specific inhibitor of MAPK-activating enzyme (MEK) (Alessi et al., 
1995; Dudley et al., 1995), were performed. Exposure of the cells for four hours and 
eight hours to 10 and 30 µM PD 098059 had no effect on the ppET-1 mRNA 
expression level (data not shown). However, in 24 hours exposure to PD 098509 (10 
and 30 µM) induced in a concentration dependent manner clear increase in the 
ppET-1 mRNA expression (2.5-fold and 3.7-fold, respectively) (Fig. 3-10). The 
stimulatory effect of 0.3 ng/ml TGF-β was highly augmented in presence of PD 
098509 (10 and 30 µM), resulting in a more than five-fold and thirteen-fold increase 
in ppET-1 mRNA, respectively, after 24 hours (Fig. 3-10).  
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Figure 3-10: Effects TGF-β in absence or presence of PD 098059 (PD) on expression of 
ppET-1 in MRC-5 fibroblasts. After dissemination, cells were cultured for 24 hours in 
presence of 10% FCS followed by 24 hours in presence of 1% FCS and absence or 
presence of TGF-β (0.3 ng/ml) and/or PD (10 or 30 µM). Thereafter, total RNA was isolated, 
treated with DNase and used for quantitative real time PCR. Height of columns: ppET-1 
mRNA (ΔCt over GAPDH) expressed as % of the Ctr. of the individual cell preparation, given 
are means + S.E.M of n≥7 independent experiments. Significance of differences: **P<0.01, 
***P<0.001 vs respective Ctr.; ++P<0.001, +++P<0.001 vs respective value in presence of 
TGF-β or PD alone. 
 
3.2.5.3. Role of the Rho-kinase on TGF-β-induced ppET-1 mRNA expression 
In order to test whether Rho kinase might be involved in the regulation of 
ppET-1 mRNA by TGF-β in MRC-5 human lung fibroblast, interaction experiments 
with a specific inhibitor of Rho-kinase, Y-27632 (Ishizaki et al., 2000; Shimokawa et 
al., 2007) were performed. As shown in figure 3-11, TGF-β, in a sub-maximally 
effective concentration of 0.3 ng/ml exerted again a clear stimulatory effect on the 
ppET-1 mRNA expression by about 390% was observed, whereas the Rho-kinase 
inhibitor (Y-27632) caused a significant reduction of the ppET-1 mRNA levels by 
about 30% and 50% at 3 μM and 10 μM, respectively. However, in presence of Y-
27632, the stimulatory effect of 0.3 ng/ml TGF-β on ppET-1 mRNA expression was 
unaffected. When expressed in relation to the respective value of 3 and 10 μM Y-
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Figure 3-11: Effects of TGF-β in absence or presence of the Rho-kinase inhibitor Y27632 on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 hours in presence of 10% FCS followed by 24 hours in presence of 1% FCS 
and absence or presence of 0.3 ng/ml TGF-β and/or (3 or 10 µM) Y-27632 (present 30 
minute prior TGF- β). Thereafter, total RNA was isolated, treated with DNase and used for 
quantitative real time PCR. Height of columns: ppET-1 (ΔCt over GAPDH) expressed as % 
of the Ctr. of the individual cell preparation, given are means + S.E.M of n=5 independent 
experiments. Significance of differences: ***P<0.001 vs Ctr.; +++P<0.001 vs value in 
presence of Y-27632 alone; ns, not significant vs TGF-β alone. 
 
3.2.6. Role of β2-adrenoceptors and muscarinic receptors in the ET-1  
expression 
3.2.6.1. Effect of β2-adrenoceptor agonist on the ET-1 expression  
β2-Adrenoceptors have an important role in regulating various cellular 
functions in lung fibroblasts, including proliferation and collagen synthesis. To 
investigate whether the expression of ppET-1 mRNA in human lung fibroblasts is 
regulated by β-adrenergic mechanism, a highly selective, long-acting β2-
adrenoceptor agonist, olodaterol was used. As shown in figure 3-12, exposure of the 
cells to olodaterol for 24 hours caused a clear reduction in the expression of ppET-1 
mRNA. An inhibition by 45% was observed at 10 nM and 100 nM, whereas 1 nM 
olodaterol had no effect on the ppET-1 mRNA expression. As 10 nM olodaterol 
appeared to be the maximum effective concentration, a concentration of 10 nM was 
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Furthermore, to determine the selectivity of olodaterol, interaction experiments 
with highly selectivity antagonists were performed using the β2-adrenoceptor 
selective antagonist ICI 118,551 (1 µM) and the β1-adrenoceptor selective antagonist 
CGP 20712 (3 µM) (Baker, 2005). As depicted in figure 3-12, ICI 118,551 (1 µM) and 
CGP 20712 (3 µM) did not affect the basal levels of ppET-1 mRNA expression in 
MRC-5 fibroblasts. However, the inhibitory effect of 10 µM olodaterol was inhibited 
by the β2-adrenoceptor selective antagonist ICI 118,551, but not affected by the β1-















Figure 3-12: Effects of olodaterol in absence or presence of the β2-adrenoceptor selective 
antagonist ICI 118,551 (ICI, 1 µM) or the β1-adrenoceptor selective antagonist CGP 20712 
(CGP, 3 µM) on expression of ppET-1 mRNA in MRC-5 human lung fibroblasts. After 
dissemination, cells were cultured for 24 h in presence of 10% FCS followed by 24 hours in 
presence of 1% FCS and in absence or presence of test drugs, the antagonists being 
present 30 minute prior to olodaterol. Thereafter, total RNA was isolated, treated with DNase 
and used for quantitative real time PCR. Height of columns: ppET-1 (ΔCt over GAPDH) 
expressed as % of the respective control (in absence or presence of antagonists) of the 
individual cell preparation, given are means + S.E.M of n=5 independent experiments. 
Significance of differences: **P<0.01, ***P<0.001 vs respective control; ns, not significant vs 
respective Ctr.. 
 
3.2.6.2. Effect of β2-adrenoceptor agonist on TGF-β-mediated ET-1 expression  
As TGF-β was shown to up-regulate and β2-adrenoceptor to reduce ET-1 
gene expression, possible interactions between TGF-β and β2-adrenoceptor agonist 
were studied. As shown in figure 3-13A, the increase in ppET-1 mRNA expression 
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concentration, was effectively opposed by 10 and 100 nM olodaterol, but not 
significantly affected by 1 nM olodaterol. This inhibitory effect of 10 and 100 nM 
olodaterol in presence of 0.3 ng/ml TGF-β (reduction by about 46% and 38% 
respectively) was comparable to that observed in absence of TGF-β (compare Figs. 
3-12 and 3-13A). However, the increase in ppET-1 mRNA expression caused by 24 
hours exposure to TGF-β, a maximally effective concentration of 1 ng/ml was not 
significantly affected by 10 or 100 nM olodaterol. i.e., in presence of 1 ng/ml TGF-β, 









Figure 3-13: Effects of olodaterol in absence or presence of 0.3 (A) or 1 ng/ml TGF-β (B) on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 hours in presence of 10% FCS followed by 24 hours in presence of 1% FCS 
and absence or presence of test substances at the concentrations given, olodaterol being 
present 30 min prior to TGF-β. Thereafter, total RNA was isolated, treated with DNase and 
used for quantitative real time PCR. Height of columns: ppET-1 (ΔCt over GAPDH) 
expressed as % of the Ctr. (presence of TGF-β alone) of the individual cell preparation, 
given are means + S.E.M. of n=5 independent experiments. Significance of differences: 
**P<0.01; ***P<0.001 vs Ctr.. 
 
3.2.6.3. Role of cyclic AMP effectors (PKA and Epac) in ET-1 expression  
Intracellular cAMP regulates different cellular functions, mainly through two 
downstream targets, PKA (protein kinase A) and Epac (Exchange protein directly 
activated by cAMP). To test whether the expression of ppET-1 mRNA in MRC-5 
fibroblasts is regulated by these intracellular targets (PKA and Epac) of the second 
messenger cAMP, the cAMP analogs 6-Bnz-cAMP and 8-CPT-2'-O-Me-cAMP, 
known to preferentially activate PKA and Epac, respectively (Holz et al., 2008; 
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Poppe et al., 2008) were used. As illustrated in figure 3-14A, the selective protein 
kinase A agonist (6-Bnz-cAMP, 500 µM) caused a substantial reduction in ppET-1 
mRNA expression by 63%, whereas the selective Epac agonist (8-CPT-2′-O-Me- 
cAMP, 100 μM) caused only a marginal inhibition by 22%. The inhibitory effect of the 
selective β2-adrenoceptor agonist oldaterol was fully mimicked by the effect of the 
selective protein kinase A (PKA) agonist (Fig. 3-14).   
Furthermore, the impact of the cyclic AMP (cAMP) effectors PKA and Epac in 
TGF-β-mediated increase in expression of ppET-1 mRNA in MRC-5 fibroblasts was 
also studied. As shown in figure 3-14B, in presence of 0.3 ng/ml TGF-β activation of 
either PKA or Epac with selective PKA-agonist 6-Bnz-cAMP (500 µM) and selective 
Epac-agonist 8-CPT-2'-O-Me-cAMP (100 µM) respectively, caused a decrease in 
ppET-1 mRNA expression comparable to that in absence of 0.3 ng/ml TGF-β. 
However, in presence of the maximum effective concentration of TGF-β, neither the 









Figure 3-14: Effects of the selective PKA (6-Bnz-cAMP, 500 µM) or Epac (8-CPT-2’-O-Me-
cAMP, 100 µM) agonist in absence or presence of 0.3 or 1 ng/ml TGF-β on expression of 
ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were cultured for 24 h in 
presence of 10% FCS followed by 24 hours in presence of 1% FCS and absence or 
presence of test substances at the concentrations given, the selective PKA and Epac 
agonists being present 30 min prior to TGF-β. Thereafter, total RNA was isolated, treated 
with DNase and used for quantitative real time PCR. Height of columns: ppET-1 (ΔCt over 
GAPDH) expressed as % of the respective Ctr. or presence of TGF-β alone of the individual 
cell preparation, given are means + S.E.M. of n=5 independent experiments. Significance of 
differences: *P<0.05; ***P<0.001 vs respective Ctr.. 
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3.2.6.4. Effect of muscarinic cholinergic receptor agonist on the ET-1
 expression 
In order to investigate, whether the muscarinic cholinergic receptor is involved 
in the regulation of ppET-1 mRNA in MRC-5 fibroblasts, effects of the muscarinic 
agonist oxotremorine (Ringdahl et al., 1983) and the muscarinic antagonist 
tiotropium were studied. As shown in figure 3-15, exposure of the cells for 24 hours 
to oxotremorine (10 µM, previously shown to be a maximally effective concentration 
in eliciting muscarinic effects in MRC-5 cells, Matthiesen et al., 2006; Haag et al., 
2008a), caused about three-fold increase in the expression of ppET-1 mRNA. This 
stimulatory effect of oxotremorine was prevented by the muscarinic antagonist 

















Figure 3-15: Effects of oxotremorine (Oxo, 10 µM) and/or tiotropium (Tio, 10 nM) on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 hours in presence of 10% FCS followed by 24 h in presence of 1% FCS and 
in absence of presence test drugs, Tio being present 30 min prior to Oxo. Thereafter, total 
RNA was isolated, treated with DNase and used for quantitative real time PCR. Height of 
columns: ppET-1 (ΔCt over GAPDH) expressed as % of the Ctr. of the individual cell 
preparation, given are means + S.E.M. of n≥4 independent experiments. Significance of 
differences: ***P<0.001 vs Ctr.; +++P<0.001 vs Oxo alone. 
 
Since β2-adrenoceptors and muscarinic receptors appear to mediate opposing 
effect on the expression of ET-1 gene (see figures 3-12 and 3-15), possible 
interaction between olodaterol and oxotremorine on ET-1 gene expression were 
examined. The results shown in figure 3-16 indicate that the stimulatory effect of 
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olodaterol (10 nM). In presence of both drugs, no significant increase by 14 ± 7% in 
ppET-1 mRNA level in comparison to the control was observed. However, in 
presence of both drugs, ppET-1 mRNA was significantly high compared to olodaterol 
alone, i.e. oxotremorine exerted still a significant stimulation effect, although smaller 









Figure 3-16: Effects of olodaterol (Oldo, 10 nM) and/or oxotremorine (Oxo, 10 µM) on 
expression of ppET-1 in MRC-5 human lung fibroblasts. After dissemination, cells were 
cultured for 24 hours in presence of 10% FCS followed by 24 hours in presence of 1% FCS 
and in absence of presence test drugs. Thereafter, total RNA was isolated, treated with 
DNase and used for quantitative real time PCR. Height of columns: ppET-1 (ΔCt over 
GAPDH) expressed as % of the Ctr. of the individual cell preparation, given are means + 
S.E.M. of n≥5 independent experiments. Significance of differences: ***P<0.01 vs Ctr.; 
++P<0.01 vs Oxo or Oldo alone. 
 
The effects of the muscarinic agonist, oxotremorine, and those of TGF-β 
appeared to be parallel in MRC-5 fibroblasts, as both mediated a strong stimulatory 
effect on ppET-1 mRNA expression. Therefore, possible interactions between 
cholinergic effects and the effects of TGF-β on ppET-1 mRNA expression were also 
studied. As illustrated in figure 3-17A, the stimulatory effect of the muscarinic 
agonist, oxotremorine was additive to that of TGF-β, but only when TGF-β was 
present in a low concentration of 0.1 ng/ml. In the presence of 0.3 ng/ml TGF-β, still 
not a maximally effective concentration, oxotremorine did not cause any further 
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Moreover, interaction experiments with the muscarinic antagonist tiotropium 
were performed to investigate whether non-neuronal acetylcholine synthesized by 
the fibroblasts might be involved in the action of TGF-β on the expression of ppET-1 
mRNA. As shown in figure 3-17B, the muscarinic antagonist tiotropium did not affect 




















Figure 3-17: Effects of oxotremorine (Oxo, 10 µM, A) or tiotropium (Tio, 10 nM, B) and/or 
TGF-β (at the concentration indicated) on expression of ppET-1 in MRC-5 human lung 
fibroblasts. After dissemination, cells were cultured for 24 hours in presence of 10% FCS 
followed by 24 hours in presence of 1% FCS and in absence or presence of test drugs, Tio 
being present 30 min prior to Oxo. Thereafter, total RNA was isolated, treated with DNase 
and used for quantitative real time PCR. Height of columns: ppET-1 (ΔCt over GAPDH) 
expressed as % of the Ctr. of the individual cell preparation, given are means + S.E.M. n≥5 
of independent experiments. Significance of differences: ***P<0.01 vs Ctr.; ++P<0.01 vs 
respective TGF-β alone; ns, not significant vs respective TGF-β alone; #P<0.001 vs Tio 
alone. 
 
In order to test whether an autocrine/paracrine ET-1 release may contribute to 
the muscarinic stimulation of ppET-1 mRNA expression, interaction experiments with 
the non-selective ET-1 receptor antagonist bosentan was performed. As shown in 
figure 3-18, the stimulatory effect caused by 24 hours exposure of MRC-5 cells to 10 
µM oxotremorine was largely attenuated by pre-treatment with bosentan (10 µM), 
suggesting that ET-1 actions via ET receptors are involved in oxotremorine-mediated 























































































































Figure 3-18: Effects of oxotremorine (Oxo, 10 µM) in presence or absence of bosentan 
(Bos, 10 µM) on expression of ppET-1 in MRC-5 human lung fibroblasts. After 
dissemination, cells were cultured for 24 hours in presence of 10% FCS followed by 24 
hours in presence of 1% FCS and in absence or presence of test drugs, Bos being present 
30 min prior to Oxo. Thereafter, total RNA was isolated, treated with DNase and used for 
quantitative real time PCR. Height of columns: ppET-1 (ΔCt over GAPDH) expressed as % 
of the Ctr. of the individual cell preparation, given are means + S.E.M. of n=7 independent 
experiments. Significance of differences: ***P<0.001 vs Ctr.; ++P<0.01 vs Oxo or Bos alone.  
 
3.3. Regulation of ET receptor subtypes in human lung fibroblasts 
3.3.1. Effects of TGF-β on ET receptor subtypes expression 
The effects of TGF-β on ET receptor subtypes expression at transcriptional 
level were studied in human lung fibroblast cells using real time PCR. For this 
purpose, phLFb and MRC-5 cells were cultured up to one week in presence or 
absence of different concentrations of TGF-β (0.1, 0.3, 1 and 5 ng/ml). As 
demonstrated in figure 3-19A and 3-19C, in both MRC-5 and phLFb cells, TGF-β 
strongly down-regulated in a concentration dependent manner the expression of ET-
B receptor mRNA. Contrary to this, the expression level of ET-A receptor was not 
significantly affected by TGF-β in MRC-5 cells (Fig. 3-19B) and only slightly reduced 
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Figure 3-19: Effects of TGF-β on expression of ET-A and ET-B receptors in MRC-5 and 
primary (phLFb) human lung fibroblasts. After dissemination cells were cultured for 24 h in 
presence of 10% FCS followed by 24, 72 hours or 7 days in presence of 1% FCS and 
absence or presence of TGF-β at the concentrations indicated. Thereafter, total RNA was 
isolated, treated with DNase and used for quantitative real time PCR. Height of columns: ET-
A or ET-B mRNA (ΔCt over GAPDH) expressed as % of the control of the individual cell 
preparation, given are means + S.E.M of n≥3 independent experiments. Significance of 
differences: ***P<0.001; **P<0.01; *P<0.05 vs respective Ctr.. 
 
3.4. Functional role of ET-1 and its receptors in human lung fibroblasts 
The functional role of ET-1 and its receptor subtypes in specific cellular 
functions, including proliferation, collagen synthesis and modulation of phenotype in 
human lung fibroblasts were studied. 
3.4.1. Effects of ET-1 and ET receptor subtype antagonists on proliferation  
To evaluate whether fibroblast proliferation is regulated by endothelinergic 
mechanisms, the effects of ET-1 on proliferation were studied using [3H]-thymidine 
incorporation assay. To establish an efficient protocol, different experimental 
conditions were examined. The conditions were checked for culture conditions and 
exposure time. 
(A) In the first set of experiments, cells were seeded into 12-well dishes at a density 
of 4 x 104 cells per well and cultured for 24 hours in the presence of 10% FCS, 
followed by 18-24 hours under FCS-free conditions. After a 24-hour FCS free period, 
phLFb
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increasing concentrations of ET-1 were added and present for 30 hours under FCS-
free conditions, and [3H]-thymidine (37 kBq) was present during the last 24 hours 
(i.e. it was added 6 hours after addition of ET-1). Under controlled conditions, ET-1 
caused a trend of increased proliferation of MRC-5 fibroblasts, but it was minor, with 
an increase in [3H]-thymidine incorporation, maximally by about 15% in MRC-5 
fibroblasts (Fig. 3-20A). However, under these conditions the proliferative effect of 
ET-1 was substantially more pronounced in phLFb than in MRC-5 fibroblasts, with an 
increase in [3H]-thymidine incorporation, maximally by about 74 ± 6% relative to the 
control levels (Fig. 3-20B). 
(B) In a second set of experiments, cells were seeded into 12-well dishes at density 
of 5 x 104 cells per well and cultured for 5 hours in the presence of 10% FCS. 
Thereafter, cells were starved overnight in serum free medium, exposed 
subsequently for 30 hours to ET-1 at varying concentrations, and [3H]-thymidine (37 
kBq) was present during the last 24 hours. Under these conditions, ET-1 
concentration-dependently increased [3H]-thymidine incorporation in both cell types, 
phLFb and MRC-5 fibroblasts maximally by about 39 ± 6% and 56 ± 10% at 100 nM 
respectively (Fig. 3-20C). 
(C) In the third protocol, with the intention of reducing the influence of a possible 
endogenous endothelinergic tone, cells were FCS-deprived and varying 
concentrations of ET-1 were applied from the onset of the test culture period, and 
cells were incubated for 30 hours with [3H]-thymidine (37 kBq) present for the last 24 
hours. Under these conditions, ET-1 strongly induced proliferation of phLFb and 
MRC-5 fibroblasts with an increase in [3H]-thymidine incorporation by about 100% 
relative to the control levels (Fig. 3-20D). Noteworthy, for both cells types the 
maximum effect appears already reached at lower concentrations of ET-1 than under 
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Figure 3-20: Effects of ET-1 on [3H]-thymidine incorporation (A-D) in MRC-5 and primary 
(phLFb) human lung fibroblasts. A and B: 4 x104 cells were seeded in 12-well dishes and 
first cultured for 24 hours in presence of 10% FCS, followed by additional 24 hours under 
FCS-free conditions. After a 24 hours FCS-free period ET-1 was added as indicated for 30 
hours. [3H]-thymidine (37 kBq) was present for the last 24 hours (i.e. it was added 6 hours 
after addition of test drugs). C: 7.5 x 104 cells were seeded in 12-well dishes and first 
cultured for 5 hours in presence of 10% FCS. Thereafter, cells were starved overnight in 
serum free medium, stimulated subsequently for 30 hours with ET-1 and [3H]-thymidine was 
present during the last 24 hours. D: 2 x 105 cells were seeded in 12-well dishes and cultured 
from the onset under FCS-free conditions for 30 hours in absence or presence of ET-1, and 
[3H]-thymidine (37 kBq) was present for the last 24 hours. Cellular radioactivity expressed as 
% of the mean value of the controls of each cell preparation. Given are means + S.E.M of 




In order to prove the specificity of the effect of ET-1 on which of the ET-
receptor subtype mediates proliferation of human lung fibroblasts, interaction 
experiments with the selective ET-receptor antagonists, BQ-123 (ET-A) and BQ-788 
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performed. For this purpose, condition (A) was applied. As depicted in figure 3-21A, 
in MRC-5 fibroblasts, bosentan and ET-A antagonist BQ-123 concentration 
dependently reduced the basal [3H]-thymidine incorporation, maximally by about 
45% and 30%, respectively, whereas the ET-B antagonist BQ-788 had no significant 
effects. ET-1 alone caused only a minor increase in [3H]-thymidine incorporation, 
maximally by about 15%. However, ET-1 was able to surmount in a concentration 


















Figure 3-21: Effects of bosentan, the ET-A (BQ-123) and ET-B (BQ-788) receptor selective 
antagonist (A) and ET-1 in absence or presence of bosentan (Bos) on [
3
H]-thymidine 
incorporation (B) in MRC-5 human lung fibroblasts. 4 x 10
4
 cells were seeded in 12-well dishes 
and first cultured for 24 hours in presence of 10% FCS, followed by additional 24 hours under 
FCS-free conditions. After a 24 hours FCS-free period test drugs were added as indicated for 30 
hours. [
3
H]-thymidine (37 kBq) was present for the last 24 hours (i.e. it was added 6 hours after 
addition of test drugs). B: Bosentan was present 30 min before addition of ET-1, and [
3
H]-
thymidine during the last 24 hours. Cellular radioactivity expressed as % of the mean value of the 
controls of each cell preparation. Given are means + S.E.M of n≥9 experiments. Significance of 
differences: **P<0.01; ***P<0.001 vs respective controls; 
+++
P<0.001 vs respective value in 
presence of Bos alone; 
#
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Furthermore, in phLFb, under basal conditions, bosentan and BQ-123 caused 
also a reduction in [3H]-thymidine incorporation, maximally by about 28% and 10% 
respectively. The maximum inhibitory effect bosentan and BQ-123 was smaller than 
that observed in MRC-5 cells, whereas, ET-B antagonist BQ-788 had no significant 
effects (Fig. 3-22A). Moreover, ET-1 was also able to surmount in a concentration 
dependent manner the inhibitory effect of bosentan and BQ-123 (Fig. 3-22B and 3-
22C). BQ-788 did not significantly affect the ET-1-mediated increase in [3H]-
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Figure 3-22: Effects of bosentan, the ET-A (BQ-123) and ET-B (BQ-788) receptor selective 
antagonist (A) and ET-1 in absence or presence of bosentan (Bos, B) or in absence or 
presence of ET-A (BQ-123, C) on [3H]-thymidine incorporation in primary human lung 
fibroblasts. 4 x 104 cells were seeded in 12-well dishes and first cultured for 24 hours in 
presence of 10% FCS, followed by additional 24 hours under FCS-free conditions. After a 24 
hours FCS-free period test drugs were added as indicated for 30 hours. [3H]-thymidine (37 
kBq) was present for the last 24 hours (i.e. it was added 6 hours after addition of test drugs). 
B: Bosentan was present 30 minute before addition of ET-1, and [3H]-thymidine during the 
last 24 hours. Cellular radioactivity expressed as % of the mean value of the Ctr. of each cell 
preparation. Given are means + S.E.M of n≥9 independent experiments. Significance of 
differences: *P<0.05; **P<0.01; ***P<0.001 vs respective Ctr.; +++P<0.001 vs respective 
value in presence of Bos alone; #P<0.001 vs respective value in absence of Bos. 
 
3.4.2. Effect of ET-1 on cell numbers 
Since DNA synthesis may occur without cell division, cell numbers were 
examined to verify that the increase in DNA synthesis induced by ET-1 in human 
lung fibroblast cells as assessed by [3H]-thymidine incorporation assay indeed 
reflects an increase in cell proliferation. MRC-5 cells were cultured under FCS-free 
condition for 28 and 48 hours which are comparable with those conditions used in 
[3H]-thymidine incorporation assay, where ET-1 exhibited strong effects. The number 
of cells under control conditions was 45000 ± 5300 (at 28 hours, n = 22) and 63500 ± 
3850 (at 48 hours, n = 18, P < 0.05 vs. 24 hours). Exposure of the cells to ET-1 (10 
nM) caused a marked increase in the number of MRC-5 cells by about 70% and 80% 
respectively (Fig. 3-23). In comparison, the addition of 1% FCS for 28 hours caused 
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were also involved in this effect, interaction experiments with bosentan (10 µM) were 
performed. The cell count in the presence of bosentan (10 µM) alone tended to be 
reduced after 28 hours and was significantly reduced by 35% after 48 hours. In 


















Figure 3-23: Effects of ET-1 in absence or presence of bosentan (Bos) on cell count in 
MRC-5 human lung fibroblasts. 7.5 x 104 cells were seeded in 12-well dishes and cultured 
from the onset under FCS-free conditions for 28 or 48 hours in absence or presence of test 
substance (include 1% FCS). Cell count expressed as % of the mean value of the Ctr. of 
each cell preparation. Given are means + SEM of n = 18–22 independent experiments. 
Significance of differences: *P < 0.05; ***P < 0.001 versus respective Ctr.; ++P < 0.01; versus 
respective value in absence of Bos. 
 
 
3.4.3. Role of the Rho-kinase in ET-1-induced proliferation  
In order to investigate whether the Rho kinase might be involved in the 
endothelinergic stimulation of proliferation of MRC-5 human lung fibroblasts, 
interaction experiments with Rho kinase inhibitor Y-27632 were performed. For this 
purpose, cells condition (C) was applied. As shown in figure 3-24, ET-1 significantly 
enhanced [3H]-thymidine incorporation, while the Rho-kinase inhibitor Y-27632 (3 
µM) reduced [3H]-thymidine incorporation by about 40 %. However, the Rho-kinase 
inhibitor Y-27632 did not inhibit ET-1 induced stimulation of [3H]-thymidine 
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Figure 3-24: Effects of the Rho-kinase inhibitor Y-27632 on ET-1 mediated increase in [3H]-
thymidine incorporation in MRC-5 human lung fibroblast proliferation. 2 x105 cells were 
seeded in 12 well dishes in the absence of FCS and cultured for 30 hours with or without test 
drugs as indicated. Y-27632 was present 30 minutes before the addition of ET-1, and [3H]-
thymidine (37 kBq) was applied for the last 24 hours (i.e. it was added 6 hours after addition 
of ET-1). Cellular radioactivity expressed as % of the mean value of the Ctr. of each cell 
preparation. Given are means ± SEM of n=6 independent experiments. Significance of 
differences: ***P<0.001 vs respective Ctr.; ns, not significant vs respective Y-27632 alone. 
 
 
3.4.4. Effects of ET-1 and ET receptor antagonist on myofibroblast 
differentiation 
To verify whether ET-1 and ET receptors were involved in the differentiation of 
MRC-5 fibroblast to myofibroblast, the effect of ET-1 and the non selective ET 
receptor antagonist, bosentan on the expression of smooth muscle actin protein (α-
SMA), a marker of myofibroblast differentiation was examined by Western blot 
analysis. MRC-5 cells cultured under standard conditions showed expression of α-
SMA (Fig. 3-25A). Exposure of the cells to bosentan (10 µM), for a 24 hour period, 
caused a clear reduction in α-SMA protein levels by about 50%, whereas ET-1 10 
nM (Fig. 3-25B) or 100 nM (data not shown) induced only a minor increase by about 
25%.  
Furthermore, exposure of the cells for 24 hours to 0.3 ng/ml TGF-β, caused an 
increase in α-SMA protein expression by about 120%, whereas bosentan (10 µM) 
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Figure 3-25: Effects of the ET-1 (10 nM), TGF-β (0.3 ng/ml) and/or bosentan (Bos, 10 µM) 
on -smooth muscle actin (-SMA) expression in MRC-5 human lung fibroblasts. 3 x 105 
cells were seeded in 35 mm dishes and cultured for 24 hours in presence of 10% FCS. After 
a 24 hours FCS-free period, cells were cultured for additional 24 hours in FCS-free medium 
in absence or presence of test substances. Cellular proteins were extracted and Western 
blot analysis for -SMA and -tubulin was performed. (A) Samples of original Western blots. 
(B) Densitometric analysis of a series of Western blots, ratio -SMA/-tubulin, expressed as 
% of Ctr.. Given are means + S.E.M of n≥7 independent experiments. Significance of 
differences: *P<0.05, **P<0.01, ***P<0.001 vs Ctr..  
 
3.4.5. Role of ET-1 and its receptors in the regulation of collagen synthesis  
To investigate whether ET-1 may contribute to fibrotic responses through the 
enhancement of collagen synthesis, the effect of ET-1 on collagen synthesis, as 
determined by [3H]-proline incorporation was investigated. In MRC-5 fibroblasts, 
under controlled conditions (i.e., absence of FCS and any test drugs) [3H]-proline 
incorporation into cellular proteins during 24 hours incubation amounted to 30.557 ± 
2.163 d.p.m. (disintegration per minute) (n=45). As shown in figure 3-26A, ET-1 (1-
100 nM) caused a concentration-dependent increase in [3H]-proline incorporation, 
maximally by about 85% at 10 nM (EC50: 0.7 nM). Therefore, in further experiments 
ET-1 at a concentration of 10 nM was used. 
Additionally, to confirm the stimulatory effect of ET-1 on collagen synthesis in 
human lung fibroblasts, [3H]-proline incorporation experiments were performed with 
primary human lung fibroblasts (phLFb). As demonstrated in figure 3-26B, [3H]-
proline incorporation was increased by ET-1 in a concentration dependant-manner, 




























































































Figure 3-26: Effects of ET-1 on [3H] proline incorporation in MRC-5 (A) and primary human 
lung fibroblasts (phLFb) (B). 105 cells were seeded in 12-well dishes and first cultured for 24 
h in presence of 10% FCS, followed by additional 24 hours under FCS-free conditions. 
Thereafter, [3H]-proline (37 kBq) was added alone or in combination with test drugs and cells 
were cultured for further 24 hours. Radioactivity incorporated in cellular and extracellular 
protein was determined. Data expressed as % of the mean value of the controls of each cell 
preparation. Given are means + S.E.M of n≥9 independent experiments. Significance of 
differences: ***P<0.001 vs controls (absence of drugs). 
 
After investigating that ET-1 stimulates collagen synthesis in both MRC-5 
fibroblasts and phlFb, it was important to further investigate which ET receptor 
subtype mediates this effect. To address this issue, interaction experiments with the 
selective ET-receptor antagonists, BQ-123 (ET-A) and BQ-788 (ET-B) as well as the 
non-selective ET-receptor antagonist, bosentan were performed. As shown in figure 
3-27A, in confirmation of preceding observations (Fig. 3-26A) ET-1 enhanced the 
[3H]-proline incorporation in MRC-5 cells in a concentration dependent manner, while 
bosentan and BQ-123 caused a reduction in [3H]-proline incorporation by about 20%. 
BQ-788 had no significant effect on basal [3H]-proline incorporation (Fig. 3-27A). The 
stimulatory effect of ET-1 on the collagen synthesis was effectively antagonized by 
pre-treatment of the cells with bosentan and BQ-123. In contrast, blocking ET-B with 
BQ-788 had no effect (Fig. 3-27A). 
Furthermore, in phLFb, none of the ET receptor antagonists significantly 
affected the basal levels of [3H]-proline incorporation (Fig. 3-27B). However, like in 
MRC-5 cells, the effect of ET-1 was effectively, but in a surmountable manner, 
antagonized by bosentan and BQ-123, whereas BQ-788, did not significantly affect 
the effect of ET-1 response (Fig. 3-27B). In both cell types the antagonistic effect of 
bosentan and BQ-123 was surmountable, suggestion a competitive interaction 
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Moreover, there is evidence that blockade of ET-A receptors could unmask an 
ET-B receptor-mediated effect in MRC-5 fibroblasts as determined by dynamic mass 
redistribution measurement (Ahmedat et al., 2013). Therefore, BQ-788 was also 
studied in presence of BQ-123 either alone or in combination with 10 or 100 nM ET-

















Figure 3-27: Concentration-dependent effects of ET-1 in absence and presence of bosentan 
(Bos) or the ET-A (BQ-123) or ET-B (BQ7-88) receptor selective antagonist on [3H]-proline 
incorporation in MRC-5 (A) phLFb (B). 105 cells were seeded in 12-well dishes and first 
cultured for 24 hours in presence of 10% FCS, followed by additional 24 hours under FCS-
free conditions. Thereafter, [3H]-proline (37 kBq) was added alone or in combination with test 
drugs and cells were cultured for further 24 hours. Bos (10 µM) or BQ-123 (1 µM) or BQ-788 
(100 nM) were present 30 minute prior to exposure to ET-1. Radioactivity incorporated in 
cellular and extracellular protein was determined. Data expressed as % of the mean value of 
the controls of each cell preparation. Given are means + S.E.M of n≥9 independent 
experiments. Significance of differences: *P<0.05, **P<0.01, ***P<0.001 vs Ctr. (absence of 
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In addition, the stimulatory effects of ET-1 on collagen synthesis was further 
evidenced by directly measuring of collagen, using the QuickZyme collagen assay 
that is based on specific binding of the dye Sirius Red to collagen. The amount of 
collagen detected in control cultures was 5.1 ± 0.7 µg (n=5). Exposure of MRC-5 
cells to ET-1 for 24 hours caused in a concentration-dependent manner, a 
substantial increase of the amount of collagen, maximally by 175% at 10 nM (Fig. 3-
28). Interestingly, there was no further increment in the collagen synthesis by 
increasing the concentration above 10 nM of ET-1. The results observed in two 
different assays ([3H]-proline incorporation assay and QuickZyme collagen assay) 








Figure 3-28: Effect of ET-1 on collagen synthesis by MRC-5 human lung fibroblasts. 105 
cells were seeded in 24-well dishes and first cultured for 24 hours in presence of 10% FCS, 
followed by additional 24 hours under FCS-free conditions. Thereafter, cells were cultured 
for further 24 hours in absence or present of different concentrations of ET-1. Collagen 
content of cells and extracellular matrix was determined by the QuickZyme collagen assay. 
Data expressed as % of the mean value of the controls of each cell preparation. Given are 
means + S.E.M of n= 5 experiments. Significance of differences: *P<0.05; **P<0.01 and 
***P<0.001 vs controls (absence of drugs). 
 
3.4.6. Effect of ET-1 on COL I-α1 mRNA expression 
To test whether an enhanced collagen gene transcription contributes to the 
ET-1-induces increase in the collagen synthesis in human lung fibroblasts, the effect 
of ET-1 on the expression of COL I-α1 mRNA, a major collagen type in lung 
fibroblasts, was examined. As shown in figure 3-29, exposure of MRC-5 cells to 10 
nM and 100 nM ET-1 for 24 hours, caused an increase in the expression levels of 
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Furthermore, the increase in COL I-α1 mRNA expression induced by 10 nM 
and 100 nM ET-1 was prevented by pre-treatment with the non-selective ET-receptor 
antagonist bosentan (10 µM), which alone had no effect on the expression of COL I-












Figure 3-29: Effect of ET-1 in absence or presence of bosentan (Bos) on COL I-α1 mRNA 
expression in MRC-5 human lung fibroblasts. 3 x 105 cells were seeded in 6-well dishes and 
first cultured for 24 hours in presence of 10% FCS, followed by additional 24 hours under 
FCS-free conditions in absence or presence of test substances at the concentrations given. 
Thereafter, total RNA was isolated, treated with DNase and used for quantitative real time 
PCR. Height of columns: collagen I-α1 mRNA (ΔCt over GAPDH) expressed as % of the Ctr. 
of the individual cell preparation, given are means + S.E.M of n≥6 independent experiments. 
Significance of differences: ***P<0.01 vs Ctr., +++P<0.001 vs respective value in absence of 
Bos. 
 
3.4.7. Effects of ET receptor subtype antagonists on TGF-β-mediated collagen 
synthesis stimulation 
As the preceding results showed that TGF-β enhanced ppET-1 expression 
and ET-1 release in MRC-5 fibroblasts, it was further examined whether the 
stimulatory effect of TGF-β on collagen synthesis involves ET-1. Therefore 
interaction experiments with the selective ET-A (BQ-123) or ET-B (BQ-788) receptor 
antagonists, as well as the non selective ET receptor antagonist bosentan were 
performed. As shown in figure 3-30A, TGF-β in the relatively low concentrations of 
0.1, 0.3 and 1 ng/ml exhibited strong stimulatory effect on [3H]-proline incorporation, 
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control conditions caused (like in preceding experiments, Fig. 3-27A) a reduction in 
[3H]-proline incorporation by about 20% (Fig. 3-30B-C), whereas BQ-788 (100 nM) 
had no effect (Fig. 3-30C). However, in presence of bosentan or BQ-123, TGF-β still 
induced significant increases in [3H]-proline incorporation, but its effect was 
significantly attenuated, interestingly, compared to control conditions (Fig. 3-30B and 
C) a significantly large fraction was sensitive to ET receptor blockade by bosentan 
(10 µM) or BQ-123 (1 µM). BQ-788 (100 nM) failed to inhibit the TGF-β-mediated 



















Figure 3-30: Effects of TGF-β (0.1, 0.3 and 1 ng/ml) (A) and of bosentan (Bos, 10 µM) (B) or 
the ET-A (BQ123, 1 µM) (C) or the ET-B (BQ788, 100 nM) (D) receptor selective antagonist 
in absence and presence of 0.3 and 1 ng/ml TGF-β on [3H]-proline incorporation in MRC-5. 
105 cells were seeded in 12-well dishes and first cultured for 24 h in presence of 10% FCS, 
followed by additional 24 hours under FCS-free conditions. Thereafter, [3H]-proline (37 kBq) 
was added alone or in combination with test drugs and cells were cultured for further 24 
hours. Radioactivity incorporated in cellular and extracellular protein was determined and 
expressed as % of the mean value of the respective Ctr. (in absence or presence of TGF-β) 
of each cell preparation. Given are means + S.E.M of n≥8 independent experiments. 
Significance of differences: *P<0.05, ***P<0.001 vs respective Ctr.; +P<0.05 vs respective 
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3.4.8. Effect of ET receptor antagonist on muscarinic agonist-mediated 
collagen synthesis stimulation 
As the preceding results showed that the muscarinic agonist oxotremorine 
increased the ppET-1 mRNA expression, it was further tested whether ET-1 up-
regulated by oxotremorine might contribute to the pro-fibrotic effects of this mediator. 
Therefore, the effects of the non-selective ET-1 receptor antagonist bosentan on the 
stimulatory effect of oxotremorine on collagen synthesis were studied. Under control 
conditions, oxotremorine (10 µM) caused an increase in [3H]-proline incorporation by 
about 50%, whereas bosentan slightly, but significantly, reduced the basal [3H]-
proline incorporation by about 20%, and attenuated the stimulatory effect of 
oxotremorine on [3H]-proline incorporation (Fig 3-31A). In presence of bosentan, 
oxotremorine induced still a significant increase in [3H]-proline incorporation, but its 
effect was smaller. In other words, in presence of oxotremorine, bosentan showed 



















Figure 3-31: Effects of oxotremorine (Oxo, 10 µM) in absence and presence of bosentan 
(Bos, 10 µM) on [3H]-proline incorporation in MRC-5 (A). 105 cells were seeded in 12-well 
dishes and first cultured for 24 h in presence of 10% FCS, followed by additional 24 hours 
under FCS-free conditions. Thereafter, [3H]-proline (37 kBq) was added alone or in 
combination with test drugs and cells were cultured for further 24 hours. Bos was present 30 
minute prior to the exposure to Oxo. Radioactivity incorporated in cellular and extracellular 
protein was determined and expressed as % of the mean value of the respective Ctr. (in 
absence of test substance, A) or the respective experiments in absence of bosentan (B) of 
each cell preparation. Given are means + S.E.M n≥9 of independent experiments. 
Significance of differences: **P<0.01, ***P<0.001 vs Ctr.; +++P<0.001 vs respective value in 
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Additionally, possible interactions between cholinergic effects and the effects 
of TGF-β on collagen synthesis in MRC-5 fibroblasts were also studied. As shown in 
figure 3-32, the stimulatory effect of oxotremorine was additive to that of TGF-β, but 
only when TGF-β was present in a relatively low concentration of 0.1 ng/ml. In 
presence of 0.3 ng/ml TGF-β, still not a maximally effective concentration, 
oxotremorine did no longer cause a significant further increase in [3H]-proline 
incorporation. The additive effect of TGF-β along with oxotremorine was consistent 

















Figure 3-32: Effects of oxotremorine (Oxo, 10 µM) and/or TGF-β (0.1 or 0.3 ng/ml as 
indicated) on [3H]-proline incorporation in MRC-5. 105 cells were seeded in 12-well dishes 
and first cultured for 24 hours in presence of 10% FCS, followed by additional 24 hours 
under FCS-free conditions. Thereafter, [3H]-proline (37 kBq) was added alone or in 
combination with test drugs and cells were cultured for further 24 hours. Radioactivity 
incorporated in cellular and extracellular protein was determined and expressed as % of the 
mean value of the respective controls (in absence of test substance) or the respective 
experiments in absence of Oxo of each cell preparation. Given are means + S.E.M of n=9 
independent experiments. Significance of differences: ***P<0.001 vs Ctr.; ++P<0.01 vs 








































































  Results 
104 
 
3.4.9. Effects of ET-1 and ET receptor subtype antagonists on ERK1/-2   
phosphorylation  
As previous studies in our laboratory demonstrated that the muscarinic 
receptor induced stimulation of proliferation and collagen synthesis in human lung 
fibroblasts was mediated by activation of the ERK MAP kinase pathway (Matthiesen 
et al., 2007; Haag et al., 2008a) a possible role of the MAPK pathway in ET-1 
induced effects was analysed. In this regard, Western blot analysis was performed to 
examine whether ERK1/-2 MAPK cascade is activated by ET-1. Data shown in figure 
3-33 indicate that ET-1, similar to the muscarinic agonist oxotremorine, induced a 
strong and rapid but transient activation of ERK1/-2. There was a rapid increase of 
phosphorylated ERK1/-2 in cells exposed to 10 and 100 nM of ET-1 maximally 
already within 5 minutes by 384 % and 409%, respectively. The maximum effect of 
ET-1 was somewhat larger than that of oxotremorine (10 μM, also a maximally 
effective concentration, Matthiesen et al., 2007; Haag et al., 2008a). The effect of 
ET-1 on ERK1/-2 rapidly declined, and phosphorylated ERK1/-2 returned to baseline 
levels within 30 minutes after ET-1 exposure. Therefore, in subsequent experiments, 
a five minute treatment with 10 nM ET-1 was used. Total amount of ERK1/-2 was not 
affected by ET-1.  
A 
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Figure 3-33: Western blot analysis of phospho-p42/44 (ERK1/-2) MAPK in MRC-5 human 
lung fibroblasts. Cells were cultured in 55 mm dishes to nearly confluence, serum-starved for 
24 hours and exposed to 10 or 100 nM ET-1, 10 µM oxotremorine (Oxo), or vehicle (Ctr.) for 
5–30 minute (as indicated). In controls, cells were treated with solvent at the respective time 
points (i.e. 5, 10, 15, and 30 min before cell lysis, respectively). Cell lysates were prepared 
and 20 µg were separated in 4-12% acrylamide Tris–glycine gels, immobilized to PVDF 
membranes and detected by antibodies specific for phosphorylated and unphosphorylated 
ERK. (A) Samples of original Western blots. (B) Densitometrical quantification of the p44/42 
bands was performed and values (arbitrary units, normalized over unphosphorylated ERK) 
expressed as % of the respective Ctr.. Given are means + S.E.M of n=3–14 independent 
Western blots. Significance of differences: **P<0.01, ***P<0.001 vs respective Ctr.. 
 
 
Furthermore, in order to identify the ET receptor involved, interaction 
experiments with selective ET receptor antagonists BQ-123 (ET-A) and BQ-788 (ET-
B) were performed. These compounds were added to MRC-5 cells for 30 minute 
prior to the ET-1 treatment and the solvent of the antagonists were also added to all 
samples 30 minute prior to the addition of ET-1 to keep all samples at the same 
experimental conditions. As shown in figure 3-34, BQ-123 caused a reduction in the 
basal phospho-p42/44 levels by about 30%. Moreover, the increase in 
phosphorylated ERK1/-2 MAPK induced by 10 and 100 nM ET-1 was significantly 
inhibited by 1 μM BQ-123 (by about 60% and 72% respectively with respect to 
presence the of ET-1), whereas BQ-788 (100 nM) showed no effects, neither in 
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(in the concentration present with BQ-788) significantly attenuated the stimulatory 
effect of ET-1. Therefore, the data in figure 3-34 show effects in relation to respective 
controls in absence or presence of the solvent.  
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Figure 3-34: Western blot analysis of p42/44 (ERK1/-2) MAPK in MRC-5 human lung 
fibroblasts. Cells were cultured in 55 mm dishes to nearly confluence, serum-starved for 24 h 
and exposed to 10 or 100 nM ET-1, or vehicle (Ctr.) for 5–30 min (as indicated). The ET-A 
(BQ-123, 1 µM) or ET-B (BQ-788, 100 nM) receptor antagonist was present 30 min prior to 
exposure to ET-1. In controls, cells were treated with solvent at the respective time points 
(i.e. 5 min and additionally 30 min before cell lysis, respectively). Cell lysates were prepared 
and 20 µg were separated in 4-12% acrylamide Tris–glycine gels, immobilized to PVDF 
membranes and detected by antibodies specific for phosphorylated and unphosphorylated 
ERK. (A) Samples of original Western blots. (B) Densitometrical quantification of the p44/42 
bands was performed and values (arbitrary units, normalized over unphosphorylated ERK) 
are expressed as % of the respective control, in absence or presence of ET-1 and absence 
or presence of the solvent DMSO (which was required to dissolve BQ-788). Given are 
means + SEM of n=4 independent Western blots. Significance of differences: *P<0.05, 
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3.4.10. Role of the Rho-kinase in ET-1-induced activation of ERK1/-2 MAPK 
In order to investigate whether Rho-kinase is involved in ET-1 induced 
activation of ERK1/-2 MAPK pathways, interaction experiments using the Rho kinase 
inhibitor, Y-27632 (3 µM) were performed. As shown in figure 3-35, under control 
conditions, Y-27632 (3 µM) by its own did not affect basal phospho-p42/44 levels; 
however the increase in phosphorylated ERK1/-2 MAPK induced by 10 nM ET-1 was 
partially inhibited by 3 µM Y-27632. In other words, in presence of Y-27632 Rho-
kinase inhibitor, ET-1 still induced a significant increase in phosphorylated ERK1/-2 
MAPK, but its effects was significantly attenuated. 
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                                                  ERK1/-2      
                                Ctr.               ET-1         Y-27632       Y-27632  














Figure 3-35: Western blot analysis of phospho-p42/44 (ERK1/-2) MAPK in MRC-5 human 
lung fibroblasts. Cells were cultured in 55 mm dishes to nearly confluence, serum-starved for 
24 h and exposed to 10 nM ET-1 or vehicle (Ctr.) for 5 min (as indicated). The Rho kinase 
inhibitor (Y-27632, 3 µM) was present 30 min prior to exposure to ET-1. In controls, cells 
were treated with solvent at the respective time points (i.e. 5 min and additionally 30 min 
before cell lysis). Cell lysates were prepared and 20 µg were separated in 4-12% acrylamide 
Tris–glycine gels, immobilized to PVDF membranes and detected by antibodies specific for 
phosphorylated and unphosphorylated ERK. (A) Samples of original Western blots. (B) 
Densitometrical quantification of the p44/42 bands was performed and values (arbitrary 
units, normalized over unphosphorylated ERK) expressed as % of the respective control and 
in absence or presence of ET-1. Given are means + S.E.M of n=3 independent experiments. 
Significance of differences: *P<0.05 vs respective Ctr.; +P<0.05 vs respective value in 
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3.5. Characterization of the involvement of signal pathway of ET-1-mediated 
collagen synthesis stimulation in human lung fibroblasts 
3.5.1. Effect of pertussis toxin on ET-1-mediated collagen synthesis 
stimulation  
Since ET-1 receptors belong to the GPCR subfamily (Arai et al., 1990; 
Sakurai et al., 1990) and the preceding results clearly demonstrated that ET-1 
mediates an increase in collagen synthesis via ET-A receptor subtype in human lung 
fibroblasts, it was investigated whether the stimulatory effect of ET-1 on collagen 
synthesis in human lung fibroblasts is mediated via Gαi-coupled receptor like the 
effect of muscarinic receptors (Haag et al., 2008a). Pertussis toxin (PTX), an 
exotoxin produced by Bordetella pertussis was used, as a pharmacological tool to 
elucidate the involvement of Gαi proteins. For this purpose, serum starved MRC-5 
fibroblasts were pre-incubated for 3 hours with 50 ng/ml PTX, followed by measuring 
the effects of 100 nM ET-1 or 10 µM oxotremorine on collagen synthesis as 
determined by [3H] proline incorporation. Under control conditions, ET-1 and 
oxotremorine increased the [3H]-proline incorporation to 173% and 146%, 
respectively. PTX reduced basal [3H]-proline incorporation by about 37% and 
completely inhibited the effect of 10 µM oxotremorine, but not that of ET-1. When 
expressed in relation to the respective untreated control values as shown in figure 3-
36, the effect of ET-1 was largely attenuated, but when expressed in relation to the 
respective (somewhat reduced) PTX value, an increase to 169% is seen, i.e. effect 








































Figure 3-36: Effects of ET-1 (10 nM), oxotremorine (Oxo, 10 µM) and/or pertussis toxin 
(PTX, 50 ng/ml) on [3H]-proline incorporation in MRC-5 human lung fibroblasts. 105 cells 
were seeded in 12-well dishes. Cells were first cultured for 24 h in presence of 10% FCS, 
followed by additional 24 hours under FCS-free conditions. Thereafter, [3H]-proline (37 kBq) 
was added alone or in combination with test drugs, and cells were cultured for further 24 
hours. PTX was present 3 hours prior to the exposure to ET-1 or Oxo. Radioactivity 
incorporated in cellular and extracellular protein was determined and expressed as % of the 
mean value of the Ctr. of each cell preparation. Given are means + S.E.M of n=9 
independent experiments. Significance of differences: ***P<0.001 vs Ctr.; +++P<0.001 vs 
respective value in presence PTX or ET-1 alone. 
 
3.5.2. Effect of pertussis toxin on ET-1-induced activation of the ERK1/-2 
MAPK pathway 
In order to characterize the involvement of Gi proteins in ET-1 induced ERK1/-
2 activation, the effect of pertussis toxin (PTX) on ET-1 induced phosphorylation of 
ERK1/-2 was studied. As shown in figure 3-38, PTX (50 ng/ml) alone caused a 
reduction in phospho-ERK1/-2 levels by about 37% and largely attenuated the 
increase in phospho- ERK1/-2 induced by 10 µM oxotremorine, but did not have 
clear effect on that of ET-1 (Fig. 3-38). When expressed in relation to untreated 
controls or in relation to the respective ET-1 values, the increase in phospho-ERK1/-
2 induced by 100 nM ET-1 was somewhat reduced by PTX, but when expressed in 
relation to the respective PTX values, the effect of ET-1 on phospho-ERK1/-2 was 
similar to that observed in absence of PTX. 
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Figure 3-38: Western blot analysis of phospho-p42/44 (ERK1/-2) MAPK in MRC-5 human 
lung fibroblasts. Cells were cultured in 55 mm dishes to nearly confluence, serum-starved for 
24 hours and exposed to 10 or 100 nM ET-1, 10 µM oxotremorine (Oxo), or vehicle (Ctr.) for 
5 min (as indicated). In the respective experiments, pertussis toxin (PTX, 50 ng/ml) was 
present 6 hours prior to exposure to ET-1. In controls, cells were treated with solvent at the 
respective time points (i.e. 5 minute and additionally 6 hours before cell lysis). Cell lysates 
were prepared and 20 µg were separated in 4-12% acrylamide Tris–glycine gels, 
immobilized to PVDF membranes and detected by antibodies specific for phosphorylated 
and unphosphorylated ERK. (A) Samples of original Western blots. (B) Densitometrical 
quantification of the p44/42 bands was performed and values (arbitrary units, normalized 
over unphosphorylated ERK) are expressed as % of the respective control and in absence 
or presence of ET-1. Given are means + S.E.M of n=4–14 independent experiments. 
Significance of differences: ***P<0.001 vs respective Ctr.; #P<0.01 vs respective value in 
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3.5.3. Role of ERK1/-2 MAPK in ET-1-mediated stimulation of collagen 
synthesis  
As previous results showed that ET-1 can activate ERK1/-2 in MRC-5 cells, it 
was tested whether ET-1 may stimulate collagen synthesis through the MAP kinase 
pathways. Therefore, interaction experiments with PD 098059, a specific inhibitor of 
the upstream kinase that activates ERK1/-2 MAP kinase were performed. As shown 
in figure 3-39, PD 098059 did not affect the basal [3H]-proline incorporation, but the 
stimulatory effect of 10 nM ET-1 on [3H]-proline incorporation was largely inhibited by 


















Figure 3-39: Effects of ET-1 (10 nM) and/or PD 098059 (PD, 10 and 30 µM) on [3H]-proline 
incorporation in MRC-5 human lung fibroblasts. 105 cells were seeded in 12-well dishes. 
Cells were first cultured for 24 hours in presence of 10% FCS, followed by additional 24 
hours under FCS-free conditions. Thereafter, [3H]-proline (37 kBq) was added alone or in 
combination with test drugs, and cells was cultured for further 24 hours. In the respective 
experiments, PD was present 30 minute prior to the exposure to ET-1. Radioactivity 
incorporated in cellular and extracellular protein was determined and expressed as % of the 
mean value of the controls of each cell preparation. Given are means + S.E.M of n=9 
independent experiments. Significance of differences: ***P<0.001 vs Ctr.; +++P<0.001 vs. 
respective value in presence of ET-1 alone. 
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3.5.4. Role of Rho kinase in ET-1-mediated stimulation of collagen synthesis  
In order to investigate whether Rho kinase is involved in endothelinergic 
stimulation of collagen synthesis in MRC-5 fibroblasts, effects of the Rho-kinase 
inhibitor Y-27632 on the stimulatory effect of ET-1 on collagen synthesis were 
studied. As shown in figure 3-40A, ET-1 (10 nM) enhanced the [3H]-proline 
incorporation to 186% while the Rho-kinase inhibitor Y-27632 reduced the basal 
level of [3H]-proline incorporation significantly to 87%, 84% and 78% at 1, 3 and 10 
μM concentration, respectively. The stimulatory effect of ET-1 (10 nM) on collagen 
synthesis was largely attenuated by Y-27632 at 1, 3 and 10 μM concentration as 
shown by the reduction in the [3H]-proline incorporation to 157%,136%, 132%, 
respectively in relation to untreated controls (Fig. 3-40A). When expressed in relation 
to the respective value the of 3 and 10 μM Y-27632, the increase caused by ET-1 
was partially but significantly attenuated to 159 % and 168%, respectively, but not 
affected by 1 μM Y-27632 (Fig. 3-40B). In another word, in presence of both drugs, 
ET-1 still induced a significant increase in [3H]-proline incorporation compared to 3 
μM or 10 μM Y-27632 alone, i.e. ET-1 exerted still a significant stimulatory effect, 
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Figure 3-40: Effects of ET-1 (10 nM) and/or Rho kinase inhibitor (Y-27632, at the 
concentrations given) on [3H]-proline incorporation in MRC-5 human lung fibroblasts. 105 
cells were seeded in 12-well dishes. Cells were first cultured for 24 hours in presence of 
10% FCS, followed by additional 24 hours under FCS-free conditions. Thereafter, [3H]-
proline (37 kBq) was added alone or in combination with test drugs, and cells was cultured 
for further 24 hours. In the respective experiments, Y-27632 was present 30 minute prior to 
the exposure to ET-1. Radioactivity incorporated in cellular and extracellular protein was 
determined and expressed as % of the mean value of the controls of each cell preparation. 
Given are means + S.E.M of n=9 independent experiments. Significance of differences: 
*P<0.05, ***P<0.001 vs respective control; ++P<0.01, +++P<0.001 vs. respective value in 
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4.1. Expression of endothelines and their receptors in human lung fibroblasts 
As outlined already in the introduction, endothelins (ET-1, ET-2 and ET-3) 
represent a family of small peptides of 21 amino acids. They are synthesised as 
biological inactive large precursor proteins (ppET), which are proteolytically cleaved 
to yield the bioactive form of 21 peptides. They are each encoded by a separate and 
unique gene (Inoue et al., 1989; Yanagisawa et al., 1989), are expressed in different 
cells and tissues with different proportions.  
The present study demonstrated by using quantitative real time PCR that 
mRNA encoding for ppET-1 and ppET-2 was clearly expressed in MRC-5 human 
lung fibroblast cell line and phLFb, whereas no transcript was detected for ppET-3. 
Nevertheless in both MRC-5 fibroblasts and phLFb cells, there were different 
expression levels of mRNA for ppET-1 and ppET-2. The expression levels of ppET-1 
mRNA exceeded 100-fold those of ppET-2 in both MRC-5 fibroblasts and phLFb 
(Fig. 3-1). This indicates that ET-1 is the predominant ET in human lung fibroblasts. 
Moreover, under similar culture condition, the transcript levels of ppET-1 and ppET-2 
were approximately five times higher in MRC-5 fibroblasts than in phLFb.  
Both subtypes of ET receptors, ET-A and ET-B, were found to be expressed 
in MRC-5 and primary cells. The expression levels of mRNA for ET-A and ET-B 
receptors were approximately equal in MRC-5 cell, whereas in primary cells, the 
levels of mRNA for ET-B receptor were substantially higher than those for ET-A. This 
is consistent with previous observations (Gallelli et al., 2005).  
In addition, the expression of ET receptors (ET-A and ET-B) was confirmed at 
the protein level by Western blot analysis, using antibodies directed against ET-B 
and ET-A receptors. A band of approximately 70 kDa, the expected size for ET-B 
receptors was detected, and an additional smaller protein band was also observed, 
that may reflect a cellular degradation product still recognized by the antibody. The 
immunoblot for ET-A showed also two bands, both smaller than the expected size. 
Nevertheless, the larger band appears to be an ET-A receptor signal as it 
corresponds to a specific band of about 45 kDa observed in ET-A receptor 
transfected cells (reference sheet of Santa Cruz). 
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4.2. Regulation of ET expression and release in human lung fibroblasts 
4.2.1. Effect of TGF-β on ET expression 
The regulation of ET-1 expression takes place principally at the mRNA level 
that involves both transcriptional and posttranscriptional mechanisms (Inoue et al., 
1989; Rodriguez-Pascual et al., 2003; Mawji et al., 2004). Expression of ET-1 mRNA 
is constitutive, but potentially regulated by a variety of biological and 
pharmacological factors (Miyauchi et al., 1999). ET-1 gene expression can be 
affected by a number of factors including TGF-β, which is one of the most potent 
regulators of ET-1 levels. TGF-β is a pro-fibrotic cytokine, which is thought to be one 
of the key mediators in tissue remodeling associated with chronic inflammatory and 
obstructive airway diseases (Königshoff et al., 2009; Datta et al., 2011; Halwani et 
al., 2011). TGF-β has been reported to cause an increase in ET-1 mRNA and 
peptide levels in different type of cells, including primary human fetal lung fibroblasts 
(IMR-90) (Kulasekaran et al., 2009), human lung fibroblasts (Shi-Wen et al., 2006) 
and aortic endothelial cells (Markewitz et al., 2001).  
The current study confirmed that TGF-β is a strong stimulator of ET-1 
expression; it caused an almost nine-fold increase of ppET-1 transcription in MRC-5 
cells and a more than fifteen-fold increase in phLFb. The stimulatory effect of TGF-β 
was rapid in onset and did not show any fatigue during prolonged exposure (the 
longest period studied being one week). This finding suggests that elevation of TGF-
β in pathological conditions might be accompanied by a sustained up-regulation of 
ET-1 expression. For example, both TGF-β and ET-1 have been reported in several 
studies to be highly expressed in the lungs of patients with pulmonary fibrosis 
(Cambrey et al., 1994; Khalil et al., 1996; Abraham et al., 1997; Sime et al., 1997; 
Mutsaers et al., 1998; Wendel et al., 2004). Taken together, the observations in the 
present study suggest that up-regulation of ET-1 in human lung fibroblasts by TGF-β 
may play an important role in fibrotic airway remodelling processes.  
Furthermore, TGF-β has been shown in this study to have different effects on 
the expression of ET isoforms in both, MRC-5 cells and phLFb. The stimulatory 
effect of TGF-β on the expression of ET is confined to ET-1, as TGF-β caused even 
a reduction of the already low levels of ppET-2 mRNA (Fig. 3-3B) and did not induce 
the expression of ppET-3 mRNA. 
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4.2.2. Effect of TGF-β on ppET-1 mRNA stability and/or transcription 
 In general, ET-1 mRNA appears to be rather labile, having an intracellular half 
life of less than an hour (Inoue et al., 1989). In the present study, the half-life of 
ppET-1 mRNA was about 30 minutes (Fig. 3-4A), indicating a relatively high turnover 
rate resulting in a close relation between mRNA levels and ppET-1 gene 
transcription. Such a rapid turnover of the ET-1 transcript permits stringent control 
over its expression in response to extracellular stimuli. Therefore, ppET-1 mRNA 
levels are expected to reflect immediately changes in ppET-1 gene transcription. In 
line with this conclusion, there was a marked increase (about sevenfold) in ppET-1 
mRNA levels already after one hour of exposure to TGF-β (Fig. 3-4B). An essential 
characteristic of ppET-1 mRNA is the existence of a number of AUUUA motifis in the 
3′ untranslated region. The AU motifis are known to mediate selective mRNA 
degradation through accelerated deadenylation, which could be contribute to the 
lability of ET-1 mRNA (Mawji et al., 2004).  
Furthermore, the up-regulation of ppET-1 mRNA expression induced by TGF-
β was prevented by the transcriptional inhibitor actinomycin D, and this was not a 
result of actinomycin D toxicity, since GAPDH steady-state mRNA levels (reference 
gene) were not affected by this substance. This indicates that an increase in 
transcription of the ET-1 gene might be responsible for the enhanced mRNA levels 
rather than an enhanced stability of the transcript. 
In an attempt to investigate whether the stimulatory effect of TGF-β on ET-1 
mRNA involved de-novo cellular protein synthesis, experiments using the protein 
synthesis inhibitor cycloheximide were performed. The observation that 
cycloheximide alone cause a rapid increase in ppET-1 mRNA indicates, that basal 
ppET-1 gene expression in human lung fibroblasts is under inhibitory control of 
short-living regulatory peptides, not yet identified, which appear also to counteract 
the stimulatory effect of TGF-β, as the TGF-β response was markedly potentiated in 
the presence of cycloheximide (Fig. 3-5B). Interestingly, the rapid onset of the 
stimulatory effect of TGF-β on ppET-1 mRNA expression occurred also in presence 
of cycloheximide, indicating that the induction of ppET-1 mRNA does not required de 
novo protein synthesis. This supports the conclusion that the up-regulation of ppET-1 
mRNA expression by TGF-β is the result of a direct regulation of ppET-1 mRNA 
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gene transcription by TGF-β signalling pathways and does not involve the up-
regulation of other regulatory proteins.  
 
4.2.3. Effect of TGF-β on ET-1 release  
MRC-5 fibroblasts appear to release ET-1 constitutively, as accumulation of 
the biologically active ET-1 in culture medium was observed under an un-stimulated 
condition. However, there was a strong increase in ET-1 accumulation in TGF-β 
stimulated cells, indicating that the TGF-β-mediated up-regulation of ET-1 mRNA 
expression was accompanied by an increase in synthesis and release of ET-1. 
Strikingly, the maximum level of ET-1 accumulation caused by TGF-β was observed 
at TGF-β concentrations of 0.1 - 0.3 ng/ml which induced only sub-maximal increase 
in ppET-1 mRNA. The further strong increase in ppET-1 mRNA caused by higher 
concentrations of TGF-β did not result in a higher rate of accumulation (compare 
figures 3-3A and 3-7A). A simple relationship between the levels of ppET-1 mRNA 
and ET-1 accumulation may not be expected, since ET-1 accumulation is 
determined by a number of processes. These include translation into the precursor 
protein, its intracellular processing to big-ET-1, release of big-ET-1 and extracellular 
conversion to ET-1 and finally degradation of the active peptide.  
Furthermore, the conversion of exogenous big ET-1 into the active peptide 
occurred in a concentration- and time-dependent manner, maximally at a 
concentration of 100 nM over 6 hours exposure time (Fig. 3-8). Since the 
concentrations of ET-1, which accumulated in presence of exogenous big-ET-1, 
were about 40-times higher than those seen in media from cells stimulated with 
TGF-β (Fig. 3-7A), it can be excluded that a limited ET converting enzyme activity 
may account for the above discussed dissociation between ppET-1 mRNA and 
accumulation of ET-1. Thus, limited translation and/or limited processing of the 
precursor protein may account for the non-linear relationship between mRNA levels 
and accumulation of the active peptide.  
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4.2.4. Role of ET receptor subtypes in TGF-β-induced expression and release 
of ET-1 
A potential role of ET receptors (ET-A and ET-B) on TGF-β-induced 
expression and release of ET-1 in MRC-5 cells was studied by using the non 
selective ET receptor antagonist bosentan as well as selective ET-A and ET-B 
receptor antagonists, which have been demonstrated to be important tools to 
examine the role of each receptor type (Davenport, 2002). The concentrations of the 
antagonists were chosen to be selective for the respective receptor. As the affinity of 
BQ-788 at the ET-B receptor is about ten-fold higher than that of BQ-123 at the ET-A 
receptor (Ishikawa et al., 1994), at the concentration used (0.1 µM BQ-788 and 1 µM 
BQ-123) a similar blockade of the respective ET receptor subtype should have been 
achieved by each antagonist.  
The up-regulation of ppET-1 mRNA expression and the accumulation of ET-1 
induced by a sub-maximal concentration of TGF-β (0.03 ng/ml) were significantly 
attenuated by the non selective ET receptor antagonist bosentan, indicating that ET-
1 may contribute in a kind of auto-regulatory positive feedback, to the regulation of 
its own expression and release. It can be conclude that ET-A receptors mediated 
these effects on the expression of ppET-1 in human lung fibroblasts, since the 
selective ET-A antagonist BQ-123, but not the ET-B selective antagonist BQ-788 
mimicked the effect of bosentan. This indicates that TGF-β-induced up-regulation of 
ppET-1 expression is augmented by concomitant ET-A receptor activation. Thus, an 
auto-regulatory positive feedback mediated via ET-A receptors appear to be involved 
in the regulation of ET-1 expression and release. A similar ET-A receptor-mediated 
feedback mechanism was also described for the TNF-α-induced up-regulation of ET-
1 in human airway smooth muscle cells (Knobloch et al., 2009).  
It was observed that neither antagonist significantly changed basal levels of ppET-1 
mRNA and release in MRC-5 fibroblasts, indicating that the autocrine and/or 
paracrine activation of ET-A and ET-B receptors does not regulate basal ppET-1 
transcription and release in human lung fibroblasts. 
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4.2.5. Role of canonical (Smad) and non-canonical (MAPK, Rho G-protein) 
signaling in TGF-β-induced ppET-1 mRNA expression  
Activation of canonical (Smad) and non-canonical (MAPK, Rho G-protein) 
signalling pathways involved in TGF-β-mediated gene transcription have been 
reported in various studies (Rodriguez-Pascual et al., 2003; Leivonen et al., 2005; 
Castanares et al., 2006; Star et al., 2009; Shimada et al., 2011). As outlined in the 
introduction, eight Smad proteins family members have been identified, which play a 
critical role in the transduction of receptor signals to particular target genes in the 
nucleus (Attisano et al., 2001). They are considered to be important mediators of 
TGF-β signalling (Heldin et al., 1997; Attisano et al., 2000; Massague et al., 2000a). 
Smad3 is part of a canonical signalling pathway of TGF-β, which is considered to be 
a mediator of TGF-β-induced regulation of gene transcription (Attisano et al., 2002). 
In endothelial cells, it was shown that, the TGF-β-Smad pathway was involved in the 
regulation of ET-1 mRNA expression (Rodriguez-Pascual et al., 2003; Castanares et 
al., 2006).            
 In the present study the TGF-β-Smad3 pathway appears also to be crucially 
involved in TGF-β-induced up-regulation of ppET-1 mRNA in MRC-5 fibroblasts, as 
indicated by the strong inhibitory effect of SIS3, a specific inhibitor of Smad3. The 
observation that SIS3 markedly reduced basal level of ppET-1 mRNA expression 
indicates that, the TGF-β-Smad3 signalling pathway was activated already under 
control culture condition. In contrast to these data, mutation of the Smad element in 
the ET-1 promoter did not affect TGF-β-mediated induction of ET-1 in lung 
fibroblasts (Shi-Wen et al., 2006).  
In addition to Smad3, the ERK MAPK signaling pathway has been shown to 
play also a role in TGF-β signalling (Zavadil et al., 2001; Leask et al., 2003; Leivonen 
et al., 2005) and to contribute to TGF-β-induced gene expression (Robinson et al., 
1997). In the present study, inhibition of the ERK MAPK pathway by the MEK 
inhibitor PD 098059 (Alessi et al., 1995; Dudley et al., 1995) had no effect on the 
basal level of ppET-1 mRNA expression after 4 or 8 hours of exposure, indicating 
that ERK1/-2 MAPK was not involved in the short term regulation of basal ppET-1 
mRNA expression in MRC-5 fibroblasts. Moreover, TGF-β-induced increases in 
ppET-1 mRNA expression was not affected by the MAPK inhibitor, indicating that 
ERK1/-2 MAPK is not required for TGF-β-induced ppET-1 mRNA expression. 
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Interestingly however, prolonged inhibition of the MAPK pathway by 24 hours 
exposure to PD 098059 caused a marked increase in ppET-1 mRNA and had 
additive effects with TGF-β. The mechanism by which inhibition of MAPK pathway 
caused up-regulation of ppET-1 mRNA remains unknown. Whether an altered gene 
expression or effects on the stability of the mRNA are involved has to be investigated 
in further studies. 
As outlined in the introduction, Rho kinase is a member of the Ras 
superfamily of small GTP-binding proteins and recognised as one of the downstream 
effectors of the small Rho GTPase Rho A. RhoA-Rho kinase activation controls a 
variety of cellular functions including, the transcriptional regulation of gene 
expression (Etienne-Manneville et al., 2002; Shimokawa et al., 2007). Participation 
of Rho kinase-dependent signalling in TGF-β-induced ppET-1 mRNA expression has 
been demonstrated in hepatic stellate cells (Shimada et al., 2011).   
 The current observation that the Rho-kinase inhibitor Y-27632 (Ishizaki et al., 
2000; Shimokawa et al., 2007) concentration dependently reduced the basal ppET-1 
mRNA levels indicates that, Rho is involved in the basal regulation of ppET-1 mRNA 
expression in human lung fibroblasts. However, it appears not to be involved in the 
regulation of ppET-1 transcription by TGF-β, as Y-27632 did not affect the TGF-β-
induced increase in ppET-1 mRNA expression. 
 
4.2.6. Role of β2-adrenoceptors and muscarinic receptors in the ET-1 
          expression 
Another aim of the present study was to illuminate a possible role of β2-
adrenoceptors and muscarinic receptors in the regulation of ET-1 expression. 
 
4.2.6.1. Effect of β2-adrenoceptor agonist on ET-1 expression 
β_Adrenoceptors are involved in the regulation of crucial cellular functions of 
human lung fibroblasts which express exclusively the β2-subtype (Lamyel et al., 
2011). 
In the present study, it was investigated whether the expression of ppET-1 
mRNA in human lung fibroblasts is regulated by β-adrenergic mechanisms. The 
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highly selective, long acting β2-adrenoceptor agonist olodaterol (Bouyssou et al., 
2010) caused a marked reduction of the expression of ppET-1 mRNA in MRC-5 
fibroblasts, indicating that ET-1 expression is regulated by inhibitory β2-
adrenoceptors in these cells. Furthermore, in line with the expression pattern of β-
adrenoceptors in human lung fibroblasts, the inhibitory effects of olodaterol on ppET-
1 mRNA expression was antagonised by the β2-adrenoceptor selective antagonist 
ICI 118,551, whereas the β1-adrenoceptor antagonist CGP 20712 was ineffective.  
As outlined in the introduction, β-adrenoreceptors typically couple to Gs and cause 
increases in cellular cAMP concentration through activation of adenylyl cyclase. 
Intracellular cAMP regulates various cellular functions primarily through two 
downstream effectors, PKA, the classic effector of cAMP (Skalhegg et al., 2000), and 
the alternative cAMP effectors Epac of which two variants, Epac-1 and -2, have been 
identified (de Rooij et al., 1998; Kawasaki et al., 1998). These effectors (Epac and 
PKA) have been shown to act independently on distinct cellular functions in human 
lung fibroblasts, such as proliferation and collagen synthesis (Huang et al., 2008; 
Haag et al., 2008b). In the present study, the selective PKA agonist 6-Bnz-cAMP 
effectively inhibited the expression of ppET-1 mRNA, suggesting that the effect of β2-
adrenoceptors may be mediated via PKA. Interestingly, the Epac agonist 8-CPT-2′-
O-Me-cAMP (Bos, 2006; Holz et al., 2008; Poppe et al., 2008) also significantly 
reduced the expression of ppET-1 mRNA, but this reduction was substantially 
smaller than that caused by the PKA agonist 6-Bnz-cAMP. In previous studies in our 
laboratory using the same cells and the same concentrations of 6-Bnz-cAMP and 8-
CPT-2'-O-Me-cAMP, these agonists mediated a strong and selective inhibition of 
either the synthesis of collagen or cell proliferation, respectively (Haag et al., 2008b). 
Collective theses observations indicate that the cellular transmission of β2-
adrenoceptor–cAMP-mediated inhibition of the transcriptional regulation of ET-1 
expression could be by the engagement of both PKA and Epac, but PKA appears to 
play the major part. 
Since TGF-β was shown to up-regulate ET-1 gene expression, and the selective β2-
adrenoceptor agonist (olodaterol) down-regulated the expression of ET-1, the 
opposing role of TGF-β and β2-adrenoceptors was further studied in interaction 
experiments. Activation of β2-adrenoceptor by olodaterol was able to oppose the 
TGF-β-induced up-regulation of ET-1, but only when a sub-maximally effective 
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concentration of TGF-β (0.3 ng/ml) was applied. The marked up-regulation of ET-1 
by TGF-β in the maximally effective concentration of 1 ng/ml was no longer affected 
by olodaterol. Interestingly, interaction experiments with the PKA and Epac agonists 
and TGF-β showed similar results. The PKA and Epac agonists were able to oppose 
the effect of a sub-maximally effective concentration of TGF-β (0.3 ng/ml), but not 
that of a maximally effective concentration of TGF-β (1 ng/ml). Noticeably, the effect 
of the PKA agonist tends to be stronger than that of the Epac agonist. Since TGF-β 
caused a large suppression of the expression of β2-adrenoceptors in human lung 
fibroblasts (Ahmedat et al., 2012), the loss of inhibitory effects of β-adrenoceptor on 
ppET-1 expression caused by TGF-β appear to result of both, down-regulation of 
receptors and uncoupling of the β-adrenoceptor-downstream signalling cascade. 
 
4.2.6.2. Effect of muscarinic cholinergic receptor agonist on ET-1 expression 
Muscarinic receptors and β2-adrenoceptors generally mediate opposing 
regulatory effects and this seems to apply also for human lung fibroblasts where 
muscarinic receptors and β2-adrenoceptors mediate opposing effects on various pro-
fibrotic features. For example, in these cells, proliferation and collagen synthesis are 
stimulated by muscarinic receptors activation (Matthiesen et al., 2006; Haag et al., 
2008a), but inhibited by activation of β2-adrenoceptors (Lamyel et al., 2011).     
In accordance with this, the present study shows that the muscarinic receptor 
agonist oxotremorine-mediated a marked stimulatory effect on the expression of 
ppET-1 mRNA in MRC-5 fibroblasts. Moreover, the stimulatory effect of 
oxotremorine was opposed by concomitant activation of β2-adrenoceptors with 
olodaterol. Altogether, these observations suggest that up-regulation of ET-1 may 
contribute to the pro-fibrotic effects of muscarinic stimuli. Thus, reduction of 
cholinergic driven induction of ET-1 expression could contribute to long-term 
beneficial effects of long-acting muscarinic antagonists such as tiotropium.  
Additionally, the present study demonstrated that the effects of the muscarinic 
agonist oxotremorine and those of TGF-β seemed to parallel in MRC-5 fibroblasts, 
as both mediated a strong stimulatory effects on ppET-1 mRNA expression. The 
muscarinic receptor agonist showed however only limited additive effects to that of 
TGF-β, an additivity on ppET-1 transcription was observed only with the relatively 
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low concentrations of 0.1 ng/ml TGF-β. However, in presence of 0.3 ng/ml TGF-β, 
still not a maximally effective concentration, oxotremorine no longer caused a 
significant further increase in ppET-1 mRNA expression.  
Acetylcholine, a classic neurotransmitter has been reported to be synthesized also 
by many non-neuronal cells including fibroblasts (Wessler et al., 1998; Wessler et 
al., 2008). However, the lack of effect of tiotropium on ET-1 expression, both under 
basal culture conditions as well as in presence of TGF-β, excludes a role of 
endogenous acetylcholine in the control of ET-1 expression. The observation that 
bosentan attenuated the muscarinic receptor agonist-induced stimulation of ET-1 
expression indicates, that similar to the above discussed observations on the mode 
of actions of TGF-β, a paracrine/autocrine positive feedback mechanism mediated 
via ET receptors is involved in oxotremorine-mediated up-regulation of ppET-1. 
 
4.3. Effects of TGF-β on the expression of ET receptor subtypes in human 
lung fibroblast  
 
In both phLFb and MRC-5 fibroblasts ET-B receptor transcription appears to 
be robustly down-regulated by TGF-β, whereas ET-A receptor appears to be highly 
constitutive. These data show that TGF-β modulates the expression of ET receptor 
subtypes differently in human lung fibroblasts. Since, TGF-β did not affect ET-A 
expression, it can be concluded that ppET-1 and ET-A receptor mRNA are not under 
the same regulation. Previously, it had also been observed in other tissues and cells 
such as rat mesenteric artery and alveolar epithelial cells that the ET-A receptor is 
constitutively expressed, whereas the ET-B receptor expression is strongly regulated 
(Uddman et al., 2002; Jain et al., 2007). 
 
4.4. Functional role of ET-1 and its receptors in human lung fibroblasts 
Another aim of the present study was to illuminate the role of the ET-1 and its 
receptor subtypes in human lung fibroblasts in specific cellular functions such as 
proliferation, collagen synthesis or modulation of phenotype. These cellular functions 
are of pathophysiological relevance in the development of lung diseases such as 
asthma, chronic obstructive disease and idiopathic pulmonary fibrosis. In fact, these 
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pathological conditions have a common tendency toward enhanced cellular activities 
including fibroblast proliferation, differentiation into myofibroblast and collagen 
synthesis leading to an increase accumulation of ECM. For example, lung fibrosis is 
characterized by abnormal proliferation, activation of lung fibroblasts and production 
of extracellular matrix that results in the excessive deposition of extracellular matrix 
proteins (Crouch, 1990; Thannickal et al., 2004; Datta et al., 2011).  
 
4.4.1. Effects of ET-1 and ET receptor subtype antagonists on proliferation  
The present study demonstrated that ET-1 exerted proliferative effects in both 
MRC-5 fibroblasts and phLFb. 
In MRC-5 fibroblasts, under the cultured conditions depicted in figure 3-20B 
(condition A), ET-1 caused only a slightly stimulatory effect on the proliferation as 
measured by [3H]-thymidine incorporation but, on the other hand, bosentan caused a 
significant reduction in the basal [3H]-thymidine incorporation, suggesting that under 
these culture conditions, endogenously released ET-1 exerted a clear proliferative 
effect. This is in line with the observed of constitutive synthesis of ET-1 in these 
cells. A mitogenic effect of endogenous ET-1 has also been demonstrated on human 
pulmonary artery smooth muscle cells and rat cardiomyocytes (Ito et al., 1993; Wort 
et al., 2001). Although ET-1 alone had only a small stimulatory effect, ET-1 was able 
to surmount the inhibitory effect bosentan, indicating a competitive interaction 
between ET-1 and bosentan, and supporting that the inhibitory effect of bosentan 
was indeed mediated by specific blockade of ET receptors. Since only BQ-123, but 
not BQ-788 mimicked the effect of bosentan, it is concluded that ET-A receptors 
mediate the proliferative stimulus.         
In phLFb, the stimulatory effect of ET-1 on proliferation was stronger than in 
MRC-5 cells, but the inhibitory effect of bosentan and BQ-123 on the proliferation 
was smaller, in addition to this BQ-788 was again ineffective. These functional 
observations suggesting a lower endothelinergic tone in phLFb compared with MRC-
5 cells are in accordance with lower expression levels of ET-1 in phLFb under 
standard cultured conditions. Like in MRC-5 cells, the inhibitory actions of bosentan 
and BQ-123 were also surmountable by exogenous ET-1 in phLFb.  
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Additionally, in both phLFb and MRC-5 cells, the proliferative effect of 
exogenous ET-1 was somewhat more pronounced when the cells were starved after 
five hours after the cell dissemination (condition B) (Fig. 3-20C), i.e. conditions, 
where a lower endogenous ET-1 tone might have been present. Moreover, in both 
cell types (phLFb and MRC-5 cells), exogenous ET-1 exerted a stronger proliferative 
effect when ET-1 was applied immediately after cells dissemination. Noteworthy, 
under these conditions the maximum proliferative effect of ET-1 was achieved at 
lower concentrations of ET-1 (Fig. 3-20D), again in line with the conclusion that 
under these conditions the endogenous ET-1 tone may be lower than under the 
standard culture conditions (condition A). 
 
Since DNA synthesis may occur without cell division, cell numbers were 
estimated in order to ascertain that the increase in DNA synthesis induced by ET-1 
in human lung fibroblast cells reflects an increase in cell proliferation. In agreement 
with the observations with the [3H]-thymidine incorporation method, it was found that 
ET-1 caused an increase in the number of cells, an effect inhibited by bosentan.  
The present observation with regard to the lack of ET-B receptors effects on human 
lung fibroblasts proliferation are in line with observations reported by Gallelli et al., 
(2005) showing that in phLFb, proliferative effects of ET-1 mediated only through ET-
A receptors, but contrast with the observations of Préfontaine et al., (2008) which 
reported that ET-A and ET-B receptor were involved in ET-1-induced proliferation in 
rat lung fibroblasts. The discrepancy may reflect species differences.  
Collectively, these observations indicate that ET-1 exerts stimulatory effects on both 
DNA synthesis and proliferation of human lung fibroblasts via activation of ET 
receptors. Thus, ET-1 may contribute to airway remodelling, at least in part by 
stimulating bronchial fibroblasts to synthesize DNA and proliferate (Dubé et al., 
2000). 
 
4.4.2. Role of Rho kinase in ET-1-induced proliferation 
As outlined in the introduction, Rho kinase is the main effector of Rho. Rho, a 
member of the family of small G-proteins, has been shown to regulate a variety of 
cellular functions including cell proliferation in part via its target, Rho kinase 
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(Coleman et al., 2004). Abnormal activation of the Rho/Rho-kinase pathway has 
been reported to play a role in various diseases including pulmonary fibrosis (Jiang 
et al., 2012) and bronchial asthma (Wettschureck et al., 2002). In a previous study, it 
has also been shown, that inhibition of Rho kinase abrogates ET-1-induced 
proliferation of rat tracheal smooth muscle cells (Yahiaoui et al., 2006). In the 
present study, the Rho kinase inhibitor Y-27632 by itself inhibited the basal 
proliferation, but failed to inhibit ET-1-induced [3H]-thymidine incorporation in MRC-5 
fibroblast. These results indicate that, Rho is not involved in the ET-1-induced 
proliferation of MRC-5 fibroblast, although it mediates proliferative signals in these 
cells. 
 
4.4.3. Role of ET-1 and its receptors in the regulation of collagen synthesis  
After establishing that ET-1 stimulates the proliferation of human lung 
fibroblasts, it was interesting to further investigate whether ET-1 might also be 
involved in the regulation of collagen synthesis. Collagen is a major extracellular 
matrix component of the lungs and is vital for maintaining the normal lung 
architecture. The major component of collagen is proline and therefore the amount of 
radioactive [3H]-proline incorporated into newly synthesised proteins provides a 
reliable index of total collagen synthesis. [3H]-Proline incorporation method has often 
been used as a measure of collagen synthesis (Peterkofsky et al., 1971; Guo et al., 
2004; Hafizi et al., 2004; Rao et al., 2008; Haag et al., 2008a). Furthermore, in 
previous experiments carried out in our laboratory, it was confirmed by collagenase 
digestion that total radioactivity incorporated into proteins largely reflects de novo 
synthesis of collagen (Haag et al., 2008a).  
Previous studies have shown that ET-1 can stimulates collagen synthesis in a 
variety of cell types including human cardiac fibroblasts, human primary dermal 
fibroblasts, and human lamina cribrosa cells (Hafizi et al., 2004; Horstmeyer et al., 
2005; Rao et al., 2008). In the present study, it was found that ET-1 increased 
collagen synthesis in a concentration-dependent manner in both phLFb and MRC-5 
fibroblasts. In accordance with the already discussed lower endogenous 
endothelinergic tone in phLFb compared to MRC-5 fibroblasts, none of the ET 
antagonists had any significant effect on basal [3H]-proline incorporation in phLFb, 
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whereas in MRC-5 fibroblasts, bosentan and the ET-A antagonist BQ-123 caused a 
small, but significant reduction in [3H]-proline incorporation. In both cell types, the 
inhibitory effect of bosentan and BQ-123 were surmountable by exogenous ET-1. On 
the other hand, BQ-788 did not affect the ET-1 response. Therefore, it can be 
conclude that the effects of ET-1 on collagen synthesis in human lung fibroblasts 
cells are mediated via the ET-A receptor subtype.  
Furthermore, the stimulatory effect of ET-1 on collagen synthesis was also 
demonstrated by direct determination of collagen as measured by the QuickZyme 
collagen assay. Also using this method it could be observed that ET-1 caused in 
concentration-dependent manner a strong increase in collagen synthesis and the 
maximal effect of ET-1 observed on collagen synthesis as measured by the two 
different assay system ([3H]-proline incorporation assay and QuickZyme collagen 
assay) was achieved at a concentration of 10 nM, i.e. the results obtained with the 
two different assay system were highly consistent.  
 
4.4.4. Effect of ET-1 on COL I-α1 mRNA expression  
In order to investigate whether the stimulatory effect of ET-1 on collagen 
synthesis involves an increase of collagen expression, the effect of ET-1 on the 
expression of COL I-α1 mRNA, a major collagen in lung fibroblasts (Kirk et al., 1984) 
was studied. ET-1 caused an increase of COL I-α1 mRNA expression in MRC-5 
fibroblasts and this effect was blocked by bosentan, indicating that ET-1 regulates 
COL I-α1 mRNA via activation of ET receptors. This observation supports the 
conclusion that an enhanced collagen gene transcription contributes to the ET-1-
induced up-regulation of collagen synthesis in human lung fibroblasts. 
 
4.4.5. Effects of ET receptor subtype antagonists on TGF-β-mediated collagen 
synthesis stimulation 
TGF-β is one of the key cytokines in the regulation of extracellular matrix 
production (Bartram et al., 2004). It has been demonstrated that TGF-β stimulates 
collagen synthesis in a variety of cells types, including human lung fibroblasts, 
human cardiac fibroblasts, and human dermal fibroblasts (Fine et al., 1987; Hafizi et 
al., 2004; Horstmeyer et al., 2005).        
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 In the present study, TGF-β proved to be a potent stimulator of collagen 
synthesis in human lung fibroblasts. Interestingly, bosentan and BQ-123, but not BQ-
788 reduced the stimulatory effect of TGF-β on the collagen synthesis, indicating that 
endogenous ET-1 acting via ET-A receptors might be involved in TGF-β-induced 
stimulation of collagen synthesis. The present findings demonstrate that the 
observed up-regulation of ET-1 gene by TGF-β is of functional significance and may 
contribute to the pro-fibrotic effects of TGF-β. Moreover, the present observation 
further indicates, that ET-1 may be a downstream pro-fibrotic mediator of TGF-β in 
human lung fibroblasts. Consequently, ET-A receptor antagonists might be 
considered as potential drugs to treat fibrotic lung diseases.  
 
4.4.6. Effect of ET receptor antagonist on muscarinic agonist-mediated 
collagen synthesis stimulation 
Another aim of the present study was to identify a possible role of ET-1 in 
muscarinic receptor-mediated stimulation of collagen synthesis in human lung 
fibroblasts.  
In line with a previous study which showed a muscarinic receptor-mediated 
stimulatory effect on collagen synthesis in human lung fibroblasts (Haag et al., 
2008a), the present data demonstrated that the muscarinic receptor agonist 
oxotremorine markedly up-regulated collagen synthesis in MRC-5 fibroblasts. 
Bosentan attenuated the oxotremorine-mediated stimulation of collagen synthesis, 
indicating that ET-1 may contribute to the pro-fibrotic effect of cholinergic stimuli, and 
that the observed up-regulation of ET-1 gene by oxotremorine is of functional 
significance.  
Furthermore, the stimulatory effect of oxotremorine on collagen synthesis 
showed limited additivity to that of TGF-β. An additive effect of the muscarinic 
agonist was observed only with the low concentrations of 0.1 ng/ml TGF-β, but 
oxotremorine no longer exhibited a significant further effect in the presence of 0.3 
ng/ml TGF-β, still a sub-maximally effective concentration. The additive effects of 
TGF-β and oxotremorine on collagen synthesis were consistent with the above 
discussed observations on ET-1 expression.  
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4.4.7. Role of ET-1 in myofibroblasts differentiation  
In addition to proliferation, the transformation of human lung fibroblasts to 
myofibroblasts is a critical pathophysiological relevant feature which appears to play 
a key role in many lung disease including lung fibrosis (Kuhn et al., 1991; Phan, 
2002; White et al., 2003). Myofibroblasts are fibroblast-like cell with smooth muscle 
cell characteristics, showing particular expression of α-SMA. 
In agreement with previous studies (Singh et al., 2008; Honda et al., 2010; 
Lamyel et al., 2011), MRC-5 fibroblasts cultured under standard conditions, showed 
significant expression levels of α-SMA, most likely induced by serum constituents of 
the culture medium. Unlike TGF-β, a well characterised stimulant of myofibroblast 
differentiation (Sandbo et al., 2009; Honda et al., 2010; Lamyel et al., 2011; Milara et 
al., 2012), exogenous addition of ET-1 caused only a minor, although significant 
increase in α-SMA. Bosentan caused a reduction in the expression of α-SMA protein 
by about 50% after 24 hours of exposure, suggesting that endogenously released 
ET-1 contributes to myofibroblast differentiation. However, ET-1, although up-
regulated by exposure to TGF-β, seems not to be involved in TGF-β-induced 
differentiation of MRC-5 fibroblasts to the myofibroblast phenotype, as bosentan did 
not affect TGF-β-induced up-regulation of α-SMA protein expression (Fig. 3-25). 
These data suggest that, the endothelinergic system may be involved in the 
transformation of lung fibroblasts to myofibroblasts and that it may contribute to the 
increased pool of myofibroblasts that has been observed in lungs of patients with 
asthma and COPD. Since myofibroblasts are key effectors in airway remodelling 
processes associated with chronic obstructive and inflammatory airway diseases 
(Davies et al., 2003; Westergren-Thorsson et al., 2010), the inhibitory effect of 
bosentan on myofibroblast differentiation could be of particular therapeutic interest. 
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4.5. Characterization of the signal pathway involved in ET-1-mediated 
collagen synthesis stimulation in human lung fibroblasts 
4.5.1. Effects of ET-1 and ET receptor subtype antagonists on ERK1/-2 MAPK 
activation 
Previous studies carried out in our laboratory showed that in human lung 
fibroblasts activation of ERK MAPK pathway was crucially involved in the muscarinic 
receptor-mediated stimulation of proliferation and collagen synthesis (Matthiesen et 
al., 2006; Haag et al., 2008a). In the present study, similar to the muscarinic receptor 
agonist oxotremorine, ET-1 induced a significant and rapid, but transient, 
phosphorylation of ERK1/-2 MAPK in MRC-5 fibroblasts (Fig. 3-33A and B). The 
maximum increase in ERK1/-2 MAPK phosphorylation was seen within 5 minutes 
after exposure to ET-1. The effect of 100 nM ET-1 was somewhat stronger than that 
of oxotremorine (10 µM, a maximally effective concentration) (Fig. 3-33B). There was 
no change in the level of total ERK under these conditions, indicating that the 
increase in phosphorylation of ERK was due to an increase in the level of ERK 
activation. Like the other functional responses, ET-1-mediated activation of ERK1/-2 
MAPK is predominately mediated by ET-A receptors, which is in line with the 
previous findings of Gallelli et al., (2005).  
 
4.5.2. Effects of pertussis toxin on ET-1-induced activation of ERK1/-2 MAPK 
and collagen synthesis stimulation 
As outlined in the introduction, various observations indicate, that MAP 
kinases may be stimulated by activation of Gi and Gq protein-coupled receptors 
through different signal pathways (Marshall, 1994) and that ERK activation may be 
triggered by stimulation of Gi-coupled receptors (Touhara et al., 1995; van Biesen et 
al., 1995; Della Rocca et al., 1997; Yahiaoui et al., 2006). GPCRs downstream 
pathways have been divided into two sub-groups, PTX-sensitive (coupled to Gi/o) or 
PTX-insensitive (coupled to Gq/11, Gs, or G12/13) (Albert et al., 2002; Pierce et al., 
2002). ET-1 mediates its biological actions through the activation of membrane G 
protein coupled ET-A and ET-B receptors (Arai et al., 1990; Sakurai et al., 1990), 
which may couple to several Gα subunits, including Gi/o, Gq/11, G12/13, and Gs (Takagi 
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et al., 1995; Cadwallader et al., 1997; Arai et al., 2003). Moreover, it has been shown 
that ET-1-mediated responses, including MAPK activation, are mediated by Gαq, Gαi, 
and Gβϒ  (Miyauchi et al., 1999).  
In the present study, the contribution of Gi signalling to the activation of ERK 
pathway in MRC-5 fibroblasts by ET-1 and muscarinic receptor oxotremorine was 
assessed by using pertussis toxin (PTX). 
In confirmation of previous observations demonstrating that muscarinic receptors in 
human lung fibroblasts are Gi coupled (Matthiesen et al., 2006; Haag et al., 2008a), 
PTX prevented oxotremorine-induced ERK activation (Fig. 3-34), whereas ERK1/-2 
activation induced by ET-1 was only partially inhibited by PTX (Fig. 3-34). Since a 
single receptor can couple to different G proteins, these results suggest that ET-1 
through the ET-A receptor subtype, may activate ERK in part via PTX-sensitive Gi, 
but to a large extent also via PTX-insensitive G-protein, possible Gq or G11/12. This is 
in line with findings in rat myometerial cells, where ET-1-mediated stimulation of 
MAPK signalling through activation of ET-A receptor was shown to occur via a 
combination of PTX-sensitive and PTX-insensitive mechanisms (Robin et al., 2002). 
The dual mechanism of activation may account for the stronger signal induced by 
ET-1 compared to oxotremorine. The observation that PTX caused a reduction in the 
basal phospho-ERK1/-2 levels suggests a background activation of Gi-mediated 
effects, possibly caused by paracrine mediators released by the fibroblasts 
themselves.  
Furthermore, in correspondence with the observation on ERK activation, the 
stimulation of collagen synthesis induced by muscarinic agonist was prevented by 
pertussis toxin, whereas that caused by ET-1 was only partially reduced (as 
discussed previously). 
 
4.5.3. Role of ERK1/-2 MAPK in ET-1-mediated stimulation of collagen 
synthesis 
ET receptors mediate their effects by generation of the second messengers 
and subsequent activation of target proteins including ERK1/-2 (Kasuya et al., 1994) 
which subsequently result in activation of mitogenic and survival signals (Rozengurt, 
2007). The MAP kinase ERK pathway regulates a number of essential cellular 
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functions (Kolch et al., 2005). Thus, ERK signalling has been demonstrated to be 
crucially involved in the proliferation and differentiation of human lung fibroblasts into 
myofibroblasts (Gallelli et al., 2005; Vancheri et al., 2005; Matthiesen et al., 2007; 
Caraci et al., 2008). Moreover, ERK activation has also been shown to be crucial for 
stimulatory effects on collagen synthesis induced by various stimuli, for example also 
for the effects of ET-1 in rat cardiac fibroblasts (Rhaleb et al., 2001), TGF-β and 
muscarinic receptors in human lung fibroblasts (Caraci et al., 2008; Haag et al., 
2008a) or vascular endothelial growth factor (VEGF) in human mesangial cells 
(Amemiya et al., 1999).  
The present study demonstrated, that in human lung fibroblasts ET-1 can 
stimulate collagen synthesis and activate ERK1/-2 MAPK via ET-A receptor. 
Therefore, it was investigated whether the MAPK pathways are involved in the ET-1-
induced stimulation of collagen synthesis by interaction studies using PD98059, a 
specific inhibitor for MAPK-activating enzyme (MEK) (Alessi et al., 1995; Dudley et 
al., 1995). ET-1-induced stimulation of collagen synthesis was completely blocked by 
this ERK-MAPK inhibitor, indicating that the ERK MAPK pathway is crucially involved 
in the collagen synthesis response of human lung fibroblasts to ET-1. Noteworthy, 
ET-1 stimulated both ERK activity and collagen synthesis via the same ET receptor 
subtype, the ET-A receptor as determined by the effect of the ET-A antagonist BQ-
123, which prevented the stimulation of collagen synthesis and activation of ERK1/-
2. Interestingly, ET-1-mediated ERK-MAPK activation has also been shown to be 
responsible for an increased expression of several other matrix-associated genes 
and the stimulation of production of other ECM components in lung fibroblasts, 
including connective tissue growth factor, an important profibrotic protein that 
induces synthesis of collagen (Shi-Wen et al., 2004; Xu et al., 2004). Since collagen 
production is one of the most recognized indicators of fibrosis (Fine et al., 1987; 
Hafizi et al., 2004), these results further suggest that there may be a potential 
therapeutic advantage in using MEK/ERK kinase inhibitors or ET-A receptor 
antagonists to alleviate lung fibrosis. A potential role of ET-A receptor and ERK1/-2 
activation in ET-1-induced lung fibrosis is supported by the observations that the ET-
A receptor antagonist and the ERK-MAPK inhibitor prevented the synthesis of 
collagen induced by ET-1. Furthermore, a pathophysiologic relevance of an ET-A 
receptor mediated activation of ERK1/-2 MAPK in human lung fibroblasts is also 
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suggested by other studies demonstrating that ET-A receptors and ERK1/-2 mediate 
the ET-1-induced proliferation and differentiation into myofibroblasts (Gallelli et al., 
2005).  
 
4.5.4. Role of Rho kinase in ET-1-mediated stimulation of collagen synthesis 
As discussed, ET-1-induced stimulation of collagen synthesis in MRC-5 
fibroblasts is mediated through the classical MEK-ERK MAPK cascade. As the low 
molecular weight G protein, Rho, is one effector of Gi, Gq and G12/13, which regulates 
ERK1/-2 activation via its target Rho kinase (Coleman et al., 2004), it was 
investigated whether Rho-kinase is involved in the ET-1-stimulated collagen 
synthesis. It has been shown that Rho kinase pathways can mediate effects of ET-1 
in a variety of cell types (Rodriguez-Vita et al., 2005; Tokuda et al., 2007; Lima et al., 
2011; Seyler et al., 2012; Undem et al., 2012).       
 In the present study, inhibition of Rho kinase by Y-27632 partially, but 
significantly attenuated the levels of phosphorylated ERK induced by ET-1 (Fig.3-
35), suggesting that Rho kinase is involved in the activation of ERK by ET-1.  
Furthermore, the stimulatory effect of ET-1 on the synthesis of collagen was 
also partially reduced by Y-27632. Interestingly, although inhibition of Rho kinase 
partially inhibited ET-1-induced activation of ERK1/-2 (Fig 3-39), it had no significant 
effect on the ability of ET-1 to stimulate [3H]-thymidine incorporation (Fig 3-24). 
These data indicate that in human lung fibroblasts, different signaling systems 
mediate the different effects of ET-A receptors. 




In conclusion, human lung fibroblasts are endowed with all elements necessary to 
build a functional autocrine/paracrine endothelinergic system which appears to be 
involved in the regulation pro-fibrotic features. ET-1 is the predominant ET isoform in 
human lung fibroblasts, and its expression appears to be highly regulated at 
transcriptional level, suggesting that ET-1 expression may rapidly respond to 
physiological or pathological changes, as well as pharmacological interventions. The 
expression of ET-1 gene is under strong inhibitory control of short-living regulatory 
peptide, not yet identified. ET-1 may in interaction with other mediators such as TGF-
β as well as the adrenergic and cholinergic system, drive pro-fibrotic features. Thus, 
ET-1 is highly up-regulated by TGF-β and via muscarinic cholinergic receptors and 
down-regulated via β2-adrenoceptors. ET-1 can mediate through ET-A receptors 
stimulatory effects on proliferation and collagen synthesis. In fact, there is no 
functional significance of ET-B receptors obtained although the expression of ET-B 
receptor was demonstrated, both at mRNA and protein level. 
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6. Summary 
Airway remodeling and fibrotic alterations are pathological key events 
determining the long-term outcome of chronic inflammatory and obstructive airway 
diseases such as lung fibrosis, bronchial asthma or COPD. In fact, these 
pathological conditions have a common tendency toward enhanced cellular activities 
mainly increased growth of connective tissue cells and excessive synthesis and 
secretion of matrix proteins. Lung fibroblasts are the most abundant cell type in 
connective tissue that produce and maintain extracellular matrix (ECM). They are 
essential in tissue homeostasis and fibrotic remodeling processes and thus play a 
key role in pathophysiologic events of airway remodelling. Hyper-activation of airway 
fibroblasts may result as a consequence of over expression of cytokines and/or 
growth factors like transforming growth factor (TGF-β) and endothelin-1 (ET-1) 
resulting from inadequate control of inflammation. The excessive ECM deposition 
and scar formation ultimately lead to functional impairment of the lung.  
Since endothelins (ETs), of which three isoforms (ET-1, ET-2 and ET-3) exist, 
can exert a number of effects which could promote remodeling processes, the 
present study aimed to characterize the endothelinergic system in human lung 
fibroblasts using the MRC-5 human lung fibroblast cell line and primary human lung 
fibroblasts in culture.  
The expression of ETs and their receptors was analyzed at the mRNA level by 
quantitative real time PCR (qPCR) and at the peptide level by immune blot for the 
ET-A and ET-B receptor and by ELISA for ET-1. Functional effects of ET-1 on cell 
proliferation were quantified using a [3H]-thymidine incorporation assay and cell 
counts, those on collagen synthesis using a [3H]-proline incorporation assay, the 
QuickZyme assay and qPCR for collagen-1 α1 mRNA. In addition ET-1-induced 
changes on phenotype were detected by measuring α-smooth muscle actin (α-SMA) 
at the protein level. 
This study demonstrates that human lung fibroblasts clearly expressed ppET-1 
and ppET-2 with the most dominantly expressed isoform being the ppET-1 followed 
by the ppET-2. On the other hand, no transcript was detected for ppET-3. Moreover, 
ET-A and ET-B receptors were also expressed in human lung fibroblasts. After the 
expression of ET-1 and its receptors in human lung fibroblasts was demonstrated, 
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mechanism involved in their regulation as well as their functional role in mediating 
proliferation and collagen synthesis were studied. 
In summary, the following results were obtained: 
1) The expression of ppET-1 and the release of ET-1 in human lung fibroblasts were 
significantly up-regulated by TGF-β. TGF-β-induced up-regulation of ppET-1 was 
augmented by concomitant ET-A receptor activation. Moreover, the stimulatory 
effect of TGF-β on the expression of ET isoforms is confined to ET-1. 
a) The expression of ppET-1 is highly regulated at the transcription level, and is 
under strong inhibitory control of not yet identified short acting living inhibitory 
proteins which also counteract TGF-β-induced up-regulation of ppET-1. 
b) The stimulatory effect of TGF-β did not show any fatigue during prolonged 
exposure, indicating that pathological conditions with prolonged elevation of 
TGF-β might be accompanied by a sustained up-regulation of ET-1 
expression.   
c) TGF-β induced an increase in ppET-1 gene transcription through its canonical 
Smad-pathway, but ERK MAPK and Rho kinase signalling pathways are not 
involved. 
d) ET-B receptor was markedly down-regulated by TGF-β, whereas ET-A 
receptor was only marginally affected after prolonged exposure to TGF-β.  
2) ET-1 expression is regulated by stimulatory muscarinic receptors and inhibitory 
β2-adrenoceptors. 
a) The stimulatory effect of muscarinic receptors on ppET-1 expression was 
opposed by concomitant activation of β2-adrenoceptors and by blocking of ET 
receptors. 
b) The inhibitory effect of β2-adrenoceptors on ppET-1 expression appears to be 
mediated via PKA, as it was mimicked by direct activation of PKA. 
c) The stimulatory effect of sub-maximally effective concentration of TGF-β on 
ppET-1 expression was opposed by β2-adrenoceptor-PKA pathway. However, 
excessive exposure to TGF-β results in loss of β-adrenoceptor expression 
and function of its down-stream signaling.  
Given that ET-1 can promote pro-fibrotic events in human lung fibroblasts, 
inhibition of ET-1 expression could contribute to long-term beneficial effects of 
Summary 
 137  
long-acting β2-adrenoceptors agonists such as olodaterol and long-acting 
muscarinic antagonists like tiotropium. 
3) ET-1-induced stimulation of proliferation of human lung fibroblasts was shown to 
be mediated via ET-A receptors, and Rho kinase pathway was not involved in 
this effect.  
4) ET-1 induced differentiation of human lung fibroblasts into myofibroblasts, but 
was not involved in TGF-β-mediated human lung fibroblasts differentiation into 
myofibroblasts.  
5) ET-1-induced stimulation of collagen synthesis in human lung fibroblasts was 
mediated via ET-A receptors and involved activation of the ERK-MAPK pathway 
partially via pertussis toxin-sensitive G proteins. The activation of collagen 
synthesis is at least in part caused by increase transcription as ET-1 induced up-
regulation of COL I-α1 mRNA expression. 
6) Interaction experiments with ET receptor antagonists indicate that activation of 
ET-A receptor contributed to the TGF-β-induced stimulation of collagen 
synthesis. Thus autocrine positive feedback indicates that the up-regulation of 
ET-1 gene by TGF-β is of functional significance and contributes to the pro-
fibrotic effects of TGF-β.  
7) Blockade of ET receptors also attenuated the muscarinic receptor-mediated 
stimulation of collagen synthesis, indicating that up-regulation of ET-1 gene by 
muscarinic receptor is of functional significance and contributes to the pro-fibrotic 
effects of cholinergic stimuli.  
 
In conclusion, human lung fibroblasts express a functional autocrine/paracrine 
endothelinergic system that appears to be involved in the regulation pro-fibrotic 
features. ET-1 is the predominant ET isoform in human lung fibroblasts, which may 
in interaction with other mediators such as TGF-β as well as the adrenergic and 
cholinergic system, regulate pro-fibrotic features. Thus, ET-1 is highly up-regulated 
by TGF-β and via muscarinic cholinergic receptors and down-regulated via β2-
adrenoceptors. ET-1 can mediate through ET-A receptors stimulatory effects on 
proliferation and collagen synthesis. In fact, there is no functional significance of ET-
B receptors obtained although the expression of ET-B receptor was demonstrated, 
both at mRNA and protein level. 
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